



**2020 World Conference
on Lung Cancer Singapore**

JANUARY 28-31, 2021 | WORLDWIDE VIRTUAL EVENT

PROGRAM

CONNECT WITH US



@IASLC



facebook.com/IASLC



@iaslungcancer



linkedin.com/IASLC



IASLC

www.IASLC.org

IASLC WCLC 2020 Program

Table of Contents

Program

Day 1 Thursday, January 28, 2021	5
Day 2 Friday, January 29, 2021	11
Day 3 Saturday, January 30, 2021	27
Day 4 Sunday, January 31, 2021	44

Posters

Featured Posters	59
Posters	74

For Sessions with Live Q&A:

Most presenters will be available to answer any questions during the live Q&A at the end of the session.

For Sessions without Live Q&A:

Most presenters will be available to answer any questions during the session via the Q&A chat box.

Day 1 | Thursday, January 28, 2021

07:00 – 09:00 JICC01: Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC

✗ NOT FOR CME CREDIT

ROOM: SCIENTIFIC PROGRAM AUDITORIUM

Chair(s): Yi-long Wu, China & Tony Mok, Hong Kong & Chunxue Bai, China & Caicun Zhou, China

- 07:00 JICC01.05: Single-Cell Sequencing Atlas of Tumor-associated Microvascular Endothelial Cell in Lung Cancer**
Dawei Yang, China
- 07:15 JICC01.06: From Antibody to Small Molecule: What is the Difference?**
Heather Wakelee, USA
- 07:30 JICC01.07: Oral VEGFR Inhibitor Monotherapy for Lung Cancer: Should We or Should We Not?**
Robert Pirker, Austria
- 07:45 JICC01.08: Target Driver Gene and Target VEGFR: Could Prolong OS?**
Ying Cheng, China
- 08:00 JICC01.09: Small Molecule Anti-VEGFR Combination with PD-1/PD-L1 Blockades: New Hope?**
Shengxiang Ren, China
- 08:15 JICC01.10: Live Panel Discussion**
- 08:25 JICC01.11: Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II-III A EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study**
Caicun Zhou, China
- 08:30 JICC01.12: Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Chinese Advanced Non-Small Cell Lung Cancer**
Xiaomin Niu, China
- 08:35 JICC01.13: Discussant**
Si-Yang Liu, China
- 08:40 JICC01.14: Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy**
Qing Zhou, China
- 08:45 JICC01.15: Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study**
Yan Wang, China
- 08:50 JICC01.16: Discussant: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC**
Xiaorong Dong, China
- 08:55 JICC01.17: Live Panel Discussion**

09:15 – 10:15 **IS01: Satellite CME Symposium by Clinical Care Options:
Advances in Antibody–Drug Conjugates for Treatment
of Non-Small-Cell Lung Cancer**

 CME ACCREDITED BY OTHER PROVIDER

ROOM: SCIENTIFIC PROGRAM AUDITORIUM

- 09:15 **IS01.01:** Welcome, Introduction and Baseline Assessment
- 09:15 **IS01.02:** Introduction to Novel Antibody–Drug Conjugates for Treatment of NSCLC
- 09:15 **IS01.03:** Presentation on Activity of ADCs in Clinical Trials for Lung Cancer
- 09:15 **IS01.04:** Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
- 09:15 **IS01.05:** Panel Discussion and Q&A
- 09:15 **IS01.06:** Summary, Final Thoughts, Post Education Assessment and Q&A

10:30 – 11:30 **IS02: Industry Symposium Sponsored by AstraZeneca: Evolving the Role of
Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 10:30 **IS02.01:** Opening Remarks
Masahiro Tsuboi, Japan
- 10:35 **IS02.02:** Current Strategies for IO Therapy for Unresectable Stage III NSCLC
Glenwood Goss, Canada
- 10:45 **IS02.03:** Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC
Suresh Senan, Netherlands
- 10:55 **IS02.04:** Defining the Role of Immunotherapy in the Treatment of ES-SCLC
Myung-Ju Ahn, Korea
- 11:05 **IS02.05:** Emerging Biomarkers in SCLC
Charles Rudin, USA
- 11:15 **IS02.06:** Panel Discussion / Q&A Panel Discussion

11:45 – 12:45**IS03: Industry Symposium Sponsored by Daiichi-Sankyo:
Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC:
Opportunities and Challenges** **NOT FOR CME CREDIT****ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- | | |
|--------------|--|
| 11:45 | IS03.01: Welcome and Introduction
<i>Tony Mok, Hong Kong</i> |
| 11:50 | IS03.02: Evolving Challenges for the Treatment of Advanced NSCLC
<i>Tony Mok, Hong Kong</i> |
| 12:00 | IS03.03: Emerging ADC Targets for the Treatment of Late-Line NSCLC
<i>Pasi Jänne, USA</i> |
| 12:15 | IS03.04: ADC Therapies as Targeted Treatment Options in Patients With Advanced NSCLC
<i>James Chih-Hsin Yang, Taiwan</i> |
| 12:30 | IS03.05: Interactive Q&A/Panel Discussion |

13:00 – 14:00 **IS04: Industry Symposium Sponsored by Lilly Oncology:
Implementing Precision Oncology in the Clinic:
Diagnostic Challenges and Best Practices**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

Chair(s): Koichi Goto, Japan

- 13:00** **IS04.01: Chair's Welcome**
Koichi Goto, Japan
- 13:04** **IS04.02: Introduction to the Topic – A Brief Overview of the
15-Year Journey of Biomarker Driven Management of NSCLC**
Koichi Goto, Japan
- 13:10** **IS04.03: Developing Best Practices for the Accurate Diagnosis and Treatment of All
Patients With NSCLC – Practical Tips on Optimising Diagnostic Capabilities in the Clinic**
Herbert Loong, Hong Kong
- 13:22** **IS04.04: The Roles of the Oncologist and Pathologist in Providing an Actionable
Diagnosis – Discuss the Role of the Tumour Board / MDT in Implementing Precision Medicine**
Fernando Lopez-Rios, Spain
- 13:34** **IS04.05: Gaining Consensus – An Overview of the IASLC, NCCN
and ESMO Guidelines for Treating and Testing Patients**
Giuseppe Curigliano, Italy
- 13:44** **IS04.06: Panel Discussion and Q&A**
- 14:00** **IS04.07: Symposium Close**
Koichi Goto, Japan

14:15 – 15:15**IS05: Industry Symposium Sponsored by MSD:
Redefining Survival Expectations in Lung Cancer****✗ NOT FOR CME CREDIT****ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- 14:15 IS05.01: Welcome and Introductions**
Rina Hui, Australia
- 14:15 IS05.02: Frontline Immunotherapy Treatment Options in mNSCLC**
Rina Hui, Australia
- 14:30 IS05.03: Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer**
Roy Herbst, USA
- 14:45 IS05.04: Choosing Immunotherapy Alone or in Combination in 1L MNSCLC**
Corey J. Langer, USA
- 15:00 IS05.05: Q&A and Closing Remarks**
Rina Hui, Australia

15:30 – 16:30**IS06: Industry Symposium Sponsored by Novartis:
Novel Frontiers in the Treatment of NSCLC****✗ NOT FOR CME CREDIT****ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- 15:30 IS06.01: Welcome and Introduction**
Yi-long Wu, China
- 15:30 IS06.02: Evolution of the NSCLC Treatment Landscape**
Yi-long Wu, China
- 15:40 IS06.03: Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET?**
Johan Vansteenkiste, Belgium
- 15:55 IS06.04: Panel Discussion**
- 16:07 IS06.05: Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target**
Yasushi Goto, Japan
- 16:21 IS06.06: Q&A**
- 16:29 IS06.07: Closing**
Yi-long Wu, China

16:45 – 17:45 **IS07: Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 16:45 IS07.01: The Past, Present and Future of Biomarker-Driven Advanced NSCLC**
Solange Peters, Switzerland
- 17:15 IS07.02: Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer**
Martin Reck, Germany

18:00 – 20:00 **PL01: Opening Plenary Session** (Japanese, Mandarin, Spanish Translation Available)

 IASLC CME ACCREDITED

ROOM: SCIENTIFIC PROGRAM AUDITORIUM

Chair(s): Yi-long Wu, China & Daniel Tan, Singapore & Ross Soo, Singapore & Tetsuya Mitsudomi, Japan

- 18:00 PL01.01: Welcome Messages & Introduction**
- 18:10 PL01.07: IASLC Distinguished Service and Lectureship Awards (Not for CME Credit)**
- 18:30 PL01.04: Lung Cancer in China**
Wanqing Chen, China
- 18:50 PL01.05: The New WHO Classification of Lung Tumors**
Ming Tsao, Canada
- 19:10 PL01.06: Molecular Epidemiology of Asian Lung Cancer**
Takashi Kohno, Japan
- 19:30 Live Q&A**

Day 2 | Friday, January 29, 2021

07:00 – 09:00 **PL02: Innovation to Bridge Lung Cancer Care Tomorrow**

(Japanese, Mandarin, Spanish Translation Available)



ROOM: SCIENTIFIC PROGRAM AUDITORIUM

Chair(s): Clarissa Mathias, Brazil & James Chih-Hsin Yang, Taiwan

- 07:00 **PL02.03: Human Data Science and the Omics Revolution: What Does It Mean for Oncology Patients?**
Patrick Tan, Singapore
- 07:20 **PL02.05: Challenges in Clinical Application of Precision Medicine: From Targeted Therapies to Immunotherapy: Advanced Non-Small Cell Lung Cancer (NSCLC) as a Model**
David Gandara, USA
- 07:40 **PL02.06: Patient-Directed Innovation, Research and Clinical Trials**
Lisa Goldman, USA
- 08:00 **PL02.07: Translational Medicine: An Engine of Change for Bringing New Technology to the Community**
Michael Boyer, Australia
- 08:20 **PL02.08: Live Q&A**

09:15 – 10:15 **ES01: Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC**



ROOM: SCIENTIFIC PROGRAM AUDITORIUM

- 09:15 **ES01.01: Non-Squamous**
Virote Sriuranpong, Thailand
- 09:35 **ES01.02: Choosing Systemic Therapies after Chemoimmunotherapy – Squamous**
Claudio Martin, Argentina
- 09:55 **ES01.03: Systemic Therapy after Chemo IO in Small Cell Lung Cancer**
Charu Aggarwal, USA

09:15 – 10:15 **OA01: Established Drugs in Special Populations and New Drugs in Established Populations**



ROOM: SCIENTIFIC PROGRAM AUDITORIUM

Chair(s): Noemi Reguart, Spain & Jiuwei Cui, China

- 09:15 OA01.03: Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC**
Saadettin Kilickap, Turkey
- 09:25 OA01.04: Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A**
Fred Hirsch, USA
- 09:35 OA01.05: Discussant**
Edward Garon, USA
- 09:40 OA01.06: Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC**
Gillianne Lai, Singapore
- 09:50 OA01.07: A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC**
Matthew G. Krebs, UK
- 10:00 OA01.08: Discussant**
Justin Gainor, USA
- 10:05 OA01.09: Live Q&A**

09:15 – 10:15 OA02: Updates in Locally Advanced NSCLC**ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Kenichi Suda, Japan & Antoinette Wozniak, USA**

- 09:15 OA02.03:** Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799
Martin Reck, Germany
- 09:25 OA02.04:** Randomized Phase II Trial (RTOG1106) on Midtreatment PET/CT Guided Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Feng-Ming (Spring) Kong, USA
- 09:35 OA02.05:** Local, Regional and Pulmonary Failures in the Randomised PET-Boost Trial for NSCLC Patients
Saskia Cooke, Netherlands
- 09:45 OA02.06:** PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC
Nan Bi, China
- 09:55 OA02.07:** Discussant
You Lu, China
- 10:05 OA02.08:** Live Q&A

10:30 – 11:30 ES02: Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?**ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 10:30 ES02.01:** We Should Choose Treatment Based on PD-L1, TMB and Other Biomarkers
Tiziana Leal, USA
- 10:45 ES02.02:** Immune Checkpoint Blockade for All NSCLC Regardless of PD-L1, TMB or Other Biomarkers
Naiyer Rizvi, USA
- 11:00 ES02.03:** We Should Use IO Alone as Maintenance
Roy Herbst, USA
- 11:15 ES02.04:** We Should Use Combination of IO and Chemotherapy as Maintenance
Marina Garassino, Italy

10:30 – 11:30 ES03: Understanding and Treating Oligometastatic Diseases **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Linda Martin, USA & Yasushi Nagata, Japan**

- 10:30 ES03.03: Characterization and Classification of Oligometastatic Disease**
Matthias Guckenberger, Switzerland
- 10:42 ES03.04: Timing of Systemic Therapy in OMD**
Simon Ekman, Sweden
- 10:54 ES03.05: Surgery as a Component of Local Consolidative Therapy**
Mara Antonoff, USA
- 11:06 ES03.06: Radiation as a Component of Treatment for Oligometastatic Disease**
Kevin Chua, Singapore
- 11:18 ES03.07: Live Q&A**

10:30 – 11:30 OA03: Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Jhanelle Gray, USA & Sukhmani Padda, USA**

- 10:30 OA03.03: Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study**
Alex Spira, USA
- 10:40 OA03.04: Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC**
Helena Yu, USA
- 10:50 OA03.05: Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer**
Atsushi Nakamura, Japan
- 11:00 OA03.06: Discussant**
Ignatius Ou, USA
- 11:10 OA03.07: Live Q&A**

11:45 – 12:45**ES04: Strategies to Increase Cure Rates in Stage III NSCLC:
Optimising Checkpoint Inhibitors and Beyond****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 11:45** **ES04.01: Navigating the Evaluation of Novel Systemic Agents in Stage III Disease**
Karen Kelly, USA
- 12:05** **ES04.02: Biology Guided Adaptive Radiation Therapy (BigART)
and Personalized Immunotherapy in Unresectable Stage**
Feng-Ming (Spring) Kong, Hong Kong
- 12:25** **ES04.03: Extending Durvalumab Maintenance to Special Populations**
Raffaele Califano, UK

11:45 – 12:45**MA01: Novel Systemic Treatment in NSCLC****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Thanyanan Reungwetwattana, Thailand & Julia Rotow, USA**

- 11:45** **MA01.03:** The Role of Gut Microbiome in the Efficacy of Chemotherapy in Patients With Locally Advanced and Advanced Lung Cancer
Zhe Zhao, China
- 11:50** **MA01.04:** A Randomized Study Comparing Cisplatin/Paclitaxel Liposome vs Cisplatin/Gemcitabine in Chemonaïve, Advanced Squamous NSCLC
Caicun Zhou, China
- 11:55** **MA01.05:** Clinical Efficacy and Safety of Pemetrexed With or Without Either Bevacizumab or Pembrolizumab in Patients With Metastatic NSCLC
Wang Chun Kwok, Hong Kong
- 12:00** **MA01.06:** Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIb/IV Squamous NSCLC
Joaquim Bosch-Barrera, Spain
- 12:05** **MA01.07:** Discussant
Benjamin Levy, USA
- 12:10** **MA01.08:** Gemcitabine Plus Capecitabine in Patients With Primary Pulmonary Lymphoepithelioma-Like Carcinoma Previously Treated With Chemotherapy
Ying Liang, China
- 12:15** **MA01.09:** Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PRECOG 0504)
Saad Khan, USA
- 12:20** **MA01.10:** MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations
Hao Sun, China
- 12:25** **MA01.11:** CD47 Agonist Peptide PKHB1 Induced Cell Death in NSCLC via Triggering Endoplasmic Reticulum Stress
Jiani Ye, China
- 12:30** **MA01.12:** Discussant
Will Lockwood, USA
- 12:35** **MA01.13:** Live Q&A

11:45 – 12:45**OA04: New Data from Rare EGFR Alterations** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Hossein Borghaei, USA & Jason Porter, USA**

- 11:45 OA04.03:** Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
Caicun Zhou, China
- 11:55 OA04.04:** Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-Small Cell Lung Cancer
Joshua K. Sabari, USA
- 12:05 OA04.05:** Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
Kazuhiko Nakagawa, Japan
- 12:15 OA04.06:** Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Initial Findings From the SUMMIT Basket Trial
Valentina Boni, Spain
- 12:25 OA04.07:** Discussant
Gillianne Lai, Singapore
- 12:35 OA04.08:** Live Q&A

13:00 – 14:00**IS08: Industry Symposium Sponsored by Janssen Oncology: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs** **NOT FOR CME CREDIT****ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- 13:00 IS08.01:** Welcome and Introductions
Tetsuya Mitsudomi, Japan
- 13:05 IS08.02:** A Light at the End of the Tunnel – Hope for Patients With EGFR Exon20 Insertion Mutations
Byoung Chul Cho, Korea
- 13:25 IS08.03:** The Dawn of a New Era – Novel Treatments for Patients With TKI Resistant Disease With Common EGFR Mutations
Enriqueta Felip, Spain
- 13:45 IS08.04:** Live Q&A: From Information to Transformation – Navigating the Evidence With Experience Sharing in a Live Forum to Improve Patient Care

13:00 – 14:00 **IS09: Industry Symposium Sponsored by Pfizer Oncology: Expert Question Time: ALK+ NSCLC**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 13:00 IS09.01: Welcome and Introduction**
Seng Weng Wong, Singapore
- 13:05 IS09.02: Navigating Recent Clinical Data for ALK+ TKIS**
Thanyanan Reungwetwattana, Thailand
- 13:05 IS09.02: Selecting Treatment and Management of ALK+ NSCLC**
Nick Pavlakis, Australia
- 13:05 IS09.02: The Importance of Managing CNS Disease**
John Chang, USA
- 13:05 IS09.02: The Future of ALK+ NSCLC**
Nir Peled, Israel
- 13:45 IS09.03: Q&A**
- 13:58 IS09.04: Summary, Thank You and Close**
Seng Weng Wong, Singapore

13:00 – 14:00 **IS10: Industry Symposium Sponsored by Bristol Myers Squibb: Thoracic Cancers, New Developments with IO**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 13:00 IS10.01: Welcome and Introductions**
Virginie Westeel, France
- 13:05 IS10.02: What Is the Role of IO in Non-Metastatic NSCLC?**
Virginie Westeel, France
- 13:20 IS10.03: IO in the Treatment of Metastatic NSCLC, Where Are We Now?**
Julie Brahmer, USA
- 13:35 IS10.04: Non-Metastatic and Metastatic NSCLC Q&A**
Virginie Westeel, France & Julie Brahmer, USA
- 13:40 IS10.05: What Is I-O's Impact on the Treatment Paradigm for Mesothelioma Patients?**
Nicolas Girard, France
- 13:55 IS10.06: Mesothelioma Q&A and Closing Remarks**
Nicolas Girard, France & Virginie Westeel, France

14:15 – 15:15**ES05: Value in Lung Cancer, from Screening to Treatment** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Antonio Calles, Spain & Lucinda Morris, Australia**

- 14:15 ES05.03: Radiation Oncology: Value and Innovation**
Fumiko Chino, USA
- 14:25 ES05.04: Lung Cancer Screening in Lower Resource Settings**
Ricardo Santos, Brazil
- 14:35 ES05.05: Age, Gender and Ethnicity: Disparities in Lung Cancer**
Linda Coate, Ireland
- 14:45 ES05.06: Molecular Testing, Targeted Agents and Immunotherapy in Lung Cancer: Are They Worth the Cost?**
Gilberto Lopes, USA
- 14:55 ES05.07: Defining Value and Common Sense in Lung Cancer**
Bishal Gyawali, Canada
- 15:05 ES05.08: Live Q&A**

14:15 – 15:15**ES06: Perioperative Therapy for Early Stage NSCLC** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 14:15 ES06.01: Neoadjuvant IO Monotherapy vs. Chemo-IO**
Mariano Provencio, Spain
- 14:30 ES06.02: Radiation and IO for Operable Early Stage NSCLC**
Suresh Senan, Netherlands
- 14:45 ES06.03: Neoadjuvant and Adjuvant Targeted Therapies**
Wen-zhao Zhong, China
- 15:00 ES06.04: MPR and pCR as Primary Endpoints in Neoadjuvant Trials**
Noriko Motoi, Japan

14:15 – 15:15**MA02: Technological Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Pieter Postmus, Netherlands & David Carbone, USA**

- 14:15 MA02.04: Initial Experience of Hybrid Operating Room Cone-Beam CT Guided Bronchoscopic Microwave Thermal Ablation of Peripheral Small Lung Lesions**
Joyce Chan, Hong Kong
- 14:20 MA02.05: NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the US**
Erik Folch, USA
- 14:25 MA02.07: Discussant**
Kazuhiro Yasufuku, Canada
- 14:40 MA02.08: Computed Tomography Attenuation Value as Considerable Predictor for Malignancy in Clinical T1 Lung Adenocarcinoma**
Zhen-Bin Qiu, China
- 14:30 MA02.09: Analysis of Targets for Lung Stereotactic Body Radiotherapy with Clinical Four Dimension (4D) Computed Tomography (CT)**
Kaile Li, USA
- 14:35 MA02.10: Deriving Pulmonary Perfusion Images from 4DCT Using Deep Learning**
Daniela Lozano, USA
- 14:40 MA02.11: Timing and Site-specific Recurrence Pattern for Resected Lung Adenocarcinoma and Association with Driver Gene Mutations**
Deng Chaoqiang, China
- 14:45 MA02.12: Discussant**
Tobias Peikert, USA
- 14:55 MA02.13: Live Q&A**

15:30 – 16:30**ES07: Pleural Effusion in a Cancer Patient****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 15:30 ES07.01: Radiological Evaluation of Pleural Effusion in a Cancer Patient**
Yeun-Chung Chang, Taiwan
- 15:45 ES07.02: Role of Pleural Fluid Molecular Markers and PD-L1 Testing**
Zoltan Lohinai, Hungary
- 16:00 ES07.03: Malignant Pleural Effusion: Patient Presentation and Diagnostic Pathway**
Laura McNaughton, UK
- 16:15 ES07.04: Chemical Pleurodesis, Indwelling Pleural Catheter or Both for Malignant Pleural Effusion**
Pyng Lee, Singapore

15:30 – 16:30**MA03: New and Revisited Prognostic Factors in Early Stage Lung Cancer****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Peter Licht, Denmark & Eric Lim, UK**

- 15:30 MA03.03: Subsolid Lesions Exceeding 3cm: Do the Ground-Glass Opacity Components Still Matter?**
Fan Fan, China
- 15:35 MA03.04: Gender-specific Radiomics Models for Predicting Recurrence in Early Stage (Stage I, II) Non-Small Cell Lung Cancer (ES-NSCLC) Patients**
Pranjal Vaidya, USA
- 15:40 MA03.05: Hierarchy of Adverse-Prognosis Quality Markers after Curative-Intent Resection of Non-Small Cell Lung Cancer (NSCLC)**
Ray Osarogiagbon, USA
- 15:45 MA03.06: Health-Related Quality of Life in Lung Cancer Patients Undergoing Thoracic Surgery**
Eagan Peters, Canada
- 15:50 MA03.07: Discussant**
Wentao Fang, China
- 15:55 MA03.08: Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer**
Roxana Reyes, Spain
- 16:00 MA03.09: Can Clinical Variables be used to Provide Better Follow up in Stereotactic Ablative Radiotherapy (SABR) Treated Lung Cancers?**
Nathaniel Hatton, UK
- 16:05 MA03.10: Venous Thromboembolism in Lung Cancer Patients: A Population-Based Study**
Gilly Akhtar-Danesh, Canada
- 16:10 MA03.11: Cognitive Bias in Lung Cancer Surgery: The Left Digit Effect**
Chi-fu Yang, USA
- 16:15 MA03.12: Discussant**
Jay Lee, USA
- 16:20 MA03.13: Live Q&A**

15:30 – 16:30 OA05: Value and Quality in Lung Cancer **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Narjust Duma, USA & CS Pramesh, India****15:30 OA05.03: Real-World Global Data on Targeting Epidermal Growth Factor Receptor in Stage III Non-Small Cell Lung Cancer: The Results of the KINDLE Study***Abdul Jazieh, Saudia Arabia***15:40 OA05.04: Clinical and Economic Impact of the Current Testing Scenario for ALK Rearrangements in Spain Compared to a Hypothetical No-Testing Scenario***Ana Laura Ortega Granados, Spain***15:50 OA05.05: Economic Impact of Next-Generation Sequencing (NGS) vs. Single-gene Testing Strategies to Detect Genomic Alterations (GAs) in mNSCLC in Asia***Herbert Loong, Hong Kong***16:00 OA05.06: Lessons Learned from the Victorian Lung Cancer Registry: Opportunities for Quality Improvement in Lung Cancer Management and Outcomes***Rob Stirling, Australia***16:10 OA05.07: Discussant***Doreen Ezeife, Canada***16:20 OA05.08: Live Q&A****16:45 – 17:45 ES08: The Solitary Pulmonary Nodule** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Haja Mohideen Salahudeen Mohamed, Singapore & Martin Phillips, Australia****16:45 ES08.03: Evidence Based Evaluation of the Indeterminant Pulmonary Nodule***Annette McWilliams, Australia***16:57 ES08.04: Biomarkers in the Evaluation of Pulmonary Nodule***James Jett, USA***17:09 ES08.05: Targeting the SPN***Kwun Fong, Australia***17:21 ES08.06: Bronchoscopic Treatment of SPN: Opportunities and Challenges***David Feller-Kopman, USA***17:33 ES08.07: Live Q&A**

16:45 – 17:45**MA04: Health Policy and the Real World****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 16:45 MA04.01: A Comparative Analysis of Lung Cancer Policies Across the Asia-Pacific Region**
Rohini Omkar Prasad, Singapore
- 16:50 MA04.02: Lung Cancer Screening Utilization and Its Correlates in Sexual Minorities: An Analysis of the BRFSS 2018**
Hui Xie, USA
- 16:55 MA04.03: Impact of Frailty Screening and Geriatrician-Led Comprehensive Geriatric Assessment in Frail Older Adults With Lung Cancer**
Isabelle Milner, UK
- 17:00 MA04.04: Assessing the Methodological Quality of Quality-of-Life Analyses in First-Line Lung Cancer Trials: A Systematic Review**
Federico Waisberg, Argentina
- 17:05 MA04.05: Discussant**
Pamela Samson, USA
- 17:15 MA04.06: Clinical Characteristics and Outcomes in Advanced KRAS Mutant NSCLC – A Multi-Centre Collaboration in Asia (ATORG-005)**
Jiyun Lee, Korea
- 17:20 MA04.07: Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations**
Nicolas Girard, France
- 17:25 MA04.08: The Effect of Packed Red Blood Cell Transfusions on the Clinical Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients**
Christopher D'Avella, USA
- 17:30 MA04.09: Impacts of Multidisciplinary Meeting Presentation: Drivers and Outcomes from a Population Registry Retrospective Cohort Study**
Tiffany Lin, Australia
- 17:35 MA04.10: Discussant**
Mark Doherty, Canada

16:45 – 17:45**OA06: Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Sun Min Lim, Korea & Boris Sepesi, USA**

- 16:45** **OA06.03: Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC**
Margarita Majem, Spain
- 16:55** **OA06.04: Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC**
Yi-long Wu, China
- 17:05** **OA06.05: Molecular and Clinical Features Associated with Relapse in Early Stage EGFR-Mutated NSCLC: A Single Institution Knowledge Bank**
Stephanie Pei Li Saw, Singapore
- 17:15** **OA06.06: Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study**
David Carbone, USA
- 17:25** **OA06.07: Discussant**
Haiquan Chen, China
- 17:35** **OA06.08: Live Q&A**

18:00 – 20:00 PL03: Bench to Bedside (Immunology) Tomorrow*(Japanese, Mandarin, Spanish Translation Available)***IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Silvia Novello, Italy & Benjamin Besse, France**

- 18:00 PL03.03: NSCLC and Immune Evasion: Insights from TRACERx**
Charles Swanton, UK
- 18:20 PL03.04: Considering Biology of “Nodes” in Response to PD-1 Blockade in NSCLC**
Matthew Hellmann, USA
- 18:40 PL03.05: Cell Therapy for Solid Tumors**
Prasad Adusumilli, USA
- 19:00 PL03.06: Improving Outcomes with Immunotherapy: Lessons from Other Diseases**
Carolyn Roberts, Canada
- 19:20 PL03.07: Monitoring Disease Through Genomic/Immune Markers**
Qing Zhou, China
- 19:40 PL03.08: Live Q&A**

Day 3 | Saturday, January 30, 2021

07:00 – 09:00 PS01: Presidential Symposium

(Japanese, Mandarin, Spanish Translation Available)



ROOM: SCIENTIFIC PROGRAM AUDITORIUM

Chair(s): Tetsuya Mitsudomi, Japan

- 07:00 PS01.01: Welcome Message**
- 07:02 PS01.02: National Lung Cancer Screening Program in Taiwan: The TALENT Study**
Pan-Chyr Yang, Taiwan
- 07:12 PS01.03: Discussant**
Ugo Pastorino, Italy
- 07:20 PS01.04: International Tailored Chemotherapy Adjuvant Trial: ITACA Trial. Final Results**
Silvia Novello, Italy
- 07:30 PS01.05: Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis**
Jay Lee, USA
- 07:40 PS01.06: Discussant**
Shinichi Toyooka, Japan
- 07:50 PS01.07: CodeBreak 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-Small Cell Lung Cancer**
Bob Li, USA
- 08:00 PS01.08: Discussant**
Pasi Jänne, USA
- 08:08 PS01.09: Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598**
Michael Boyer, Australia
- 08:18 PS01.10: Discussant**
Yun Fan, China
- 08:26 PS01.11: Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial**
Dean Fennell, UK
- 08:36 PS01.12: Discussant**
Rina Hui, Australia
- 08:44 PS01.13: Live Q&A**

09:15 – 10:15 ES09: Biomarkers in Immunotherapy IASLC CME ACCREDITED**ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Katerina Politi, USA & Melina Marmarelis, USA**

- 09:15 **ES09.03: Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy**
Solange Peters, Switzerland
- 09:25 **ES09.04: Individual Genomic Alterations as Predictive Factors for NSCLC Immunotherapy**
Ferdinandos Skoulidis, USA
- 09:35 **ES09.05: Blood-based Biomarkers for Immunotherapy: Applications and Limitations**
Lizza Hendriks, Netherlands
- 09:45 **ES09.06: Immune Contexture and Immunotherapy Response in NSCLC**
Kurt Schalper, USA
- 09:55 **ES09.07: Immunotherapy Biomarkers in NSCLC: Looking into the Future**
Vamsidhar Velcheti, USA
- 10:05 **ES09.08: Live Q&A**

09:15 – 10:15 ES10: Advances in Lung Cancer Screening Through Imaging and Data Analytics IASLC CME ACCREDITED**ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Charlene Liew, Singapore & Yeol Kim, Korea**

- 09:15 **ES10.03: AI-Enabled Lung Cancer Predictive Analytics – The Future of Lung Cancer Screening?**
Zaiyi Liu, China
- 09:27 **ES10.05: Size Isn't Everything – Other High-Risk CT Imaging Features**
Heber MacMahon, USA
- 09:39 **ES10.06: Putting It Together: Current Best Practices in the Evaluation and Follow-Up of the Indeterminate Pulmonary Nodule**
David Baldwin, UK
- 09:51 **ES10.07: Live Q&A**

09:15 – 10:45 ES11: Practice Changing Initiatives IASLC CME ACCREDITED**ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Maria Ftanou, Australia & Anne Fraser, New Zealand**

- 09:15 ES11.03: Managing the Psychological Needs of Patients in a Screening Service**
Lisa Burgess, USA
- 09:27 ES11.04: Assessment of Physical Function in Patients Undergoing Lung-sparing Surgery for Malignant Pleural Mesothelioma**
Simon Ho, USA
- 09:39 ES11.05: Effect of Qigong on Symptom Management of Lung Cancer Patients**
Shirley Siu-yin Ching, Hong Kong
- 09:51 ES11.06: Developing a Care Board**
Manuela Eicher, Switzerland
- 10:03 ES11.07: Preoperative Exercise Training for Patients with Non-Small Cell Lung Cancer**
Catherine Granger, Australia
- 10:18 ES11.08: Live Q&A**

10:30 – 11:30 ES12: Public Health Issues in Lung Cancer Screening IASLC CME ACCREDITED**ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 10:30 ES12.01: Patient Perspective on Lung Cancer Screening and Health Disparities**
Andrea Borondy-Kitts, USA
- 10:45 ES12.02: Defining High Risk**
Martin Tammemagi, Canada
- 11:00 ES12.03: Screening in Indigenous Maori Population**
Sue Crengle, New Zealand
- 11:15 ES12.04: Mobile CT and Effective Screening for Underserved Populations**
Carlijn van der Aalst, Netherlands

10:30 – 11:30**OA07: Immuno-biology and Novel Immunotherapeutics from Bench to Bed** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Jyoti Patel, USA & Aaron Lisberg, USA**

- 10:30 OA07.03: Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients**
Wei Nie, China
- 10:40 OA07.04: LKB1 Deficiency Leads to an “Adenosine-Rich” Tumor Microenvironment by Recruiting Myeloid-Derived Suppressive Cells**
Xue Bai, China
- 10:50 OA07.05: Discussant**
Myung-Ju Ahn, Korea
- 10:55 OA07.06: Interdependence of KRAS and TP53 Mutations in Predicting ICI Efficacy in EGFR/ALKWT Non-Squamous NSCLC: Results From 1129 Patient-Level Data**
Lin Li, China
- 11:00 OA07.07: PARP1 Inhibitors Enhanced IFN γ -Induced PD-L1 Expression in LKB1-Mutant Lung Cancer**
Xue Bai, China
- 11:05 OA07.08: HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy**
Benjamin Besse, France
- 11:10 OA07.09: Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints**
Baohui Han, China
- 11:15 OA07.10: Discussant**
Laura Mezquita, Spain
- 11:20 OA07.11: Live Q&A**

11:45 – 12:45**ES14: Novel Immunotherapy Strategies in NSCLC****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 11:45** **ES14.02: Cellular Therapies in NSCLC**
Melissa Johnson, USA
- 11:57** **ES14.03: Combining Epigenetic Therapy and Immunotherapy in NSCLC**
Julie Brahmer, USA
- 12:09** **ES14.04: Combining Immunotherapy and Anti-Angiogenic Agents**
Enriqueta Felip, Spain
- 12:21** **ES14.05: Combining Targeted Therapies With Immunotherapy**
Daniel Tan, Singapore
- 12:33** **ES14.06: Novel Immunotherapy Targets in NSCLC**
Jie Wang, China

11:45 – 12:45**MA05: Lung Cancer Screening** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Chong Kin Liam, Malaysia & Jacob Sands, USA**

- 11:45 MA05.03: Differential Frequency of Blood Immune Cells as Biomarkers for Risks Assessment in bioMILD Lung Cancer Screening Trial**
Gabriella Sozzi, Italy
- 11:50 MA05.04: Why are Lung Cancer Detection Rates Higher in the Manchester Lung Health Checks than in the National Lung Screening Trial?**
Hilary Robbins, France
- 11:55 MA05.05: Low-Dose Chest Computed Tomographic Screening and Invasive Diagnosis of Pulmonary Nodules for Lung Cancer in Never-Smokers**
Yeon Wook Kim, Korea
- 12:00 MA05.06: Lung Cancer Screening – Cumulative Results from Five UK-Based Programmes**
Haval Balata, UK
- 12:05 MA05.07: Discussant**
Stephen Lam, Canada
- 12:10 MA05.08: Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST**
Chloe Chang Su, USA
- 12:15 MA05.09: Evaluation of Alternative Diagnostic Follow-Up Intervals for Lung-RADs Criteria on the Effectiveness of Lung Cancer Screening**
Mehrad Bastani, USA
- 12:20 MA05.10: Performance of Draft 2020 USPSTF Lung-Cancer Screening Guidelines and Potential for use of Risk Models to Reduce Racial/Ethnic Disparities**
Rebecca Landy, USA
- 12:25 MA05.11: Effect of Lowering the Starting Age for Lung Cancer Screening by Low-Dose Computed Tomography Among Women: A Harm-Benefit Analysis**
Yihui Du, Netherlands
- 12:30 MA05.12: Discussant**
Hui Zhong Chai, Singapore
- 12:35 MA05.13: Live Q&A**

11:45 – 12:45**OA08: Putting the Patient at the Center: Holistic Patient Care** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Csaba Degi, Romania & Yeur-Hur Lai, Taiwan**

- 11:45** **OA08.03: Joint Modeling of Stress and Survival in Patients with Advanced Non-Small Cell Lung Cancer**
Nicole Arrato, USA
- 11:55** **OA08.04: Providing Thoracic Prehabilitation during COVID-19: Review of a Virtual Model**
Stephanie Wynne, UK
- 12:05** **OA08.05: Illness Perception Profiles at Lung Cancer Diagnosis and Physical and Psychological Symptom Trajectories During Treatment**
Thomas Valentine, USA
- 12:15** **OA08.06: How Complex is Fatigue? Occupational Therapy Playing a Lead Role in Fatigue Management**
Pippa Labuc, UK
- 12:25** **OA08.07: Discussant**
Andreas Charalambous, Cyprus
- 12:35** **OA08.08: Live Q&A**

13:00 – 14:00**IS11: Industry Symposium Sponsored by Amgen Oncology: Advancing the Next Frontier of Innovation in Lung Cancer Therapies** **NOT FOR CME CREDIT****ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- 13:00** **IS11.01: Introductions**
- 13:00** **IS11.02: Current Biomarker Landscape in NSCLC**
Stephen Fox, Australia
- 13:20** **IS11.03: Current Unmet Need in KRAS G12C-Mutated NSCLC**
Koichi Goto, Japan
- 13:40** **IS11.04: Emerging Novel Targets for Lung Cancer**
Julie Brahmer, USA

**13:00 – 14:00 IS12: Industry Symposium Sponsored by: Boehringer Ingelheim:
Know Your Patients With NSCLC****✕ NOT FOR CME CREDIT****ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB**

- 13:00 IS12.01: Introduction**
David Gandara, USA
- 13:05 IS12.02: Know How to Test Your Patients**
John Gosney, UK
- 13:15 IS12.03: Know How to Sequence EGFR TKIS**
Barbara Melosky, Canada
- 13:25 IS12.04: Know Your Patients With Uncommon EGFR Mutations**
Satoru Miura, Japan
- 13:35 IS12.05: What's Next for Treatment of Advanced Stage Squamous NSCLC**
David Gandara, USA
- 13:45 IS12.06: Know What's Next for Your Patients: Looking to the Future**
David Gandara, USA
- 13:55 IS12.07: Closing**
David Gandara, USA

13:00 – 14:00 **IS13: Satellite CME Symposium by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances**

 CME ACCREDITED BY OTHER PROVIDER

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 13:00 IS13.01: Welcome, Introduction, and Interactive Quiz**
Daniel Tan, Singapore
- 13:05 IS13.02: When Is the Right Time to Use NGS-Based Liquid Biopsy in Advanced NSCLC?**
Herbert Loong, Hong Kong
- 13:20 IS13.03: Integrating New Targeted Therapy for NSCLC With Rare Oncogenic Drivers Into Clinical Practice**
Terufumi Kato, Japan
- 13:35 IS13.04: Enhancing Immune Checkpoint Inhibition With Bifunctional Antibodies**
Daniel Tan, Singapore
- 13:50 IS13.05: Quiz Questions Revisited and Q&A**
- 13:59 IS13.06: Pearls for Practice**
Daniel Tan, Singapore

14:15 – 15:15 **ES15: Getting All NSCLCs Genotyped: How Can We Get to 100%?**

 IASLC CME ACCREDITED

ROOM: SCIENTIFIC PROGRAM AUDITORIUM

- 14:15 ES15.01: Reflex Genotyping of Advanced NSCLC: The Benefits and the Barriers**
Dara Aisner, USA
- 14:30 ES15.02: Supplementing Tumor Genotyping with ctDNA Genotyping: What Is the Best Approach?**
Fernando Lopez-Rios, Spain
- 14:45 ES15.04: Engaging Lung Cancer Patients in their Molecular Testing**
Andrew Ciupek, USA
- 15:00 ES15.05: Effective and Interpretable Reporting of Genotyping Results**
Stacy Gray, USA

14:15 – 15:15**ES16: Joint Global Lung Cancer Coalition/IASLC Session:
Hot Topics for Advocates****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Matthew Peters, Australia & Satoko Kono Yamaoka, Japan**

- 14:15** **ES16.03: Pro – New Trend and Tool**
Kazuo Hasegawa, Japan
- 14:27** **ES16.04: Campaigning for Lung Cancer Screening – A Tool for Advocates**
Sarah Winstone, UK
- 14:39** **ES16.06: Insights in Global Lung Cancer Patient Experience**
Lillian Leigh, Australia
- 14:51** **ES16.07: Live Q&A**

14:15 – 15:15**MA06: Molecular Developments and Novel Treatments in Mesothelioma and Thymoma****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Harvey Pass, USA & Joachim Aerts, Netherlands**

- 14:15 MA06.03: Phosphorylated Ribosomal Protein S6, Correlation With Characteristics and Clinical Outcome in Patients With MPM: Results from ETOP Mesoscape**
Isabelle Opitz, Switzerland
- 14:20 MA06.04: FGF5 Expression in Malignant Pleural Mesothelioma: Impact on Cell Growth, Cisplatin Resistance and Patient Survival**
Michael Grusch, Austria
- 14:25 MA06.05: Targeting Anti-Apoptotic Mechanisms in Malignant Pleural Mesothelioma**
Ren-Wang Peng, Switzerland
- 14:30 MA06.06: Intracavitary Cisplatin-Fibrin followed by Irradiation After Lung Sparing Surgery in a Rat Model of Malignant Mesothelioma**
Michaela Kirschner, Switzerland
- 14:35 MA06.07: Discussant**
Rabab Gaafar, Egypt
- 14:40 MA06.08: A Safety Study of Avelumab plus SBRT in Malignant Mesothelioma**
Andreas Rimner, USA
- 14:45 MA06.09: Preliminary Safety, Efficacy Results of KN046 (Bispecific Anti-PD-L1/CTLA4) in Subjects With Rare Thoracic Tumors**
Gary Richardson, Australia
- 14:50 MA06.10: A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA**
Margaret Ottaviano, Italy
- 14:55 MA06.11: The Collision of Good Syndrome and Autoimmunity in Thymic Epithelial Tumors**
Giovannella Palmieri, Italy
- 15:00 MA06.12: Discussant**
Jan von der Thüsen, Netherlands
- 15:05 MA06.13: Live Q&A**

15:30 – 16:30**ES17: The New WHO Classification of Lung Tumors****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Ming Tsao, Canada & Dong-Mei Lin, China**

- | | |
|--------------|---|
| 15:30 | ES17.03: Updates in Squamous Cell Carcinoma and Neuroendocrine Tumors of the Lung
<i>Andrew Nicholson, UK</i> |
| 15:42 | ES17.04: Updates in Mesothelioma
<i>Sanja Dacic, USA</i> |
| 15:54 | ES17.05: Updates in Lung Adenocarcinoma, Mucinous and Non-mucinous
<i>Keith Kerr, UK</i> |
| 16:06 | ES17.06: Updates in Molecular Pathology and Genomics of Lung Tumors
<i>Yasushi Yatabe, Japan</i> |
| 16:18 | ES17.07: Live Q&A |

15:30 – 16:30**MA07: Improving Care for People with Lung Cancer: Decision Making, Survivorship, and New Challenges During COVID-19****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 15:30 MA07.01: How Lung Cancer Patients Perceive their Treating Doctors and Engage in Medical Decision-Making: Lessons from Project PRIORITY**
Jill Feldman, USA
- 15:35 MA07.02: Are People with Lung Cancer Satisfied with the Care they Receive?**
Yvonne Nartey, UK
- 15:40 MA07.03: Current Practice of Lung Cancer Survivorship Care: Is a Care Plan Enough?**
Hina Khan, USA
- 15:45 MA07.05: Survivors from Anti-PD-(L)1 Immunotherapy in NSCLC: Clinical Features, Survival Outcomes and Long-term Toxicities**
Melinda Hsu, USA
- 15:50 MA07.06: Discussant**
Haryana Dhillon, Australia
- 16:02 MA07.07: Assessing the Impact of the COVID-19 Pandemic on Patient Advocacy and Support Organisations**
Matthew Peters, Australia
- 16:07 MA07.08: Needs Assessment of Lung Cancer Patients & Caregivers in the Post-Shelter-in-Place Era in the United States during COVID-19**
Jessica Selig, USA
- 16:12 MA07.09: Lung Cancer Patients Survey Under COVID-19 Epidemic**
Kazuo Hasegawa, Japan
- 16:17 MA07.10: Discussant**
Amy Moore, USA

15:30 – 16:30**OA09: Mesothelioma from Pathogenesis to Therapy** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Bruce Robinson, Australia & Steven Kao, Australia**

- 15:30 OA09.03: MESOMICS Project: Molecular Characterization of Malignant Pleural Mesothelioma Using a Multi-Omic Approach**
Lise Mangiante, France
- 15:40 OA09.04: The Course of the Risk of Mesothelioma in Karain Cohort With Erionite Exposure Living in Stockholm: No Erionite Exposure No Mesothelioma**
Muzaffer Metintas, Turkey
- 15:50 OA09.05: Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician's Choice of First-line Platinum Chemotherapy**
Kathleen Kerrigan, USA
- 16:00 OA09.06: Nivolumab in Recurrent Malignant Pleural Mesothelioma: Real-World Data From Expanded Access Program In The Netherlands**
Robert Belderbos, Netherlands
- 16:10 OA09.07: Discussant**
Thomas John, Australia
- 16:20 OA09.08: Live Q&A**

16:45 – 17:45**ES18: The Future of Immunotherapy in Unresectable Mesothelioma** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 16:45 ES18.01: Immunotherapy – Current State of Play (Concentrating on Current Data for First Line and Salvage Strategies)**
Sanjay Popat, UK
- 17:00 ES18.02: Molecular Profiling as Biomarker for Checkpoint Inhibitors in Mesothelioma**
Nicola Waddell, Australia
- 17:15 ES18.03: Checkpoint Inhibitors – How to Combine and Which Combination is Most Promising**
Anna Nowak, Australia
- 17:30 ES18.04: BAP1 as a Biomarker – Implications for Treatment (Including Immunotherapy)**
Michele Carbone, USA

16:45 – 17:45 ES19: Patient-Reported Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients**ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Catherine Holliday, Switzerland & Vanessa Beattie, UK**

- 16:45 ES19.03: Understanding the Feasibility of Patient Reported Outcomes**
Karla Gough, Australia
- 17:00 ES19.04: Improving Lung Cancer Survival Through Tracking of Patient Reported Outcomes**
Massimo Di Maio, Italy
- 17:15 ES19.05: Incorporating Patient Reported Outcomes into the Lung Cancer Registry**
Jennifer King, USA
- 17:30 ES19.06: Live Q&A**

16:45 – 17:45**MA08: Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma****IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Keith Kerr, UK & Teh-Ying Chou, Taiwan**

- 16:45 MA08.03: Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling**
Wallace Akerley, USA
- 16:50 MA08.04: LIPI and Outcomes of Durvalumab as Consolidation Therapy after ChRT in Patients with Locally-Advanced NSCLC**
Mariona Riudavets, France
- 16:55 MA08.05: High Concordance in Scoring PD-L1 in NSCLC Using the Roche Digital Pathology uPath system and PD-L1 Assessment Algorithm**
Alexander Haragan, UK
- 17:00 MA08.06: Stratifying PD-L1 Expression Level Based on Multimodal Genomic Features for the Prediction of Immunotherapy Benefit in NSCLC**
Yue Li, China
- 17:05 MA08.07: Discussant**
Wendy Cooper, Australia
- 17:10 MA08.08: Implementation of Diagnostic Biomarker Testing in Lung Cancer: Real-World Data in Japan**
Yasushi Yatabe, Japan
- 17:15 MA08.09: Clinical Management of Lung Adenocarcinoma Patients With HER2 V659E Mutation**
Ziqi Jia, China
- 17:20 MA08.10: LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis**
Philip Mack, USA
- 17:25 MA08.11: Identification of Clinical Features to Predict the Consistency of Mutational Profiles Obtained From Plasma and Tissue of Advanced NSCLC Patient**
Yuansheng Zang, China
- 17:30 MA08.12: Discussant**
Lukas Bubendorf, Switzerland
- 17:35 MA08.13: Live Q&A**

18:00 – 20:00 PS02: Presidential Symposium (Re-Broadcast)*(Japanese, Mandarin, Spanish Translation Available)***IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Tetsuya Mitsudomi, Japan**

- 18:00 PS02.01: Welcome Message**
- 18:02 PS02.02: National Lung Cancer Screening Program in Taiwan: The TALENT Study**
Pan-Chyr Yang, Taiwan
- 18:12 PS02.03: Discussant**
Ugo Pastorino, Italy
- 18:20 PS02.04: International Tailored Chemotherapy Adjuvant Trial: ITACA Trial. Final Results**
Silvia Novello, Italy
- 18:30 PS02.05: Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis**
Jay Lee, USA
- 18:40 PS02.06: Discussant**
Shinichi Toyooka, Japan
- 18:50 PS02.07: odeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer**
Bob Li, USA
- 19:00 PS02.08: Discussant**
Pasi Jänne, USA
- 19:08 PS02.09: Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598**
Michael Boyer, Australia
- 19:18 PS02.10: Discussant**
Yun Fan, China
- 19:26 PS02.11: Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial**
Dean Fennell, UK
- 19:36 PS02.12: Discussant**
Rina Hui, Australia
- 19:44 PS02.13: Live Q&A**

Day 4 | Sunday, January 31, 2021

07:00 – 09:00 **PL04: A Vision for Clinical Trials in 2020 and Beyond**

(Japanese, Mandarin, Spanish Translation Available)



ROOM: SCIENTIFIC PROGRAM AUDITORIUM

Chair(s): Heather Wakelee, USA & Myung-Ju Ahn, Korea

- 07:00 **PL04.03: Evolving Challenges in Drug Development**
Bruce Johnson, USA
- 07:15 **PL04.04: Implementing New Paradigms for Delivering Radiation Therapy in the Clinic**
Billy Loo, USA
- 07:30 **PL04.05: Uptake of RWD and RWE in Clinical Trial Design**
Xiaoyuan Chen, China
- 07:45 **PL04.06: Diversifying Clinical Trial Inclusion Criteria: Current Challenges and Potential Solutions**
Jill Feldman, USA
- 08:00 **PL04.07: Looking Into the Future of Drug Development**
Jean Charles Soria, France
- 08:15 **PL04.08: The Future of Clinical Trials – The Surgical Perspective**
Masahiro Tsuboi, Japan
- 08:30 **PL04.09: Live Q&A**

09:15 – 10:15 ES20: Evidence Base for Symptom Management**ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 09:15 ES20.01: What Symptoms Do Patients Experience in the Lung Cancer Illness Trajectory?**
Janelle Yorke, UK
- 09:25 ES20.02: Breathlessness: Multi-Pronged Approach for a Multi-Dimensional Symptom**
Masanori Mori, Japan
- 09:35 ES20.03: Fatigue**
Deidre Morgan, Australia
- 09:45 ES20.04: Cancer Cachexia: Pathophysiology and Treatment**
David Currow, Australia
- 09:55 ES20.05: Anxiety and Depression: Association with Patient Outcomes and Management Approaches**
Erica Glass, USA

09:15 – 10:15 ES21: The “How To” of Modern Tobacco Control**ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Sita Andarini, Indonesia & Henry Marshall, Australia**

- 09:15 ES21.03: The Specifics of Smoking Cessation for Cancer Patients**
Magdalena Cedzynska, Poland
- 09:30 ES21.04: Starting a Smoking Cessation Service in Cancer Clinics: Added Urgency in the Time of COVID-19**
Matthew Steliga, USA
- 09:45 ES21.05: Global Blindspots in Tobacco Control – Time for the Tobacco Free Generation Endgame**
Heng Nung Koong, Singapore
- 10:00 ES21.06: Live Q&A**

09:15 – 10:15**MA09: Prognosis and Staging** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Young Tae Kim, Korea & Valerie Rusch, USA**

- 09:15 MA09.03: Comparative Effectiveness of a Lymph Node Collection Kit Versus 'Heightened Awareness' on Lung Cancer Surgery Quality and Outcomes**
Ray Osarogiagbon, USA
- 09:20 MA09.04: A Tool to Estimate the Probability of Nodal Under-Staging Based on the Number of Examined Nodes: A SEER Study in Lung Cancer**
Kay See Tan, USA
- 09:25 MA09.05: A Comparison of the Number of Involved Nodal Stations With Currently Used Pathological N Stage on Predicting Prognosis in NSCLC**
Long Xu, China
- 09:30 MA09.06: The Influence of the Number of Lymph Nodes Removed on the Accuracy of a Newly Proposed N Descriptor Classification in Patient with NSCLC**
Dariusz Dziedzic, Poland
- 09:35 MA09.07: Discussant**
Kenji Suzuki, Japan
- 09:40 MA09.08: Improving Overall Survival in Non-Small Cell Lung Cancer by Reducing R-Uncertain Resections With a Lymph Node Specimen Collection Kit**
Matthew Smeltzer, USA
- 09:45 MA09.09: Positive EGFR Mutation Status is a Risk of Recurrence in pN0-1 Lung Adenocarcinoma When Considering pStage and Histological Subtype**
Masaoki Ito, Japan
- 09:50 MA09.10: Location of Lymph Nodes Missed after Invasive Mediastinal Staging in a Well-Staged Non-Small Cell Lung Cancer Cohort**
Meredith Ray, USA
- 09:55 MA09.11: Surgical Outcome of Lung Cancer Volumetric Screening According to Ldct Intervals in Two Prospective Trials**
Ugo Pastorino, Italy
- 10:00 MA09.12: Discussant**
Ana Gelatti, Brazil
- 10:05 MA09.13: Live Q&A**

10:30 – 11:30**ES22: Quality of Life** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Grace Yang, Singapore & Natasha Leighl, Canada**

- 10:30 ES22.03: Quality of Life – Does It Really Matter**
Natasha Leighl, Canada
- 10:42 ES22.04: Measuring Quality of Life – The Making of the Singapore Caregiver Quality of Life Scale**
Yin Bun Cheung, Singapore
- 10:54 ES22.05: Strategies to Improve Quality of Life**
Andrea Bezjak, Canada
- 11:06 ES22.06: Early Integration of Palliative Care Is the Answer to Improving Quality of Life**
Marie Bakitas, USA
- 11:18 ES22.07: Live Q&A**

10:30 – 11:30**ES23: Beyond the TNM** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 10:30 ES23.01: Pro-Con: Non-Anatomic Parameters Should Be Included Into Current TNM Classification (Genetic, Molecular, Histology, etc)**
Ray Osarogiagbon, USA
- 10:42 ES23.02: Pro-Con: Non-Anatomic Parameters Should Not Be Included into Current TNM Classification (Genetic, Molecular, Histology, etc)**
Hisao Asamura, Japan
- 10:54 ES23.03: Revision of N Descriptors Should Include Microscopic vs Bulky Mets, # of Mets vs Stations, Nodal Zones, etc**
James Huang, USA
- 11:06 ES23.04: Revision of N Descriptors Should NOT Include Microscopic vs Bulky Mets, # of Mets vs Stations, Nodal Zones, etc**
Isabelle Opitz, Switzerland
- 11:18 ES23.05: GGN Issues**
Nan Wu, China

10:30 – 11:30**OA10: The Slow Pandemic – Tobacco Control in the Prevention of Lung Cancer** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Emily Stone, Australia & Mike Cummings, USA**

- 10:30** **OA10.03: Reporting of Tobacco Use and Impact on Outcomes in Cancer Cooperative Group Clinical Trials: A Systematic Scoping Review**
Lawson Eng, Canada
- 10:40** **OA10.04: Testing ‘Hardening Hypotheses’: Hard-Core Smoking and Heaviness of Smoking Index in 30 Global Adult Tobacco Survey Countries**
chandrashekhara Sreeramareddy, Malaysia
- 10:50** **OA10.05: Global Patterns and Trends in Lung Cancer Incidence: A Population-Based Study**
Yanting Zhang, China
- 11:00** **OA10.06: Achieving the Tobacco Free Generation Endgame: #1 Reimagining the Implementation of Better Mass Tobacco Prevention Education**
Lynn Ong, Singapore
- 11:10** **OA10.07: Discussant**
Douglas Arenberg, USA
- 11:20** **OA10.08: Live Q&A**

11:45 – 12:45 ES24: Challenges in Tobacco Control IASLC CME ACCREDITED**ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 11:45 ES24.01: Heat-Not-Burn and Other Alternatives Tobacco Products – Is This the Answer?**
Carolyn Dresler, USA
- 12:05 ES24.02: The Rationale for FDA (and EMA) Regulatory Review of Tobacco Use in Clinical Trials**
Stephanie Land, USA
- 12:25 ES24.03: Current Status of Smoking Cessation with Heated Tobacco Products Use in Japan**
Takahiro Tabuchi, Japan

11:45 – 12:45 ES25: Unmet Need Issues of Current TNM IASLC CME ACCREDITED**ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Ramon Rami-Porta, Spain & Paula Ugalde, Canada**

- 11:45 ES25.04: Multiple Pulmonary Lesions: Metastasis vs Multiple Primaries, From Martini's Criteria to Molecular Profiling**
Erik Thunnissen, Netherlands
- 11:55 ES25.05: LN Map**
Shun-ichi Watanabe, Japan
- 12:05 ES25.06: Special Issues: Subsolid Tumors**
Philippe Joubert, Canada
- 12:15 ES25.07: Essential TNM**
David Harpole, USA
- 12:25 ES25.08: Live Q&A**

11:45 – 12:45**MA10: Assessing and Managing Supportive Care Needs****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Masanori Mori, Japan & Pippa Labuc, UK**

- 11:45 MA10.03: The FITNESS Study: An Innovative Approach to Assessing Disability in Older Adults with Lung Cancer**
Nicole Arrato, USA
- 11:50 MA10.04: A New Predictive Score for Venous Thromboembolism Associated with Advanced Lung Cancer: A Multicenter, Prospective Study (Rising-VTE/NEJ037)**
Yukari Tsubata, Japan
- 11:55 MA10.05: Distress Screening in Lung Cancer Patients Using a Distress Thermometer: A Meta-Analysis**
Lemeng Zhang, China
- 12:00 MA10.06: Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers**
Mohana Roy, USA
- 12:05 MA10.07: Discussant**
Alexandre Chan, USA
- 12:10 MA10.08: Omega-3 Fatty Acids for Cancer Cachexia in Advanced Non-Small Cell Lung Cancer: A Meta-analysis**
Alfredo Chua, Philippines
- 12:15 MA10.09: Efficacy of Thalidomide in the Treatment of Extensive Stage SCLC with CACS**
Xi Fang Wang, China
- 12:20 MA10.10: Lung Cancer Admission Rates During the COVID-19 Pandemic to a Tertiary Cancer Centre in South East Scotland**
Felix Torrance, UK
- 12:25 MA10.11: End of Life Health Resource Utilization for Limited English Proficient Patients with Advanced NSCLC**
Bonnie Leung, Canada
- 12:30 MA10.12: Discussant**
Grace Yang, Singapore
- 12:35 MA10.13: Live Q&A**

13:00 – 14:00 **IS14: Industry Symposium Sponsored by AstraZeneca:
Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC:
The MDT Perspective**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 13:00** **IS14.01: Welcome and Introduction**
Edward S. Kim, USA
- 13:05** **IS14.02: Advances and Challenges in EGFR-Mutated NSCLC**
Edward Kim, USA
- 13:15** **IS14.03: Panel Discussion: The MDT Approach to Managing EGFR-Mutated NSCLC**
Edward Kim, USA, Alessandro Brunelli, UK, Yoonla Choi, Democratic People's Republic of Korea, Hidehito Horinouchi, Japan & Karen Reckamp, USA
- 13:45** **IS14.04: Q&A**

13:00 – 14:00 **IS15: Industry Symposium Sponsored by Amoy:
Lung Cancer Biomarker Panel Testing**

 NOT FOR CME CREDIT

ROOM: INDUSTRY SYMPOSIUM AUDITORIUM VIA INDUSTRY HUB

- 13:00** **IS15.01: Opening Remarks**
Tony Mok, Hong Kong
- 13:03** **IS15.02: Biomarker for Lung Cancer: Right Patient, Right Time, Right Test**
Tony Mok, Hong Kong
- 13:21** **IS15.03: Biomarker Panel Testing: PCR Panel vs NGS Panel**
Koichi Goto, Japan
- 13:39** **IS15.04: Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC**
Caicun Zhou, China
- 13:57** **IS15.05: Closing Remarks**
Tony Mok, Hong Kong

14:15 – 15:15**ES26: Future Horizons in the Management of Small Cell Lung Cancer** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 14:15** **ES26.01: DDR/PARP as a Target**
Li Zhang, China
- 14:30** **ES26.02: Antibody Drug Conjugates and T-cell Engagers**
Charles Rudin, USA
- 14:45** **ES26.03: Genomics of Lung Cancer**
Julie George, Germany
- 15:00** **ES26.04: Novel Radiation Strategies**
Benjamin Lok, Canada

14:15 – 15:15**ES27: Heterogeneity, Metastases and Resistance** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Pan-Chyr Yang, Taiwan & Wai Leong Tam, Singapore**

- 14:15** **ES27.03: Genomic Heterogeneity**
Mariam Jamal-Hanjani, UK
- 14:27** **ES27.04: Phenotypic Heterogeneity**
Tuomas Tammela, USA
- 14:39** **ES27.05: Heterogeneity and Metastases**
Priscilla Brastianos, USA
- 14:51** **ES27.06: Heterogeneity and Drug Resistance**
Seji Yano, Japan
- 15:03** **ES27.07: Live Q&A**

14:15 – 15:15**MA11: Expanding Targetable Genetic Alterations in NSCLC****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Shirish Gadgil, USA & Koichi Goto, Japan**

- 14:15 MA11.03:** Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
Egbert Smit, Netherlands
- 14:20 MA11.04:** Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
Robin Cornelissen, Netherlands
- 14:25 MA11.05:** Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
Paul Paik, USA
- 14:30 MA11.06:** Discussant
Mark Awad, USA
- 14:35 MA11.07:** Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
Byoung Chul Cho, Korea
- 14:40 MA11.08:** Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
Julien Mazieres, France
- 14:45 MA11.09:** Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
Daniel Tan, Singapore
- 14:50 MA11.10:** Lung Master Protocol (Lung-MAP) Next Generation Sequencing Analysis of Advanced Squamous Cell Cancers (SWOG S1400)
David Kozono, USA
- 14:55 MA11.11:** Discussant
David Planchard, France
- 15:00 MA11.12:** Live Q&A

15:30 – 16:30**ES28: Targeting KRAS** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM**

- 15:30 ES28.01: Biology of KRAS Targeting Agents**
Tetsuya Mitsudomi, Japan
- 15:42 ES28.02: Clinical Data for KRAS G12C Inhibitors**
Hye Ryun Kim, Korea
- 15:54 ES28.03: Mechanisms of Resistance to KRAS G12C Inhibitors**
Chiara Ambrogio, Italy
- 16:06 ES28.04: Emerging Mechanisms to Target KRAS Directly**
Misako Nagasaka, USA
- 16:18 ES28.05: Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors**
Miriam Molina-Arcas, UK

15:30 – 16:30**ES29: Advances in Omics – Next Generation** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Maximilian Diehn, USA & Nick Pavlakis, Australia**

- 15:30 ES29.04: Proteogenomics of Lung Cancer**
Ramaswamy Govindan, USA
- 15:42 ES29.05: Genomics and Artificial Intelligence**
Obi Griffith, USA
- 15:54 ES29.06: Radiomics**
Anant Madabhushi, USA
- 16:06 ES29.07: Live Q&A**

15:30 – 16:30**OA11: A Symphony of Progress** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Pilar Garrido, Spain & Luis Paz-Ares, Spain**

- 15:30 OA11.03:** A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immune Therapy Against DLL3, in SCLC
Taofeek Owonikoko, USA
- 15:40 OA11.04:** Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial
Santiago Ponce-Aix, Spain
- 15:50 OA11.05:** Whole Exome Sequencing Reveals the Potential Role of Hereditary Predisposition in Small Cell Lung Cancer, a Tobacco-Related Cancer
Nobuyuki Takahashi, USA
- 16:00 OA11.06:** IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer
Martin Reck, Germany
- 16:10 OA11.07:** Discussant
Stephen Liu, USA
- 16:20 OA11.08:** Live Q&A

16:45 – 17:45**ES30: What is the Best Treatment Strategy to Target Rare Mutations** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Rolf Stahel, Switzerland & Yiqing Huang, Singapore**

- 16:45 ES30.03:** Multiple Generations of TKIs Which Target the ErbB Receptors
Alexander Drilon, USA
- 16:57 ES30.04:** Monoclonal Antibodies Targeting the ErbB Receptors
Byoung Chul Cho, Korea
- 17:09 ES30.05:** Combination Therapy Approaches to Target Rare Mutations (ErbB Receptors and KRAS pG12C) in NSCLC
Toshio Shimizu, Japan
- 17:21 ES30.06:** Antibody Drug Conjugates and Other Novel Therapies Targeting ErbB Receptors
Bob Li, USA
- 17:33 ES30.07:** Live Q&A

16:45 – 17:45**MA12: Controversies Old and New** **IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Fiona Blackhall, UK & Lynette Sholl, USA**

- 16:45** **MA12.03: Prognostic Value of Clinical Staging According to TNM in SCLC Patients; A Real-World SEER Database Analysis**
Eduarne Arriola Aperribay, Spain
- 16:50** **MA12.04: Should the Role of Surgery Be Re-Evaluated in Small Cell Lung Cancer?**
Sara Ricciardi, Italy
- 16:55** **MA12.05: Is there a Role for Surgery in Stage I Small Cell Lung Cancer? A National VA Database Analysis**
Ibrahim Azar, USA
- 17:00** **MA12.06: A Study of the Prognosis of Patients With Limited-Stage SCLC Who Did Not Receive Prophylactic Cranial Irradiation After Chemoradiotherapy**
Xiao Hu, China
- 17:05** **MA12.07: Discussant**
Anne Chiang, USA
- 17:10** **MA12.08: Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma**
Chan-Yuan Zhang, China
- 17:15** **MA12.09: Retrospective Analysis of DIPNECH and Carcinoid Tumorlets as Precursors to Invasive Pulmonary Carcinoid Tumors**
Thomas Yang Sun, USA
- 17:20** **MA12.10: Treatment and Survival Differences in Patients with Large Cell Neuroendocrine Carcinoma of the Lung: A SEER Database Analysis**
Jing-Hua Chen, China
- 17:25** **MA12.11: What Regimen Should Be Chosen for Pulmonary Large Cell Neuroendocrine Carcinoma? A Systemic Review and Meta-Analysis**
Jiaxi He, China
- 17:30** **MA12.12: Discussant**
Anne-Marie Dingemans, Netherlands
- 17:35** **MA12.13: Live Q&A**

16:45 – 17:45 **MA13: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment**


IASLC CME ACCREDITED

ROOM: SCIENTIFIC PROGRAM AUDITORIUM

- 16:45 MA13.01: A Validation Study on DNA Repair Gene Variant for Lung Cancer Survival Prediction after Chemoradiation: A Secondary Analysis for RTOG-0617 Study**
Weili Wang, USA
- 16:50 MA13.02: Novel Non-Invasive Radiomic Signatures Extracted from Radiographic Images can Predict Response to Systemic Treatment in Small Cell Lung Cancer**
Prantesh Jain, USA
- 16:55 MA13.03: DNA Damage Response Gene Alterations and their Association with Tumor Mutation Burden and Response to Immunotherapy in NSCLC and SCLC**
Zihuang Li, China
- 17:00 MA13.04: Harnessing Natural Killer Cells to Treat Metastatic Small Cell Lung Cancer**
Sarah Best, Australia
- 17:05 MA13.05: Discussant**
Saiama Waqar, USA
- 17:15 MA13.06: Deciphering the Characterization of Tumor Microenvironment in EGFR-Mutated Non-Small Cell Lung Cancer**
Meng Qiao, China
- 17:20 MA13.07: Structural Classification of Atypical EGFR Mutations Identifies 4 Major Subgroups with Distinct Patterns of Drug Sensitivity**
Jacquelyne Robichaux, USA
- 17:25 MA13.08: Genomic and Transcriptomic Features of Distinct Resistance Trajectories in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)**
Aaron Tan, Singapore
- 17:30 MA13.09: Heterogeneous Genomic Evolution and Immune Microenvironments in Metastatic Lung Cancer**
Wen-Fang Tang, China
- 17:35 MA13.10: Discussant**
Jin-Yuan Shih, Taiwan

18:00 – 20:00 PL05: Affordable and Accessible Lung Cancer Care*(Japanese, Mandarin, Spanish Translation Available)***IASLC CME ACCREDITED****ROOM: SCIENTIFIC PROGRAM AUDITORIUM****Chair(s): Yi-long Wu, China & Ross Soo, Singapore & Daniel Tan, Singapore & David Harpole, USA**

- 18:00 PL05.06: Non-Invasive Biomarkers in Lung Cancer Screening: Achievements, Promises and Challenges**
Luis Montuenga, Spain
- 18:15 PL05.07: Legislating Tobacco Out of Business**
Wanda de Kanter, Netherlands
- 18:30 PL05.08: How to Double Cancer Cure Rate by 2025**
Giorgio Scagliotti, Italy
- 18:45 PL05.09: Cancer Treatment in Asia – What is Available, and Is It Effective Enough?**
Sumitra Thongprasert, Thailand
- 19:00 PL05.10: A TeleTrial Model in Lung Cancer – Improving Access & Outcomes**
Melanie Poxton, Australia
- 19:15 PL05.11: Live Q&A**
- 19:45 Closing Remarks and Invitation to WCLC 2021**

Featured Posters

✕ NOT FOR CME CREDIT

FP01	Early Stage/Localized Disease
FP02	Health Services Research/Health Economics
FP03	Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
FP04	Locoregional and Oligometastatic Disease
FP05	Mesothelioma, Thymoma and Other Thoracic Malignancies
FP06	Palliative and Supportive Care
FP07	Pathology
FP09	Screening and Early Detection
FP10	Small Cell Lung Cancer/NET
FP12	Tumor Biology and Systems Biology
FP13	Immunotherapy (Phase II/III Trials)
FP14	Targeted Therapy – Clinically Focused

FP01: Early Stage/Localized Disease NOT FOR CME CREDIT

-
- FP01.01:** Uniportal Versus Multiportal Video-Assisted Thoracoscopic Surgery for Non-Small Cell Lung Cancer: An Updated Meta-Analysis
Maria Fergadi, Greece
- FP01.02:** The Efficacy of Postoperative Radiotherapy in IIIA-N2 Non-Squamous NSCLC with Different EGFR Mutation Status: A Retrospective Analysis
Fang Wu, China
- FP01.03:** Genetic Predisposition for Pre-Invasive Lung Adenocarcinoma Manifesting as Ground-Glass Nodules with Family History of Lung Cancer
Rui Fu, China
- FP01.04:** BTCRC LUN19-396: Adjuvant Chemotherapy Plus Atezolizumab in Stage IB-IIIA Resected NSCLC and Clearance of ctDNA
Melissa Yan, USA
- FP01.05:** The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC
Andrew Piper-Vallillo, USA

FP02: Health Services Research/Health Economics

 NOT FOR CME CREDIT

-
- FP02.01:** Patient Responses to Passive Enrollment into a Large, Pragmatic Clinical Trial: A Qualitative Content Analysis
Emily Rozema, USA
- FP02.02:** Real-World Outcomes Among Advanced Non-Small Cell Lung Cancer Patients Re-Treated with Immunotherapy in the US
Alex Spira, USA
- FP02.03:** Changing Survival and Treatment Patterns in Patients Aged 80 or Older with Stage IV Non-Small Cell Lung Cancer (NSCLC)
Matthew Anaka, Canada
- FP02.04:** NSCLC with TPS>90% could have Higher Possibility of Causing Severe irAE; Retrospective Investigation in one Institution
Yuki Akazawa, Japan
- FP02.05:** Value-Based Healthcare Study (VBHC) for Treating Lung Cancer in Victoria, Australia
Susan Harden, Australia
- FP02.06:** Implementation of a Lung Cancer Value-Based Care Framework in a Low and Middle-Income Country Institution
Clarissa Baldotto, Brazil
- FP02.07:** Predicting the Future: Using AI to Predict Treatment Outcomes in Lung Cancer
Lawek Berzenji, Belgium
- FP02.08:** Importance of Stakeholder Engagement in a Patient-Centered Outcomes Research Trial
Visanee Musigdilok, USA
- FP02.09:** Effects of Chinese Reimbursement Policy on Molecular Diagnosis and Therapy of NSCLC from the Northern Part of Henan Province
Min Zhang, China
- FP02.10:** Predictors of Moderate-to-Severe Symptoms in Stage IV NSCLC: A Population-Based Study of Patient Reported Outcomes
Michael Tjong, Canada

FP03: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) NOT FOR CME CREDIT**FP03.01: Immune Microenvironment Features and Efficacy of PD-1/PD-L1 Blockade in Non-Small-Cell Lung Cancer Patients with EGFR or HER2 Exon 20 Insertions**

Yun Fan, China

FP03.02: Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Min Hee Hong, Korea

FP03.03: Clinical Activity of BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer

Neal Ready, USA

FP03.04: Selinexor can Inhibit Nuclear Export of HMGB1, a Negative Predictive Marker for Immunotherapy Response

Jillian Bracht, Spain

FP03.05: TLR9 Agonist CMP-001 Plus Atezolizumab +/- Radiation Therapy in Patients With PD-1 Blockade Resistant Advanced NSCLC

Marcelo Negrao, USA

FP04: Locoregional and Oligometastatic Disease

 NOT FOR CME CREDIT

FP04.01: Heart Dose is a Dosimetric Predictor of Overall Survival in Patients with NSCLC Undergoing Post-Operative Radiation Therapy

Annemarie Shepherd, USA

FP04.02: Feasibility of Radiotherapy Planning in the First 50 Patients Recruited to the ADSCaN Clinical Trial

Romaana Mir, UK

FP04.03: Dynamic Liquid Biopsy for Selecting Advanced NSCLC Patients for Primary Tumor Resection After Targeted Therapy

Weitao Zhuang, China

FP04.04: EGFR Mutations Predict Superior Survival of NSCLC Patients with Oligometastatic Disease Treated with Local Consolidative Therapy

Ahsan Farooqi, USA

FP04.05: Anti-Vascular Drug Anlotinib Combined With SRS Versus SRS Alone for Brain Metastases From NSCLC: A Case Control Study

Hongqing Zhuang, China

FP05: Mesothelioma, Thymoma and Other Thoracic Malignancies

 NOT FOR CME CREDIT

FP05.01: Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy

Kathleen Kerrigan, USA

FP05.02: An Early Detection and Prognostic Blood Biomarkers Signature for Malignant Pleural Mesothelioma Based on Targeted Proteomics

Ferdinando Cerciello, USA

FP05.03: Association Between Baseline Tumor Thickness and Response to Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma

Nicolas Zhou, USA

FP05.04: Outcomes of Resected Thymic Epithelial Tumors (TET), Insights from RYTHMIC

Jose Carlos Benitez, France

FP06: Palliative and Supportive Care

 NOT FOR CME CREDIT

FP06.01: Discrete Choice Experiment to Estimate Physicians' Preferences in Terms of G-CSF use for Febrile Neutropenia Primary and Secondary Prophylaxis

Christos Chouaïd, France

FP06.02: Treatment Decision-Making and Decisional Support Experiences Among Lung Cancer Patients and Survivors

Kelly Clark, USA

FP06.03: Treatment Past Progression with Second Line Nivolumab in Advanced Stage NSCLC

Zamzam Al-Hashami, Canada

FP06.04: Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic

Domenico Galetta, Italy

FP07: Pathology

✖ NOT FOR CME CREDIT

FP07.01: Dysbiosis of Gut Microbiota Suppress the Brain Metastasis of Non-Small Cell Lung Cancer

Xiaorong Dong, China

FP07.02: Deep Learning Based Analysis of Multiplex IHC Accurately Interprets PD-L1 and Provides Prognostic Information in NSCLC

Alexander Haragan, UK

FP07.03: Landscape Heterogeneity of PD-L1 Expression and Immune Cells Predicts Prognosis of Metastatic Non-Small Cell Lung Cancer

Dong-Mei Lin, China

FP07.04: Predictive Efficacy of Morphological Biomarkers Based on Digital Pathology for ICI Therapy of Non-Small Cell Lung Cancer

Noriko Motoi, Japan

FP07.05: An Optimized Neoantigen Load Model Based on Immune Editing to Predict Response and Prognosis of Immune Checkpoint Therapy

Haoxuan Jin, China

FP07.06: Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.

Laura Mezquita, Spain

FP07.07: Value of the Lung Immune Prognostic Index (LIPI) As a Prognostic Tool for Real-World Patients Treated for Mutation-Positive Metastatic NSCLC

Amanda Gibson, Canada

FP07.08: A Pan-Canadian Validation Study for the Detection of EGFR-T790M Mutations Using Circulating Tumour DNA (ctDNA) from Blood

Shamini Selvarajah, Canada

FP07.09: Detection of Early Lung Cancer from Average-Risk Individuals and from Benign Nodule Carriers with a DNA Methylation Blood Test

Baohui Han, China

FP07.10: Circulating Tumor DNA Analysis in NSCLC with MET exon 14 Skipping Alterations

Xiuning Le, USA

FP07.11: Circulating Tumor DNA (ctDNA) Clearance as a Biomarker in Patients With Locally Advanced NSCLC Following Chemoradiation

Brendan Knapp, USA

FP07.12: Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real-World Datasets

Joshua M. Bauml, USA

FP07.13: Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer

Bruna Pellini, USA

FP07.14: Implementation of a Lung Biopsy Histology Protocol Supports Successful Cancer Biomarker Testing

Sarah Wu, USA

FP07.15: Real-world ALK Testing Trends and Patterns in Patients with Advanced NSCLC in the United States

Christine Lovly, USA

FP07.16: Trends in Biomarker Testing Among Advanced NSCLC Patients in Oncology Practice Settings in the US

Lauren Bartolome, USA

FP07.17: The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC

Eric Schaefer, USA

FP09: Screening and Early Detection

 NOT FOR CME CREDIT

- FP09.01:** Economic Impact of Screening Selection with the PLCom2012 Risk Model Versus USPSTF-Guidelines in the International Lung Screening Trial (ILST)
Sonya Cressman, Canada
- FP09.02:** Calibration of the LLP Lung Cancer Risk Stratification Model: Prospective Validation in the UKLS Cohort of 76,000 People
John Field, UK
- FP09.03:** Circulating Nucleosomes in Lung Cancer Diagnosis Following Low-Dose Computed Tomography
Tung Ming Tsai, Taiwan
- FP09.04:** Association Between Family History and Other Risk Factors for Lung Cancer: Analysis of an Internet-Based Risk Assessment
Ryan O'Keefe, USA
- FP09.05:** Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study
Laura Mezquita, Spain

FP10: Small Cell Lung Cancer/NET NOT FOR CME CREDIT

-
- FP10.01:** Survival in Advanced SCLC: Projected Impact of Immuno-Oncology-Associated Durable Response on Population Health Gains in US
Jason Gordon, UK
- FP10.02:** Investigating the Immunophenotype of Small Cell Lung Cancer to Improve Immunotherapeutic Targeting
Kate Sutherland, Australia
- FP10.03:** Multi-Region Exome Sequencing Reveals the Intratumoral Heterogeneity of Surgically Resected Small Cell Lung Cancer
Huaqiang Zhou, China
- FP10.04:** RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer
Luis Paz-Ares, Spain
- FP10.05:** A Prospective Phase II Study of Apatinib Plus Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer
Kewei Ma, China

FP12: Tumor Biology and Systems Biology – Basic and Translational Science

 NOT FOR CME CREDIT

-
- FP12.01:** Circulating Tumor DNA to the Identification of EGFR Positive NSCLC Long-Term Survivors
Fernando Franco, Spain
- FP12.03:** SRC-Homology 2 Domain-Containing Phosphatase 2 (SHP2) in Resected Lung Adenocarcinoma (LUAD)
Masaoki Ito, Japan
- FP12.04:** Intelligent Label-Free Image-Based Profiling for Lung Cancer Cell Detection and Classification
Michelle Lo, Hong Kong
- FP12.05:** Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Chinese Advanced Non-Small Cell Lung Cancer
Xiaomin Niu, China
- FP12.06:** GRIm-Score Variations Predict Outcome in Metastatic NSCLC Patients Treated with First-Line Pembrolizumab
Edoardo Lenci, Italy
- FP12.07:** Prognostic Value of HLA-I Homozygosity in Non-Small Cell Lung Cancer Patients Treated with Single Agent Immunotherapy
Afaf Abed, Australia
- FP12.08:** The Survival Impact of Circulating T Regulatory Cells Subsets in Patients with Untreated Lung Cancer
Dahiana Amarillo, Uruguay
- FP12.09:** Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.
Raquel Laza Briviesca, Spain
- FP12.10:** IGF-1R Inhibition in Small Cell Lung Cancer: Role of Brigatinib
Apar Kishor Ganti, USA
- FP12.11:** Single-Cell RNA Sequencing Analyses Distinguishes Transcriptional Activity of c-Myc and L-Myc in Small Cell Lung Cancer
Ayushi Patel, USA
- FP12.12:** Lung Cancer in Women Never-Smokers: A Genomics Perspective of the Women's Health Initiative (WHI) Cohort.
Sitapriya Moorthi, USA
- FP12.13:** Therapeutic Index Predicts Clinical Outcome of both Treated and Treatment-Naïve NSCLC Patients Receiving Targeted- and Immune-Therapy
Xiaomin Niu, China

FP13: Immunotherapy (Phase II/III Trials) NOT FOR CME CREDIT

-
- FP13.01:** 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1-Positive Advanced NSCLC
Roy Herbst, USA
- FP13.02:** Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
Jhanelle Gray, USA
- FP13.03:** IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC
Roy Herbst, USA
- FP13.04:** KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
Byoung Chul Cho, Korea

FP14: Targeted Therapy – Clinically Focused

 NOT FOR CME CREDIT

- FP14.02:** A Phase II Study of Osimertinib versus Combination of Osimertinib and Chemotherapy for EGFR and T790M-Mutation Positive NSCLC
Atsuto Mouri, Japan
- FP14.03:** Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis
Ji-Youn Han, Korea
- FP14.04:** Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors
Richard Riedel, Germany
- FP14.05:** LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
Koichi Goto, Japan
- FP14.06:** Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study
Joshua M. Bauml, USA
- FP14.07:** Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
Julia Rotow, USA
- FP14.08:** Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
Joel Neal, USA
- FP14.09:** Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
Rémi Veillon, France
- FP14.10:** Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC
Herbert Loong, Hong Kong
- FP14.11:** Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study
Caicun Zhou, China
- FP14.12:** Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.
Yi-long Wu, China
- FP14.13:** Molecular Characterisation and Clinical Outcomes in RET Rearranged Non-Small Cell Lung Cancer (NSCLC)
Aaron Tan, Singapore

- FP14.14:** Post Hoc Analyses from an Open Label, Multi-Centre, ASTRIS Trial of Efficacy of Osimertinib for CNS Metastases with T790M-Positive Advanced NSCLC
Beung-Chul Ahn, Korea
- FP14.15:** Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies.
Bob Li, USA
- FP14.16:** Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer (WJOG10818L/Alt Trial)
Hidetoshi Hayashi, Japan
- FP14.17:** Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy
Qing Zhou, China

Posters

✕ NOT FOR CME CREDIT

P01	Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
P02	Diagnostics and Interventional Pulmonology
P03 – P08	Early Stage/Localized Disease
P09 – P13 + P74	Health Services Research/Health Economics
P14 – P16	Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
P17 – P21	Locoregional and Oligometastatic Disease
P22 – P26 + P92	Mesothelioma, Thymoma and Other Thoracic Malignancies
P27 – P28	Nursing and Allied Health Professionals
P29 – P32	Palliative and Supportive Care
P33 – P38 + P94	Pathology
P39	Patient Advocacy
P40	Risk Reduction and Tobacco Control
P41 – P46	Screening and Early Detection
P47 – P51	Small Cell Lung Cancer/NET
P52	Staging
P53 – P73	Tumor Biology and Systems Biology
P74	Health Services Research/Health Economics
P75 – P83	Immunotherapy (Phase II/III Trials)
P84 – P90	Targeted Therapy – Clinically Focused
P92	Mesothelioma, Thymoma and Other Thoracic Malignancies
P94	Pathology

P01: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

 NOT FOR CME CREDIT

- P01.01:** HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC
Pasi Janne, USA
- P01.02:** Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study
Hossein Borghaei, USA
- P01.03:** Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC
Pasi Jänne, USA
- P01.04:** Dynamics of Molecular Markers in EGFR-Mutated NSCLC Patients Treated with Patritumab Deruxtecan (HER3-DXd; U3-1402)
Pasi Jänne, USA
- P01.05:** Pilot Study of Inhaled Azacitidine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Haiying Cheng, USA
- P01.06:** CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase
Melissa Johnson, USA
- P01.07:** Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6
Lindsey Fitzgerald, USA
- P01.08:** Evaluation of Long-Term Pemetrexed Responders in a United States Cohort
Sylvia Alarcon, USA
- P01.09:** Improved Outcomes With Ramucirumab & Docetaxel in Metastatic Non-Small Cell Lung Cancer After Failure of Immunotherapy
Kunal Gawri, USA
- P01.10:** Patients Experienced Pseudoprogression to Anti-PD-1/PD-L1 Inhibitor Have Better Response Than Those Without in Lung Cancer
Wencheng Zhao, China
- P01.11:** Clinical Outcomes After Discontinuation of Immunotherapy in Patients With Non-Progressing Metastatic Lung Cancer
Matias Cerini, Argentina
- P01.12:** Brain Necrosis in Patients With Metastatic Lung and Breast Cancer Successfully Treated With Bevacizumab
Luis Raez, USA
- P01.13:** Anti-PD1 Inhibitors Combined With Anti-Angiogenesis Showed Superior Efficacy in Control of Malignant Pleural Effusion for NSCLC
Wencheng Zhao, China

- P01.14:** Safety and Feasibility of Standard Dosing Carboplatin AUC 5 Every 3rd Weeks With Daily Navelbine® 20/30mg During 4 Cycles, Treating Advanced NSCLC
Maria Kandi, Denmark
- P01.15:** Immune-Related Adverse Effects of Immunotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma
Cláudia Freitas, Portugal
- P01.16:** Tamoxifen Might Enhance the Effect of EGFR-TKIs on EGFR-Mutant NSCLC Cells
Yun-Ting He, China
- P01.17:** An Exploratory Study of Associating Factors for Disease Progression After Response to Immune Checkpoint Inhibitor Monotherapy
Osamu Kanai, Japan
- P01.18:** Adjuvant Chemotherapy With Modified Nab-Paclitaxel and Carboplatin for Completely Resected NSCLC: Survival Analysis of FAST-Nab
Hisasahi Saji, Japan
- P01.19:** Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in Asia: A Systematic Literature Review
Adam Lee, UK
- P01.20:** Short-Term Efficacy of Intrapleural Hyperthermic Perfusion for Malignant Pleural Effusion in Lung Carcinoma
Minhua Ye, China
- P01.21:** ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era
Jordi Remon, France
- P01.22:** Outcomes in NSCLC Patients with Early Termination of Immune Checkpoint Inhibitors Due to Toxicities
Amy Davies, Australia
- P01.23:** Veliparib (V) in Combination with Carboplatin/Paclitaxel (C/P)-Based Chemoradiotherapy (CRT) in Patients With Stage III NSCLC
David Kozono, USA
- P01.24:** Ramucirumab + Docetaxel (DOC) vs PBO + DOC for Stage IV NSCLC after Disease Progression (REVEL): Indian Sub-Group Analysis
Kumar Prabhash, India

P02: Diagnostics and Interventional Pulmonology

✗ NOT FOR CME CREDIT

- P02.01:** Evaluation of PFS for Pulmonary Adenocarcinoma Patient Treated With EGFR Tyrosine Kinase Inhibitors Using Deep Learning Based on CT Image
Junfeng Xiong, China
- P02.02:** Pulmonary Rebiopsy is 'Here to Stay' in Non-Small Cell Lung Carcinoma (NSCLC) Patients with Progression on Tyrosine Kinase Inhibitors (TKIs)
Abhishek Bansal, India
- P02.03:** Comparison of the Efficiency of 22G Versus 25G Needle in EBUS-TBNA for Diagnosis of Lung Cancer; A Prospective Randomized, Crossover Study
Tetsuya Sakai, Japan
- P02.04:** Pectoral Muscle Area Correlates with LENT Score in Non-Small Cell Lung Cancer Associated Pleural Effusion Survival Prediction
Austin Meggyesy, USA
- P02.05:** A Nomogram to Predict Survival in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab: An Analysis of OAK and POPLAR Cohorts
Haiyong Wang, China
- P02.06:** A Novel Loop-Mediated Isothermal Amplification Method for Robust Detection of EGFR Mutations
Yuichi Saito, Japan
- P02.07:** Impact of Diagnostic Test Sequencing on Effectiveness, Efficiency and Survival in Metastatic Non-Small Cell Lung Cancer
Prachi Bhawe, Australia
- P02.08:** A UK Survey of Current Methods for Conducting Cancer Multidisciplinary Team Meetings and Opportunities for Digital Solutions
Clarissa Gardner, UK
- P02.09:** Comprehensive Investigation of Resected Benign Lesions Suspected for Lung Cancer: Implications for Avoiding Unnecessary Pulmonary Resection
Zelin Ma, China
- P02.10:** Patterns of Care for Elderly Patients over Age 80 with Stage IIIA-N2, IIIB, and IIIC NSCLC
Yajie Yin, USA
- P02.11:** Treatment Strategy for Postoperative Chylothorax after Lung Cancer Surgery
Chihaya Maeda, Japan
- P02.12:** Is there a Need for Staging EBUS in Lung Cancer?
Avinash Aujayeb, UK
- P02.13:** Pneumothorax and CT Guided Biopsy for the Investigation of Lung Cancer
Avinash Aujayeb, UK
- P02.14:** Radiotherapy-Associated CT Imaging as a Potential Screening Tool for COVID-19
Abraham Wu, USA

- P02.15:** Intraparenchymal Blood Patch after CT Guided Biopsy of Lung and Mediastinal Lesions Reduces the Risk of Pneumothorax
Binoy Choudhury, India
- P02.16:** Rigid Medical Thoracoscopy in a Large UK District General Hospital
Avinash Aujayeb, UK
- P02.17:** Feasibility and Safety of ENB Guided Microwave Ablation for Lung Cancer: A Preliminary Report
Feichao Bao, China
- P02.18:** Indwelling Pleural Catheter Placement in a Large UK District General Hospital
Avinash Aujayeb, UK
- P02.19:** Prognostic Nomogram for Advanced Non-Small Cell Lung Cancer Patients Treated With Anti-PD-1 Inhibitors
Rong Chai, China
- P02.20:** Does Response at 1st Scan Imaging After Any Line Correlate With PFS?
Fadi Nasr, Lebanon
- P02.21:** The Impact of Inflammatory Serum Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Élia Cipriano, Portugal
- P02.22:** Identification of FGFR Mutations in Chinese Lung Cancer Patients by Next-Generation Sequencing
Hongxia Ma, China
- P02.23:** Robotic Thoracic Surgery – A Comparison of Age-Groups Outcomes
Rui Haddad, Brazil
- P02.24:** Liquid Biopsy Mutation Profiling in Non-Small Cell Lung Cancer
Vaida Gedvilaitė, Lithuania
- P02.25:** Coexistence of Invasive Adenocarcinoma, Minimally Invasive Adenocarcinoma and Atypical Adenomatous Hyperplasia: A Case Report
Kewei Ma, China

P03: Early Stage/Localized Disease – Clinical Trials in Progress

✖ NOT FOR CME CREDIT

- P03.01:** A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation after Curative Resection for Stage I NSCLC with Primary Tumors Between 1-4 cm
Gregory Durm, USA
- P03.02:** Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
Masahiro Tsuboi, Japan
- P03.03:** MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery
Solange Peters, Switzerland
- P03.04:** Phase II Study of TKIs as Neo(adjuvant) Therapy in Stage II–III Resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 Alterations
Jay Lee, USA
- P03.05:** CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in Patients With Surgically Resectable Non-Small Cell Lung Cancer
Jay Lee, USA
- P03.06:** Nausea in Patients Had Thoracomy: A Pilot Study
Feng-Ming (Spring) Kong, Hong Kong

P04: Early Stage/Localized Disease – Perioperative Therapy (Neoadjuvant Therapy, Surgery, Adjuvant Therapy)

 NOT FOR CME CREDIT

-
- P04.01:** Adjuvant Chemotherapy is not Associated with Worse Disease-Free Survival in the Elderly Population
Luciana Beatriz Mendes Gomes, Brazil
- P04.02:** Three Definitions of Normal Lung Volumes for Predicting Radiation Pneumonitis in Advanced NSCLC Treated With Radical Chemoradiation Therapy
Zhiyong Chen, China
- P04.03:** Patient Characteristics and Clinical Outcomes of Stage III NSCLC in a Real-World Setting: KINDLE Korean Subset Data
Byoung Chul Cho, Korea
- P04.04:** Thrombus Formation at Stump of Pulmonary Vein after Pulmonary Lobectomy: A Prospective Multi-institutional Study
Takayoshi Yamamoto, Japan
- P04.05:** Efficacy of Uniportal Video-Assisted Thoracic Surgery (U-VATS) Simple Segmentectomy for Early Lung Cancer
Kyoji Hirai, Japan
- P04.06:** Early Surgical and Oncological Outcomes After Single Port Video Assisted Thoracoscopic Surgery Lung Resection; KHCC Experience
Riad Abdeljalil, Jordan
- P04.07:** Long-term Postoperative Prognosis of Adenocarcinoma in Situ and Minimally Invasive Adenocarcinoma of Lung
Masaya Yotsukura, Japan
- P04.08:** Dynamics of Coagulation Factor XIII Activity After Thoracoscopic Lobectomy for Early-Stage Lung Cancer Patients
Yoshikane Yamauchi, Japan
- P04.09:** Real-Time CT Guided Video-Assisted Thoracoscopic Partial Resection of Peripheral Small-Sized Lung Tumors in Hybrid OR –A Phase 2 Trial–
Taisuke Kaiho, Japan
- P04.10:** Relapsed or Metastatic Organotropism in Early Stage Lung Cancer after Radical Surgery
Fei Xu, China
- P04.12:** A Novel Lung Autotransplantation Technique for Treating Central Lung Cancer and Bronchial Malignancy
Jaixi He, China

P05: Early Stage/Localized Disease – Radiotherapy

✗ NOT FOR CME CREDIT

- P05.01:** Multicenter Retrospective Study of Stereotactic Body Radiotherapy in Non-Small Cell Lung Cancer in South Korea (KROG 17-09)
Seung Gyu Park, Korea
- P05.02:** International Delphi Consensus on Radical Thoracic Re-Irradiation for Non-Small Cell Lung Cancer (NSCLC)
Robert Rulach, UK
- P05.03:** Circulating Lymphocyte Counts after Lung Stereotactic Body Radiation Therapy May Predict after Optimal Short-term Efficacy
Meng Chen, China
- P05.04:** Association of Lymphopenia and Disease Progression in Unresectable NSCLC Treated with Definitive Chemoradiation and Immunotherapy
Cole Friedes, USA
- P05.05:** Real-World Data on Patients With Stage I Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy (SBRT)
Lisa Van Der Woude, Netherlands
- P05.06:** Stereotactic Ablative Radiotherapy for Early Stage Non-Small Lung Cancer and Pulmonary Oligometastases in a New Zealand Population
Nur Azri Bin Haji Mohd Yasin, New Zealand
- P05.07:** Single-Fraction Carbon ion Radiotherapy for Patients with Early-Stage Lung Cancer with or without Interstitial Pneumonitis
Takashi Ono, Japan
- P05.08:** A Propensity Score-Weighted Analysis for SBRT, Lobectomy and Sublobar Resection in Elderly Patients with cStage I NSCLC
Noriko Kishi, Japan
- P05.09:** Thoracic Re-Irradiation Dose Constraints for Late Lung Fibrosis: Preliminary Modelling Results
Robert Rulach, UK
- P05.10:** Risk Factors Associated with Pulmonary Toxicities from Multiple Courses of Lung Stereotactic Body Radiation Therapy (SBRT)
Xingzhe Li, USA
- P05.11:** Preoperative Low Muscle Quality Predicts Poor Outcomes After Surgery for Early-Stage Non-Small Cell Lung Cancer
Atsushi Kamigaichi, Japan
- P05.12:** Hospitalisation Rate in Radical Re-Irradiation of NSCLC are no Different Between Local Recurrences or Second Primaries
Robert Rulach, UK
- P05.13:** Central vs Peripheral Thoracic Malignancies Treated with SBRT: Early Outcomes of a Prospective Quality of Life Study
Michael Carrasquilla, USA

- P05.14:** Dosimetric Impact of Using the Acuros XB for Planning of SBRT of Centrally Located NSCLC
Hing Ming Hung, Hong Kong

P06: Early Stage/Localized Disease – Multiple Primary Lung Cancer

✗ NOT FOR CME CREDIT

- P06.01:** Therapeutic Strategies for Metachronous Multiple Primary Lung Cancer
Jitsuo Usuda, Japan
- P06.02:** Prognostic Factors and Strategies for Metachronous Second Primary Lung Cancer
Dai Shimizu, Japan
- P06.03:** Regression of the Ground Glass Component in Patients with Multifocal Primary Lung Cancers Receiving Pembrolizumab
Jessica Li, Canada
- P06.04:** Single-Stage Bilateral Pulmonary Resections by Uniportal Video-Assisted Thoracic Surgery for Multiple Small Nodules
Xiaotong Guo, China

P07: Early Stage/Localized Disease – Imaging and Biomarkers

✗ NOT FOR CME CREDIT

- P07.01:** Less Accuracy of CT and PET in the Evaluation of N1 Node may Result in Overlooking Skip Metastasis of Single Station cN2 Non-Small Cell Lung Cancer
Satoshi Shiono, Japan
- P07.02:** Detection of Molecular Residual Disease (MRD) using ctDNA in NSCLC: A Systematic Review and Meta-Analysis
Antonio Galvano, Italy
- P07.03:** The Impact of PD-L1 Expression on the Prognosis of Early-Stage Resected NSCLC: A Meta-Analysis of Literatures
Shuai Zhu, China
- P07.04:** Using ctDNA to Detect Minimal Residual Disease after Surgery in Resectable Lung Cancer
Jun Huang, China
- P07.05:** Characterization of Clinicopathologic Features and Molecular Recurrence Risk Profiles in Patients with Early-Stage NSCLC
Sara Riordan, USA
- P07.06:** Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity
Vivienne Rebel, USA
- P07.07:** Computed Tomography of Lymph Nodes to Predict Occult pN2 Disease in Non-Small-Cell Lung Cancer
Hiroto Onozawa, Japan

P08: Early Stage/Localized Disease – Epidemiology

✗ NOT FOR CME CREDIT

-
- P08.01:** Prognostic Impact of Second Predominant Pattern in Lung Adenocarcinoma: Analysis From a Large Multicentric European Database
Pietro Bertoglio, Italy
- P08.03:** Clinicopathological Factors Associated With Recurrence Patterns of Resected Non-Small Cell Lung Cancer
Tomonari Kinoshita, Japan
- P08.04:** Progress in Early Stage Lung Cancer Among Economically Disadvantaged Patients
Brendon Stiles, USA
- P08.05:** Risk Factors Associated with Recurrence Following Curative Therapy for Stage I NSCLC
Emily Butts, USA
- P08.06:** Factors Associated with the Diagnosis of Lymphatic Vascular Invasion and its Impact on Prognosis
Christine Hebert, USA
- P08.07:** Clinical Characteristics and Treatment Patterns of NSCLC Stage III Patients from Real World
Julia Roeper, Germany
- P08.08:** Surgical Resection of Non-Small Cell Lung Cancer: Uncertain Resection Margins and Patterns of Recurrence
Hannah Scholes, UK
- P08.09:** Optimal Follow Up Care for Patients with P-stage I Non-Small Cell Lung Cancer After Surgical Treatment
Hirotugu Notsuda, Japan
- P08.10:** Clinical Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer with Same Pathological Types
Ying Liu, China

P09: Health Services Research/Health Economics – Real World Outcomes

 NOT FOR CME CREDIT

- P09.01:** Different Administration Routes of Endostar Combined with Chemotherapy in the Treatment of Advanced NSCLC, a Real World Study
Wei Jiang, China
- P09.02:** Impact of COVID-19 in Portuguese Lung Cancer Patients' Treatment: Portuguese Lung Cancer Study Group Survey
Fernanda Estevinho, Portugal
- P09.03:** Thyroid Dysfunction in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors (ICI): Outcomes in a Multiethnic Urban Cohort
Angelica D'Aiello, USA
- P09.04:** Changing Survival and Treatment Patterns in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) in Alberta, Canada
Matthew Anaka, Canada
- P09.05:** Surveillance, Patterns of Recurrence and Survivorship in Early Stage Lung Cancer Patients Following Curative Intent Treatment
Sobasha Perera, Australia
- P09.06:** CNS Metastasis Negatively Impact Overall Survival of Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immune Checkpoint Inhibitors
Camila Souza, Brazil
- P09.07:** Oncologists Practices and Perceptions on Management of Brain Metastases from Non-Small Cell Lung Cancers-: A Nationally Representative Survey
Srinivas Chilukuri, India
- P09.08:** Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort
Heidi Grosjean, Canada
- P09.09:** Overall Survival in Elderly Metastatic Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade
Maria Fernanda Simões, Brazil
- P09.10:** Nationwide Effect of High Procedure Volume in Lung Cancer Surgery on In-House Mortality in Germany
Philip Baum, Germany
- P09.11:** Nutritional Risk Status Predicts Overall Survival of Mexican Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Saul Campos-Gomez, Mexico
- P09.12:** SARS- CoV2 Impact in a Spanish Lung Cancer Cohort?
Virginia Calvo, Spain
- P09.13:** Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab
Parthib Das, USA

- P09.14: Predictive Analytics in Real-World Data from Peru: The New Models for Personalized Oncology**
Luis Pino, Colombia
- P09.15: Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19**
Laia Fernández-Mañas, Spain
- P09.16: Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). Real-Life Experience from Castile and Leon**
Soledad Medina Valdivieso, Spain
- P09.17: Changes in the Management of Patients Having Radical Radiotherapy in the UK During the COVID-19 Pandemic (COVID-RT Lung)**
Kathryn Banfill, UK
- P09.18: COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)**
Umit Tapan, USA
- P09.19: Health Disparities Characteristics in Cancer Survivorships among Sexual Minorities in the US – A Cross-Sectional Study Using BRFSS 2018 Data**
Yannan Li, USA
- P09.20: Impact of Antibiotics During Immune Checkpoint Inhibitor (ICI) Therapy for Non-Small Cell Lung Cancer: A Real-World Analysis**
Ajeet Gajra, USA
- P09.22: Curative Intent Treatment for Small Cell Lung Cancer in England**
Susan Harden, Australia
- P09.23: Real-World Treatment Patterns and Outcomes in Patients with NSCLC in England (ROSANNE): A Retrospective Study**
Alastair Greystoke, UK
- P09.24: Real-World Data in Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors in a Latin American Institution**
Tania Paytan, Peru
- P09.25: Role of Immune Checkpoint Inhibitors (ICPi) in KRAS-Mutated Non-Small Cell Lung Cancer (NSCLC)**
Monica Peravali, USA
- P09.26: Cause of Death in Patients with Squamous Cell Lung Cancer (SCC) Treated with Surgery**
Nirav Antao, USA
- P09.27: Descriptive Review of Breast Cancer Patients With Subsequent Lung Cancer**
Mah Noor, USA
- P09.28: Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period**
Teresa Gorria, Spain
- P09.29: Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China**
Xiaoling Chen, China

- P09.30:** A Clinical and Molecular Portrait of a Younger Population with Advanced Non-Small Cell Lung Cancer
Sophie Stock-Martineau, Canada
- P09.31:** Adherence to Treatment Recommendations from Multidisciplinary Tumor Boards
Julia Roeper, Germany
- P09.32:** Is the New Patient Respiratory Appointment an Appropriate Time to Refer Patients With Likely Lung Cancer for Prehabilitation?
Lauren Glanville, UK
- P09.33:** Outcomes of Patients with Lung Cancer Tested for COVID-19 in a Chicago Hospital System (LungCOVID-Chicago)
Ryan Nguyen, USA
- P09.34:** Curating Online Journal Clubs to Advance Global Oncology Lung Cancer Care
Ian Pereira, Canada
- P09.35:** COVID-19 in Patients with Lung Cancer – Experience from a Thoracic Oncology Center
David Coelho, Portugal
- P09.36:** Impact of Medicaid Enrollment on Mortality in Elderly Dual-Eligible Lung Cancer Patients
Meera Ragavan, USA
- P09.37:** Pragmatic Trial Design to Compare Surveillance Strategies for Patients with Small Pulmonary Nodules: The Watch the Spot Trial
Beth Creekmur, USA
- P09.38:** 2020: COVID19 Impact in Lung Cancer Resection in a University Hospital of Brazil
Paulo Alfredo Schulze, Brazil
- P09.39:** PD-L1 Testing Patterns and Treatment in Patients With Metastatic Non-Small Cell Lung Cancer in Israel – Analysis of Real-World Data
Sarah Sharman Moser, Israel
- P09.40:** Treatment Pattern in Patients with Stage III Non-Small-Cell Lung Cancer (NSCLC) in South China
Joseph Siu-Kie Au, Hong Kong
- P09.41:** Body Mass Index (BMI) Is Associated With Overall Survival in Patients With Metastatic Non-Small Cell Lung Cancer
Maria Fernanda Medeiros, Brazil
- P09.42:** Second-Line Immunotherapy Treatment Patterns in Non-Small Cell Lung Cancer in Portugal: An I-O Optimise Cohort Study
Marta Soares, Portugal
- P09.43:** Familial History of Cancer and Overall Survival in NSCLC Patients
Débora Maciel Santana, Brazil
- P09.44:** Outcomes of Covid-19 Infection in Lung Cancer Patients: Experience from a Large Tertiary Care Cancer Center
Kiran Munawar, Pakistan
- P09.45:** Ten Year Report of Lung Cancer in Never Smokers from Southeast of Brasil
Sabina bandeira Aleixo, Brazil

- P09.46: Non-Small Cell Lung Cancer Comorbid with Tuberculosis is Associated with Better Prognosis**
Ho-Sheng Lee, Taiwan
- P09.47: Implementation of Lung Cancer Multidisciplinary Care: A Rapid Review of Evidence-Practice Gaps**
Nicole Rankin, Australia
- P09.48: Experience and Outcome of COVID-19-Positive Lung Cancer Patients from a Eastern Indian Hospital**
Satya Padmaja, India
- P09.49: Experience with Immunotherapy Treatment in Fundación Santa Fe Bogotá: Real World Data in Metastatic Non-Small Cell Lung Cancer Patients**
Aylen Vanessa Ospina Serrano, Colombia
- P09.50: Lung Cancer Hospitalization Burden. Generating Knowledge from Administrative Data to Optimize Management**
Virginia Calvo, Spain
- P09.51: Lung Adenocarcinoma in Morocco**
Ouassima Erefai, Morocco
- P09.52: Explore-LC: Uniting Existing Real-World Data Sources to Create a Novel Asia-Pacific Wide Research Platform for Non-Small Cell Lung Cancer**
David Horsburgh, Singapore
- P09.53: Comparative Effectiveness of Crizotinib versus Entrectinib in ROS1+ Non-Small Cell Lung Cancer (NSCLC) using Clinical Trial and Real-World Data**
Laura Iadeluca, USA
- P09.54: Pneumonitis Following Durvalumab: A Real-World Analysis in Patients with Lung Cancer and Other Tumor Types**
Ajeet Gajra, USA
- P09.55: A Platform to Prospectively Link Real-World Clinico-Genomic, Imaging, and Outcomes Data for Patients With Lung Cancer**
Guneet Walia, USA
- P09.56: Real-World Outcomes Among Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)**
Lauren Bartolome, USA
- P09.57: Estimating the Total US Incidence of Advanced/Metastatic Non-Small Cell Lung (NSCLC) Including Recurrent Disease**
Shervin Shirvani, USA
- P09.58: Replication of Overall Survival in Chemotherapy Arms of 1L NSCLC Trials using Real-World Data External Controls**
Navdeep Pal, USA
- P09.59: Real-World Treatment Patterns and Outcomes for Patients With Advanced Non-Small Cell Lung Cancer in Greece**
Konstantinos Syrigos, Greece

P09.60: Using Patient-Level Data from Electronic Health Records to Replicate PFS Outcomes for Four 1L NSCLC Trials

Michael Bretscher, Switzerland

P09.61: Epidemiological and Clinical Burden of EGFR Exon 20 Insertion in Advanced NSCLC: Results of a Systematic Literature Review

Tracy Li, USA

P10: Health Services Research/Health Economics – Health Economics

 NOT FOR CME CREDIT

- P10.01:** Bias Comparison in Studies Funded by Industry and by Other Sources: An Analysis of Prospective Studies of the Last Five Years
Silvio Matsas, Brazil
- P10.02:** A comparison Between the Cost of Lung Cancer Treatment and How Much is Made Available by Brazilian Government
Marina Silveira, Brazil
- P10.03:** Health Insurance Coverage and Racial Disparities in Early-Stage Detection and Treatment of Lung Cancer: A Causal Mediation Analysis
Zhe Pan, China
- P10.04:** A Budget Impact Analysis for Treatment with Ramucirumab Plus Erlotinib in Metastatic EGFR-Mutated NSCLC in the US
Katherine Winfree, USA

P11: Health Services Research/Health Economics – Quality of Life

 NOT FOR CME CREDIT

- P11.01:** Exploring Patient Reported Quality of Life in Lung Cancer Patients: A Qualitative Study
Elena Jensen-Marini, Australia
- P11.02:** Patient Reported Outcome Measures (PROM) after Thoracic Surgery: A Pilot Study
Jitian Zhang, China
- P11.03:** Importance of Capturing the Patient Experience of Overall Symptoms and HRQoL Impact in Patients With ALK+ NSCLC
Yanyan Zhu, USA

P12: Health Services Research/Health Economics – Health Policy

 NOT FOR CME CREDIT

- P12.01:** Pilot Training Program, Redesign of the Attention System and Time Reduction on Lung Cancer Patients in a Mexican Hospital
Saul Campos-Gomez, Mexico
- P12.02:** Implementation of a Timeliness-of-care Pathway System for Lung Cancer Patients in a Private Outpatient Oncology Service
Iuri Santana, Brazil
- P12.03:** Public Versus Private Care Patients Treated in the Same Hospital. Are the Patients the Same?
Maria Teresa Tsukazan, Brazil
- P12.04:** Access of Lung Cancer to High Technology Radiation Therapy in Brazil
Lilian Faroni, Brazil
- P12.05:** Current State and Challenges of Lung Cancer Treatment in Georgia
Elene Mariamidze, Georgia

P13: Health Services Research/Health Economics – Misc. Topics **NOT FOR CME CREDIT**

-
- P13.01:** **Analysis of the Effect of Personalized Nursing in Patients Undergoing Thoracoscopic Surgery for NSCLC**
Yuanyong Wang, China
- P13.02:** **Role of Management Checklist in the Prevention and Control of NCP in Oncology Ward**
Li Li, China
- P13.03:** **The Role of Nurse Practitioners Within Thoracic Radiation Oncology and the Benefit to Patients, Physicians and the Healthcare System**
Ulrike Gorgens, USA
- P13.04:** **Should We Offer Germline Testing to All Patients With Lung Cancer? An Ethical Point of View**
Guillermo Pacheco-Cuellar, Mexico
- P13.05:** **Real-World Treatment Patterns and Sequencing of Immunotherapy and Chemotherapy Based on PD-L1 TPS in European Patients With mNSCLC**
Megan Gower, USA

P14: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) – Immuno-Biology

 NOT FOR CME CREDIT

- P14.01:** Impact of Stimulator of Interferon Genes (STING) Signaling on the Tumor Immune Microenvironment in Lung Adenocarcinoma
Jiewei Liu, China
- P14.02:** Expression and Significance of Indoleamine 2,3 Dioxygenase on Tumor Cell and Tumor Stroma Compartments of Lung Squamous Cell Carcinoma
Wei Wang, China
- P14.03:** Increased Tumor-Associated LAG-3+ Lymphocytes Correlate with Aggressive Tumor Behavior and Worse Prognosis in Lung Adenocarcinoma
Dan Shepherd, USA
- P14.04:** cfRNA from Liquid Biopsies Is More Abundant Than cfDNA, Informs Treatment Outcome and Is Concordant with Tissue
Luis Raez, USA
- P14.05:** The Relationship Between Genomic Alterations and the Efficacy of Immune Check Point Inhibitor for KRAS Mutated Non-Small Cell Lung Cancer
Naoki Furuya, Japan
- P14.06:** Dysregulation of m6a Reader IGF2BP1 in Lung Adenocarcinoma Affects the Immune Microenvironment and Indicates a Poor Recovery
Xuequan Wang, China
- P14.07:** Clinically Predictive Value of Plasma Cell-Free DNA in Lung Cancer Immunotherapy
Lin Li, China
- P14.09:** Early Expansion of M-MDSCs and High Plasma TSLP levels as Predictors of Primary Resistance to PD1 Inhibitors in Metastatic NSCLC
Sally Lau, Canada
- P14.10:** Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells
Yuanyong Wang, China
- P14.11:** Optimal Combination of Biomarkers to Improve the Predictive Value of Immunotherapeutic Response in Non-Small Cell Lung Cancer
Soohyeon Kwon, Korea
- P14.12:** MET Amplification and Immune Checkpoint Inhibitor Efficacy in NSCLC
Shan Su, China
- P14.13:** Notch Family Gene Mutations Predict Clinical Benefit from Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Huaqiang Zhou, China
- P14.14:** PTPRD: A Positive Predictive Biomarker for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
Jiayi Shen, China

- P14.15:** Circulating Tumor DNA Predict the Response and Survival after Tislelizumab Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
Qiong He, China
- P14.16:** The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors
Jianguo Zhou, Germany
- P14.17:** Low BMI is Associated with Inferior Overall Survival in HIV Patients with Advanced NSCLC Undergoing Immunotherapy
Emily Lin, USA
- P14.18:** Expression and Clinical Significance of CMTM6 in Non-Small Cell Lung Cancer
Sisi He, China
- P14.19:** CD8 α -Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1
Mehmet Altan, USA
- P14.20:** Multi-Spectral Imaging of Lung Adenocarcinoma Reveals Importance of Cancer Specific HLA-DR on the TME and Clinical Outcome
Erin Schenk, USA
- P14.21:** Baseline Derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Clinical Outcomes to First-Line Pembrolizumab in NSCLC with High PD-L1 ($\geq 50\%$)
Joao Victor Alessi, USA
- P14.22:** Radiotherapy With Sequential anti-PD-1 mAb Is Better in Enhancing the Abscopal Effect by Promoting the Inflammatory Tumor Microenvironment
Xiaoxia Zhu, China
- P14.23:** Different in Situ Immune Pattern Between Primary Tumor and Metastatic Lymph Node in NSCLC: Potential Impact on Neoadjuvant Immunotherapy
Ze-Rui Zhao, China
- P14.24:** Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC
Sally Lau, Canada
- P14.25:** Immune Cell Profiling of Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Antibodies
Kyung Hwan Kim, Korea
- P14.26:** Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status
Biagio Ricciuti, USA
- P14.27:** Pathogenic Genomic Alterations of CDKN2A Predict Immunotherapy Resistance in NSCLC
Stanley Gutiontov, USA
- P14.28:** Association Between the Type of First-Line Chemotherapy and Outcome of Second-Line Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Mihyun Kim, Korea

P14.29: Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study

Baohui Han, China

P14.32: Predictive Value of Neutrophil-Lymphocyte Ratio on the Outcome of Patients with Advance NSCLC Treated with PD-1 Inhibition and Radiotherapy

Fen Wang, USA

P14.33: Soluble PD-L1 as Biomarker of Benefit from Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)

Carlo Genova, Italy

P15: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) – Novel Immunotherapeutics (Phase I)

 NOT FOR CME CREDIT

-
- P15.01:** AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
Keegan Cooke, USA
- P15.02:** Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC
Sonam Puri, USA
- P15.03:** A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC
Koichi Goto, Japan
- P15.04:** A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer
Jonathan Riess, USA
- P15.06:** Safety of BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody Plus Platinum/Etoposide in Untreated Extensive-Stage SCLC
Luis Paz-Ares, Spain
- P15.07:** Safety and Efficacy Profile of TQB-2450 Alone/with Anlotinib in Previously-Treated Advanced NSCLC: A Phase IB Single-Arm Trial
Baohui Han, China
- P15.08:** Phase I Trial of in situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
Aaron Lisberg, USA
- P15.09:** A Promising Result of Two Therapeutic Peptides Combined with Chemotherapy in the Treatment of Advanced NSCLC
Jiangnan Feng, China

P16: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) – Novel Immunotherapeutics (Translational)

 NOT FOR CME CREDIT

-
- P16.01:** The Effect of Different Dose and Sites of Irradiation on Lymphocyte Subsets in Peripheral Blood of Patients With Lung Cancer
Xiaoxia Zhu, China
- P16.02:** Impact of Number and Location of Metastatic Sites on Survival in Stage IV ICI-Treated NSCLC
Amanda Gibson, Canada
- P16.03:** Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients
Amanda Gibson, Canada
- P16.04:** CDK4/6 Inhibitors Reverse Resistance to Anti-PD-1 Therapy in Lung Adenocarcinoma with LKB1 Deficiency Through pRB-ICAM1 Dependent Signaling
Zhong-Yi Dong, China
- P16.05:** Exploratory Study of Sintilimab Intrapleural Therapy for NSCLC-Mediated Malignant Pleural Effusion
Tangfeng Lv, China
- P16.06:** Exploration of Efficacy and irAEs of Pembrolizumab Plus Chemotherapy for Advanced NSCLC as 1st Line Treatment in Real World
Teng Li, China
- P16.07:** Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON)
Benjamin Besse, France

P17: Locoregional and Oligometastatic Disease – Biomarkers

 NOT FOR CME CREDIT

- P17.01:** Adaptive Elastic-Net Nomogram Predicting Disease-Free Survival in Resected Stage IIIA (N2) Non-Small Cell Lung Cancer
Chenchen Zhang, China
- P17.02:** Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients – a Phase II Translational and Biomarker Study
Vilde Drageset Haakensen, Norway
- P17.03:** Lung Adenocarcinoma with Lymph Node Metastasis: Is Ground Glass Opacity Component a Prognostic Factor?
Xiangyi Ma, China

P18: Locoregional and Oligometastatic Disease – Misc. Topics

✗ NOT FOR CME CREDIT

- P18.01:** Prognostic Value of the LIPI in Patients with LA-NSCLC Receiving Definitive RT: A Retrospective Study of 1079 Patients
Wenji Xue, China
- P18.02:** Factors Influencing Multi-Disciplinary Tumor Board Recommendations in Stage III Non-Small Cell Lung Cancer
Merle Ronden, Netherlands
- P18.03:** Randomized Trial With BIALOE to Prevent Esophagitis in Lung Cancer Patients Treated With Concurrent Radical Chemoradiotherapy
Francesc Casas, Spain
- P18.04:** Individualized Fraction Regimen of SBRT Patients with Non-Small Cell Lung Cancer Based on Uncomplicated and Cancer-free Control Probability
AiHui Feng, China
- P18.05:** Immunotherapy Beyond First-Line in NSCLC, Still An Option
Andrea Modrego, Spain
- P18.06:** Retrospective Epidemiological Study of Locally Advanced Non-Small Cell Lung Cancer Patients in Brazil – RELANCE (LACOG 0118)
Vladmir Claudio De Lima, Brazil

P19: Locoregional and Oligometastatic Disease – Oligometastatic Disease

✗ NOT FOR CME CREDIT

- P19.01:** Local Ablative Radiotherapy on Oligo-Progression While Continued on EGFR-TKI in Advanced NSCLC Patients: A Longer Cohort
Florence Siu Ting Mok, Hong Kong
- P19.02:** Association between Number of Residual Metastases and Patterns of Progression on EGFR TKI in EGFR mutated Non-Small Cell Lung Cancer
Taichi Miyawaki, Japan
- P19.03:** Operative Outcomes of Local Consolidation with Cytoreductive Surgery for Oncogenic-Driven Advanced NSCLC
Byung Jo Park, Korea
- P19.04:** Effect of Local Therapy on Survival in Oligometastatic Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC)
Yu Yang Soon, Singapore
- P19.05:** Postoperative Recurrence of Early-Stage Non-Small Cell Lung Cancer (NSCLC): Clinical Outcomes of Oligo versus Poly-recurrence Disease
Maria Giorlando, Argentina
- P19.06:** Radiosurgery followed by Tumor Treating Fields for Brain Metastases (1-10) from NSCLC in the Phase 3 METIS trial
Minesh P. Mehta, USA
- P19.07:** Immune Checkpoint Inhibitors and Additional Local Treatment in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
Akin Atmaca, Germany
- P19.08:** Clinical Outcome of Local Treatment in Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Preliminary Analysis of Prospective Data
Xiaoxia Zhu, China
- P19.09:** Lung Stereotatic Body Radiation Therapy: Outcomes from a Brazilian Cohort
Lilian Faroni, Brazil
- P19.10:** Evaluation of Local Therapy for Oligoprogressive Disease in Metastatic NSCLC Patients on Immunotherapy
Nicholas Giustini, USA
- P19.11:** Endobronchial Brachytherapy as Curative Therapy for Postoperative Intrabronchial Oligometastasis in Non-Small Cell Lung Cancer
Atsushi Ito, Japan
- P19.12:** Immunotherapy as Single Treatment for Brain Metastases of Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Viviane Alencar, Brazil

P20: Locoregional and Oligometastatic Disease – Radiation

✖ NOT FOR CME CREDIT

- P20.01:** Stereotactic Body Radiation Therapy for Residual Primary Lesions After First Line Treatment for Advanced Non-Small Cell Lung Cancer
Lin Zhou, China
- P20.02:** To Evaluate the Efficacy and Optimal Timing of Postoperative Radiotherapy in Completely Resected stage IIIA(N2) Non-Small Cell Lung Cancer
Wen Feng, China
- P20.03:** Impact of Radiotherapy Timing After Induction Chemotherapy on Survival of Patients With Locally Advanced Non Small Cell Lung Cancer
Danijela Scepanovic, Slovakia
- P20.04:** Dosimetric Comparison of the Real and Virtual Plans in Non-Small Cell Lung Cancer Patients Treated With Respiratory Motion Management
Sureyya Sarihan, Turkey
- P20.05:** Oesophageal Dose Predicts on Treatment Toxicity in Patients Receiving Concurrent Chemo-Radiotherapy for Non-Small Cell Lung Cancer
Cameron Keogh, UK
- P20.06:** Dosimetric Comparison of the Real and Virtual Plans in Non-Small Cell Lung Cancer Patients Treated With Respiratory Motion Management
Sureyya Sarihan, Turkey

P21: Locoregional and Oligometastatic Disease – Treatment of Locally Advanced NSCLC

 NOT FOR CME CREDIT

- P21.01:** Phase I Study of Carboplatin/Nab-Paclitaxel and Concurrent TRT in Elderly Patients with Unresectable Locally Advanced NSCLC
Shota Omori, Japan
- P21.02:** Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
Sandip Patel, USA
- P21.03:** Dutch Lung Cancer Audit-Radiotherapy: Real-World Data on Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy Only
Liselotte Van Bockel, Netherlands
- P21.04:** Comparing Outcomes for Patients Receiving Chemoradiation Followed by Surgery vs. Immune Checkpoint Inhibitors in Non Small Cell Lung Cancer
Turja Chakrabarti, USA
- P21.05:** Overall Survival by PD-L1 Status in Stage III NSCLC Following Implementation of Durvalumab: The Real-World Application of PACIFIC
Shelley Kuang, Canada
- P21.06:** Patterns of Post-Progression Treatment and Impact of Subsequent Immunotherapy in Stage III Unresectable Non-Small Cell Lung Cancer Patients
Sarah Shin, USA
- P21.07:** Immune-Related Adverse Events with Durvalumab Consolidation in a Real-World Cohort of Patients with Non-Small Cell Lung Cancer (NSCLC)
Gabriela Bravo Montenegro, USA
- P21.08:** Durvalumab Consolidation Following Chemoradiation for Unresectable Non-Small Cell Lung Cancer: A “Real-World” Experience
Claire Griffiths, USA
- P21.09:** Does Duration of Maintenance Durvalumab Matter? Relationship between Length of Durvalumab Therapy and PFS
Kamya Sankar, USA
- P21.10:** Real-World Treatment Patterns in Chinese Stage III NSCLC Patients – A Prospective, Non-Interventional Study (MOOREA trial)
Ligang Xing, China
- P21.11:** Durvalumab after Concurrent cChemotherapy and High-Dose Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Yosef Landman, Israel
- P21.12:** An Observational Study of Treatment Outcome in Stage III Lung Cancer Patients in Taiwan: KINDLE study
Po-Lan Su, Taiwan

- P21.13:** Durvalumab in Locally-Advanced NSCLC in LATAM: Real World Data from Patients Included in the Early Access Program
Florencia Tsou, Argentina
- P21.14:** The Promising role of Chemo-Immunotherapy in Non-Small Cell Lung Cancer Neoadjuvant Setting
Helena Bote, Spain
- P21.15:** Sparing Preserved Lobes to Reduce Lung Dose for Operable IIIA NSCLC Patients Treated with Neoadjuvant Chemoradiotherapy
Hengle Gu, China
- P21.16:** Do Patients who Underwent Lung Resection for Non-Small Cell Lung Cancer and Skip-N2 Metastases Show Better Survival?
Alejandra Libreros, Spain
- P21.17:** Pneumonectomy for Locally Advanced Non-Small Cell Lung Cancer after Neoadjuvant Concurrent Chemo-Radiation Therapy
Kazunori Okabe, Japan

P22: Mesothelioma, Thymoma and Other Thoracic Malignancies – Case Reports

 NOT FOR CME CREDIT

-
- P22.01:** A Case of Intimal Sarcoma with Osteosarcomatous Differentiation
Etsuko Satoh, Japan
- P22.02:** Outcome of Heart Rupture Repair During Huge Mediastinal Mass Resection
Riad Abdeljalil, Jordan
- P22.03:** Not Every FDG Avid Spot is Tumor
Isabelle Opitz, Switzerland
- P22.04:** Lung Metastasis of Thyroid Transcription Factor 1 Positive Endometrioid Carcinoma;
A Case Report
Masao Saito, Japan
- P22.05:** Chest Wall and Diaphragm Reconstruction; a Technique not well Established in Literature
Riad Abdeljalil, Jordan
- P22.06:** A Large Solitary Fibrous Tumor of the Pleura Causing Paraneoplastic Hypoglycemia
Kohei Hashimoto, Japan
- P22.07:** Nivolumab Immunotherapy as a Promising Therapy in Relapsed Malignant Pleural Mesothelioma
Sara Costa-Martins, Portugal
- P22.08:** Paraganglioma of the Anterior Mediastinum
Motohisa Shibata, Japan

P23: Mesothelioma, Thymoma and Other Thoracic Malignancies –Esophageal Cancer and Rare Tumors

 NOT FOR CME CREDIT

- P23.01:** “Multidisciplinary Approach for the Management of Primary Tracheal Carcinoma”- Institutional Experience of 9 Bangladeshi Cases
Qamruzzaman Chowdhury, Bangladesh
- P23.02:** Clinicopathological and Prognostic Features of 67 Cases With Pulmonary Sarcomatoid Carcinoma: An 18-Year Single Center Experience
Adnan Aydinler, Turkey
- P23.03:** The New Therapy on Esophageal Leiomyosarcoma in the Upper Esophagus
Chun-wei Xu, China
- P23.04:** Primary Pulmonary Myxoid Sarcoma with EWSR1 Rearrangement: A Case Report
Mai Nishina, Japan

P24: Mesothelioma, Thymoma and Other Thoracic Malignancies –Mesothelioma Clinical and Trials in Progress

 NOT FOR CME CREDIT

-
- P24.01:** Entire Pleural Intensity-Modulated Radiotherapy in a Neoadjuvant Setting for Resectable Malignant Mesothelioma
Yeonsil Kim, Korea
- P24.03:** A Multicenter Randomized Phase III Trial of Dendritic Cell Maintenance Therapy After Chemotherapy in Mesothelioma; Denim Trial
Robert Belderbos, Netherlands
- P24.04:** Outcome of Neoadjuvant or Adjuvant Radiotherapy in Multimodality Setting with EPP for Malignant Pleural Mesothelioma
Alireza Hoda, Austria
- P24.05:** Malignant Mesothelioma Related to Environmental Asbestos Exposure in a Rural Area: 30-year Follow-up
Guntulu Ak, Turkey
- P24.06:** Real World use of Cisplatin and Carboplatin Based Therapy in Patients with Malignant Pleural Mesothelioma (MPM)
Susana Cedres, Spain
- P24.07:** Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)
Åslaug Helland, Norway
- P24.08:** Radiological Response to TTFields Plus Chemotherapy for Malignant Pleural Mesothelioma from the Phase 2 STELLAR Trial
Federica Grosso, Italy
- P24.09:** Pooled Safety Analysis of Clinical Trials Delivering Tumor Treating Fields (TTFields) to the Upper Torso
Federica Grosso, Italy

P25: Mesothelioma, Thymoma and Other Thoracic Malignancies – Mesothelioma Preclinical, Prognostic and Predictive Factors

 NOT FOR CME CREDIT

-
- P25.01:** Metabolic Characterization of Drug Resistance to Antifolate in Malignant Pleural Mesothelioma
Yuzo Sato, Japan
- P25.02:** Lymph Node Metastasis of Malignant Pleural Mesothelioma
Aki Kobayashi, Japan
- P25.03:** Novel Diagnosis Technique for Identification of Asbestos Fibres in Mesothelioma Samples using LA-ICP-MS Imaging
Oana Voloaca, UK
- P25.04:** The Role of miRs in Determining the Response to Chemotherapy in MPM Patients Treated with Chemotherapy
Muzaffer Metintas, Turkey
- P25.05:** The Brims Decision Tree Model for Prognosis in a UK Malignant Mesothelioma Group
Avinash Aujayeb, UK
- P25.06:** Malignant Pleural Mesothelioma: Patient Characteristics, Treatments and Outcomes from a Spanish Center
Yago Garitaonaindia, Spain
- P25.07:** Nutritional Risk Status Predicts Outcomes of Mexican Patients with Malignant Pleural Mesothelioma
Saul Campos-Gomez, Mexico
- P25.08:** National Organisational Audit of Specialist Mesothelioma Service and Support Provision for the United Kingdom
Susan Harden, Australia
- P25.09:** Effectiveness of Tumor Treating Fields plus Cisplatin/Pemetrexed Combination in Mesothelioma, in Vitro and in Vivo
Moshe Giladi, Israel
- P25.10:** Computational Simulations on Safety of Tumor Treating Fields Delivered to the Lungs in Mesothelioma and NSCLC
Ze'ev Bomzon, Israel
- P25.11:** Evaluation of the Safety of Tumor Treating Fields (TTFields) Application to the Torso – in Vivo Studies
Moshe Giladi, Israel
- P25.12:** The Vienna Mesothelioma Inflammation Score (VMIS) is Independently Associated with Overall Survival in Malignant Pleural Mesothelioma
Berta Mosleh, Austria

P26: Mesothelioma, Thymoma and Other Thoracic Malignancies – Thymic Malignancies

 NOT FOR CME CREDIT

-
- P26.01:** Survival Impact of Adjuvant Postoperative Radiation Therapy (PORT) in Locally Advanced Thymic Carcinoma (TC): An Up-To-Date Meta-Analysis
Philip Haddad, USA
- P26.02:** The Impact of Clinicopathologic Factors on the Overall Survival of Thymic Neuroendocrine Tumors (TNET): A Pooled Analysis
Philip Haddad, USA
- P26.03:** The Impact of Postoperative Radiation Therapy on the Overall Survival of Resected Stage II Thymoma: An Up-to-date Meta-Analysis
Philip Haddad, USA
- P26.04:** Correlation of Somatostatin Receptor 2 Expression, DOTATATE scan and Octreotide Treatment in Thymic Epithelial Tumors
Anja Roden, USA
- P26.05:** Comprehensive Genomic Sequencing in Thymic Epithelial Tumors: Identification of Multiple Poor Prognosis Biomarkers in Chinese Patients
Baohui Han, China
- P26.06:** High frequency of Fatal Immune Checkpoint Inhibitor Associated Myocarditis in B2/B3 Thymoma Patients
Yue-Li Sun, China
- P26.07:** Video-Assisted Thoracoscopic Surgery for Stage I Thymoma: Short-Term Outcomes and Appropriate Indications
Takahiro Suzuki, Japan
- P26.08:** Postoperative Course of Thymoma with Myasthenia Gravis
Fumihiko Hoshi, Japan
- P26.09:** Is Thymectomy alone through Video-Assisted Thoracic Surgery Appropriate for Clinical Stage I (T1N0M0) Thymoma 5cm or Less?
Kazuo Nakagawa, Japan
- P26.10:** Molecular Characterization of Patients with Thymoma and Thymic Carcinoma
Xun Yang, China

P27: Nursing and Allied Health Professionals – Symptom Management

 NOT FOR CME CREDIT

- P27.01:** Multidisciplinary Management of Lung Cancer Patients Presenting with Oropharyngeal Dysphagia
Abigail Camps, UK
- P27.02:** Symptom Burden and Referral to Allied Health Professionals at time of Diagnosis for Patients with Malignant Pleural Mesothelioma
Faye Dickinson, UK

P28: Nursing and Allied Health Professionals

– Regional Roles of Nurses and Allied Health Professionals

 NOT FOR CME CREDIT

- P28.01:** The Clinical Pharmacist as a Member of a Multidisciplinary Team for Lung Cancer Patients Assistance
Gisele Moreira, Brazil
- P28.02:** Individualized Nutritional Management in Patients Eligible for Thoracic Surgery Experience of a Chest Tumor Center in Brazil
Imanuely Gonçalves, Brazil
- P28.03:** An Autoethnographic Study Exploring the Role of the Lung Cancer Nurse Specialist in the National Optimal Lung Cancer Pathway
Alice Bobat, UK

P29: Palliative and Supportive Care – Clinical Trial in Progress

 NOT FOR CME CREDIT

P29.01: Therapeutic Thoracentesis vs Iodopovidone Pleurodesis in Malignant Pleural Effusion Secondary to Lung Cancer–Randomized trial

Satya Padmaja, India

P29.02: TIP: Romiplostim for Chemo-Induced Thrombocytopenia in Adults with Solid Tumors; A P3 Randomized Placebo-Controlled Double-Blind Studies

Armando Armas, USA

P30: Palliative and Supportive Care

✗ NOT FOR CME CREDIT

-
- P30.01:** Machine Learning can be used to Predict need to see a Dietitian in Patients with Advanced Lung Cancer
Iain Phillips, UK
- P30.02:** Assessing SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion) Management and Outcome Among Lung Cancer Patients: The Assert Trial
Rossana Berardi, Italy
- P30.03:** A Simple Solution to Screening for Dietetic Need in Patients with Advanced Non-Small Cell Lung Cancer
Iain Phillips, UK
- P30.04:** The Value of Clinical and Genetic Factors in Pain Management in EGFR Mutated Advanced Lung Adenocarcinoma Patients
Milena Cavic, Russia
- P30.05:** Perception of Palliative Care and Prognostic Awareness of Lung Cancer Treatment in an Oncogene-Driven Lung Cancer Community
Ivy Elkins, USA
- P30.06:** Outcome Differences Amongst Histopathological Variants of Non Small Cell Lung Cancer Treated With Palliative Radiotherapy
Abhirup Chanda, India
- P30.07:** Can Response to Chemotherapy Be a Surrogate of Response to Immunotherapy in Second and Subsequent Lines- Real World Data
Ewa Chmielowska, Poland
- P30.08:** The Evaluation of Fatigue in Malignant Pleural Effusion
Avinash Aujayeb, UK
- P30.09:** Exposure to Antibiotics May Affect Progression-Free Survival Negatively in NSCLC Patients Receiving First-Line Chemotherapy
Xiaoman Tian, China
- P30.10:** Local Pulmonary Administration of Tranexamic Acid as Inhalational or Nebulized for the Control of Hemoptysis: A Systematic Review of Case Reports, Case Series, and an RCT
Lawrence Cyril Vitug, Philippines
- P30.11:** Psychosocial Requirements in Lung Cancer Care
Csaba Degi, Romania
- P30.12:** The Impact of Pacemaker and Methylprednisolone Pulse Therapy on Immune-Related Myocarditis With Complete Atrioventricular Block
Fang Wu, China
- P30.13:** The Effect of Anlotinib Instead of Glucocorticoids for Encephaledema Induced by Brain Metastases in NSCLC Patients With Anti-PD1/PDL1 Therapy
Hongqing Zhuang, China

P31: Palliative and Supportive Care – Case Report

✕ NOT FOR CME CREDIT

P31.01: A False Alarm of COVID-19 Pneumonia in Lung Cancer: A Case Report of Anti-PD-1 Related Pneumonitis
Ying Dai, China

P32: Palliative and Supportive Care – Misc. Topics

 NOT FOR CME CREDIT

-
- P32.01:** Effect of Refined Nursing on Postoperative Early Ambulation in Patients with Thoracoscopic Surgery for Lung Cancer
Heling Zhou, China
- P32.02:** Cohort Study of Rehabilitation Quality in Patients With U-VATS and M-VATS Lobectomy
Xiaoqin Liu, China
- P32.03:** Comparison of Two Nursing Effects in Patients With NSCLC Within 2 Hours After General Anesthesia
Yuanrong Wang, China
- P32.04:** Preoperative Self-Reported Symptom Burden and Quality of Life of Patients Undergoing Lung Cancer Surgery: A Cross-Sectional Study
Wei Dai, China
- P32.05:** Correlation Between Malnutrition Universal Screen Tool Score and Outcomes Following Surgical Treatment of Lung Cancer
Tomoyo Fujiwara, UK
- P32.06:** Investigation of the Current Use of Opioid Analgesics After Lung Resection and the Analysis of Its Influencing Factors
Yuanqiang Zhang, China
- P32.07:** Shortness of Breath in Patients After Thoracomy: A Pilot Study
Guangqiang Shao, China
- P32.08:** Chest Pain After Thoracomy: A Prospective Pilot Study
Guangqiang Shao, China

P33: Pathology – Immunotherapy Biomarker

✗ NOT FOR CME CREDIT

-
- P33.01:** Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC
Diego Signorelli, Italy
- P33.02:** Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients
Myrto Moutafi, USA
- P33.03:** Alteration of Circulating Blood Lymphocyte Subtypes Reveal Therapy Effect in Non-Small Cell Lung Cancer
Liangliang Xu, China
- P33.04:** Programmed Death-Ligand 1 (PD-L1) Changes in Non-Small-Cell Lung Cancer (NSCLC): Clinical, Pathologic, and Genomic Correlates
Stephanie Alden, USA
- P33.05:** Identifying Biomarkers of Immune Signature Related to Smoking and Overall Survival in NSCLC on Gene Co-Expression Network
Kunsong Li, China
- P33.06:** Utilizing Serum Proteome to Understand Response and Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Won Kyung Hur, USA
- P33.07:** Peripheral CD4+ T cell Signatures in Predicting Response to Anti-PD-1 Monotherapy for Chinese Advanced Non-Small Cell Lung Cancer Patients
Ying Wang, China
- P33.08:** Granulocyte Colony-Stimulating Factor-Producing Lung Cancer With Highly Expresses PD-L1 Protein Expression Level
Kazuhito Miyazaki, Japan
- P33.09:** Tumor Mutational Burden in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy: Outcomes in a Multiethnic Cohort
Laura Munoz-Arcos, USA
- P33.10:** Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients
Mariona Riudavets, France
- P33.11:** Immunotherapy Outcomes in KRAS Mutated vs KRAS Wild-Type Advanced Lung Adenocarcinoma
Danielle Collons, USA
- P33.12:** Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study
Dong-Mei Lin, China
- P33.13:** Prognostic and Predictive Value of Complete Blood Count Parameters in Patients with NSCLC Treated with PD-1 Inhibitors
Ioannis Tourkantonis, Greece

- P33.14:** STK11/LKB1, KRAS Mutations and Immune-Related Adverse Events as Predictors of Response to Immunotherapy in Lung Cancer
Luis Raez, USA
- P33.15:** TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors
Valerio Gristina, Italy
- P33.16:** Relationship Between PD-L1 Expression and FDG-PET Imaging in Non-Small Cell Lung Cancer
Ken Onodera, Japan
- P33.17:** Incidence of PD-L1 Expression at Clinically Significant Cut Offs in NSCLC EGFR Mutated Population Compared to Wild Type
Barbara Melosky, Canada
- P33.18:** The Prevalence of PDL-1 Expression in Lung Cancer: Real-World Experience from a Tertiary Care Oncology Centre
Rajiv Kumar, India
- P33.19:** Association Between Expression of Immune Response-Related Genes and Response to Nivolumab in Metastatic Non-Small Cell Lung Cancer
Augusto Obuti Saito, Brazil
- P33.20:** Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Hayat Ramdani, Germany
- P33.21:** Epidemiological Characteristics and Survival in Patients With Lung Cancer in a Peruvian Private Institution Between 2011-2014
Jose Maria Gutierrez, Peru
- P33.23:** Tumor Infiltrating Immune Cells Predict Clinical Outcome after Immune Checkpoint Inhibitor Therapy in NSCLC
Guojie Lu, China

P34: Pathology – Liquid Biopsy

✗ NOT FOR CME CREDIT

-
- P34.01:** Utility of Assessment of the EGFR Resistance Genotype Using Cell-Free DNA and CTCs from Liquid Biopsies
Martin Barr, Ireland
- P34.02:** Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells From Patients With Non-Small-Cell Lung Cancer
Yuxin Cheng, China
- P34.03:** A ‘Plasma-First’ Molecular Profiling Approach Complements Actionable Mutation Detection in Suspected Lung Cancer Patients
Jamie Mong, Singapore
- P34.04:** Circulating Tumor DNA (ctDNA) as a Marker of Progressive Disease in Patients with Advanced Lung Cancer
Bryan Ulrich, USA
- P34.05:** Perioperative Driver Mutation Detection in Circulating Tumor DNA from Lung Cancer Patients across Multiple Timepoints
Yue Pu, China
- P34.06:** The Clinical Utility of Liquid Biopsy by Digital Droplet PCR in Patients with Advanced NSCLC
Virginie Lamberts, France
- P34.07:** Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer
Kazutoshi Isobe, Japan
- P34.08:** Circulating Tumor Cell as a Predictive Marker for Immunotherapy in Advanced Non-Small Cell Lung Cancer
Cheol-Kyu Park, Korea
- P34.09:** The Dynamic Changes of ctDNA and cfDNA in the Perioperative Period of Early NSCLC have the Potential to Predict the Risk of Recurrence
Zheng Ma, China
- P34.10:** Transformation to Small Cell Lung Cancer from an Adenocarcinoma EGFR+ as Resistance Mechanism. Utility of Liquid Biopsy in Treatment Selection
Miguel Muñoz, Argentina

P35: Pathology – Genomics

✗ NOT FOR CME CREDIT

-
- P35.01:** Genomic Origin and Immune-related Status of Pulmonary Sarcomatoid Carcinoma
Likun Chen, China
- P35.02:** Lung Adenocarcinoma with Oncogenic SMARCA4 Mutation: Possible Target of Cancer Immunotherapy
Hee Sang Hwang, Korea
- P35.03:** Methylation Signatures Associated with T790M Status in Progressive NSCLC
Grainne O’Kane, Canada
- P35.04:** The Prognostic Value of Metastasis to Different Organs in EGFR-Mutated Stage IV NSCLC Patients Treated with First-Line Icotinib
Yudong Wang, China
- P35.05:** The Monitoring of Mutated EGFR Levels in Liquid Biopsy from Patients on EGFR-TKIs – Early Detection of NSCLC Progression
Joanna Chorostowska-Wynimko, Poland
- P35.06:** The Biomarkers of Radiation Pneumonia in NSCLC Were Based on Serum Proteomic Changes
Jiancheng Li, China
- P35.07:** Analysis of Inter-Tumor Heterogeneity Among Lesions in Autopsy Cases With Untreated Lung Cancer by DNA Methylation Profiling
Hiroaki Harada, Japan
- P35.08:** RNA-Based Gene Alteration and Expression Analysis in Sq-NSCLC with known FGFR1 Amplification and Protein Expression Status
Joanna Chorostowska-Wynimko, Poland
- P35.09:** Oncogenetic Differences in Never-Smokers versus Smokers with NSCLC Adenocarcinoma Treated at the Mt Sinai Tisch Cancer Institute
Philip Mack, USA
- P35.10:** Concomitant Driver Gene Mutations in Non-Small Cell Lung Cancer
Jianping Wang, China
- P35.11:** Molecular Profiling Can Distinguish Multiple Lung Primary Tumors From Intrapulmonary Metastases
Wei Cheng, China
- P35.12:** Assessment of Molecular Heterogeneity in Multiple Primary Lung Cancer Patients by Whole-Exome Sequencing
Lizhu Lin, China
- P35.14:** NGS-Based Molecular Profiling of ‘Quadruple-Negative’ (EGFR/KRAS/ALK/ROS1) Advanced Non-Small-Cell Lung Cancer (aNSCLC)
Sara Pilotto, Italy
- P35.15:** Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
Herbert Loong, Hong Kong

- P35.16:** Biomarker Landscape in Multicenter China Lung Cancer Precision Medicine Registry
Jinbo Wu, China
- P35.17:** Novel Genetic Characteristics in Low-Grade Fetal Adenocarcinoma of the Lung
Shuyang Zhang, China
- P35.18:** Genomic Alteration Profiles in Rare Types of Lung Cancer
Jirapath Wiwitkeyoonwong, Thailand
- P35.19:** The Mutational Landscape in South Asian Patients with Non-Small Cell Lung Cancer at an US Academic Medical Center
Mohana Roy, USA
- P35.20:** Genomic Profiling and PD-L1 Expression Association Analysis in Epstein-Barr Virus (EBV)-infected Lung Cancer Patients
Xiahui Yang, China
- P35.21:** Comprehensive Genomic Profiling of Lung Metastases in Cancer Patients
Li Wang, China
- P35.23:** Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma with Micropapillary Component
Yang Xu, China
- P35.24:** Evaluation of an Up-To-Date Knowledge Base to Aid in Interpreting Somatic Mutations Detected in NGS Testing of Lung Cancer
Stephanie Yaung, USA
- P35.26:** Comparative Genomic Profiling of Lung Adenocarcinoma in Self-Reported Asian and White Patients, a Propensity Matched Study of 1400 Samples
Jian Zhou, China
- P35.27:** Next Generation Sequencing Reveals the Genetic Landscape of JAK Family in Chinese Lung Cancer Patients
Lin Gui, China
- P35.29:** The Genomic Landscape of Lung Cancer Patients Highlights Age-Dependent Mutation Frequencies and Clinical Actionability in Young Patients
Xiaoling Tong, Canada

P36: Pathology – Prognosis

✗ NOT FOR CME CREDIT

-
- P36.01:** KEAP1 and NRF2 Mutations in Hispanic and Non-Hispanic Patients with NSCLC: Clinicopathologic Characteristics and Prognosis
Khadeja Khan, USA
- P36.02:** CHEK1: Unfavourable Prognostic Hub Gene and Potential Therapeutic Target for Lung Adenocarcinoma
Zhibo Tan, China
- P36.03:** Identification of Immune-Related lncRNA Clusters and Prognostic Effects for Lung Adenocarcinoma Patients
Haiyong Wang, China
- P36.04:** Molecular Prognostic Factors in Neuroendocrine Thymic Tumors: A Retrospective Multicentre Study
Niccolò Daddi, Italy
- P36.05:** Metastatic NSCLC Outcomes With Guideline-Recommended Treatment By KRAS Subtype
Anifat Elegbede, Canada
- P36.06:** The Association Between Prognostic Value and Mutations in TGF- β Signaling Pathway in Small Cell Lung Cancer Patients
Qing Bu, China
- P36.07:** Pleckstrin Homology-Like (PHLDA) Domain Family Members Immunoexpression as Prognostic Marker in Lung Cancer and Mesothelioma
Camila Machado Baldavira, Brazil
- P36.08:** Effect of Soluble CD39 and PD-L1 Levels on Diagnosis and Prognosis of Lung Cancer Patients with Malignant Pleural Effusion
Tangfeng Lv, China
- P36.09:** Overexpression of KIAA0101 Promotes the Progression of Non-Small Cell Lung Cancer
He Cao, China
- P36.10:** Prognostic Value and Transcriptional Expression Profile of GINS Family Members in Lung Adenocarcinoma
Fangyan Zhong, China
- P36.11:** Clinicopathological Features of Long-Term Survivors in Lung Cancer
Ioannis Tourkantonis, Greece

P37: Pathology – Biomarker Testing

✗ NOT FOR CME CREDIT

- P37.01:** Detection of NTRK Rearrangements by Next-Generation Sequencing in Chinese Lung Carcinoma Patients
Ming Wu, China
- P37.02:** Identification of Gene Fusions and Mutations in Patients with NSCLC using two Diagnostic Approaches: Rapid qPCR and NGS
Andrzej Tysarowski, Poland
- P37.03:** Analysis of Ddrug-Induced RNA Expression Changes in NSCLC Patient-Derived Explants as a Potential Tool for Personalized Therapy Choice
Evgeny Imyanitov, Russia
- P37.04:** EGFR Mutations in US Hispanics with Lung Adenocarcinoma are Common and Portend a Worse Prognosis
Jonathan Villena-Vargas, USA
- P37.05:** Prognostic Characteristics and Immunotherapy Response of Non-Squamous NSCLC Patients with KRAS Mutation in East Asian Populations
Shang-Gin Wu, Taiwan
- P37.06:** Are all ALK Gene Rearrangements Created Equal??
Ullas Batra, India
- P37.07:** Discordance on Repeat PD-L1 Testing in Non-Small Cell Lung Carcinoma
Julia Naso, Canada
- P37.08:** Oncomine™ Dx Target Test Companion Diagnostic System for Advanced Non-Small Cell Lung Cancer
Fumiyoshi Ohyanagi, Japan
- P37.09:** Comparison of 3 Different Methods for Determination of EGFR p.Thr790Met mutation in patients with NSCLC
Andrzej Tysarowski, Poland
- P37.10:** PD-L1 Expression in Lymphovascular Tumor Emboli in Lung Adenocarcinoma
Yi-Chen Yeh, Taiwan
- P37.11:** Assessment of Plasma D-Dimer as a Predictive Biomarker for Treatment Response in Lung Cancer Treated with Radiation Therapy
Abhirup Chanda, India
- P37.12:** Concordance of Next-Generation Sequencing Between Tissue and Liquid Biopsies in Non-Small Cell Lung Cancer
Fahmin Basher, USA
- P37.13:** Diagnostic Performance of Aptamer-Based Multiplex PCR Compared to Luminex Assay for Detection of Non-Small Cell Lung Cancer
Yunha Nam, Korea
- P37.14:** Comparative Evaluation of IHC versus FISH for Detection of ROS1 Fusion in Lung Cancer
Rajiv Kumar, India

- P37.15:** Prevalence of Targetable Mutations using a RT-qPCR Multiplex Assay in Asian NSCLC Patients: A Single Laboratory Experience
Shi Feng Nyaw, Hong Kong
- P37.16:** Alterations in HRR Related Genes as Potential Markers of Clinical Benefit from PARP Inhibitor and PD-1/PD-L1 Blockade in Advanced Lung Cancer
Yu Lei, China
- P37.17:** Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer (NSCLC): A Global Meta-analysis
Barbara Melosky, Canada
- P37.18:** Lung NSCLC Molecular Diagnostic Comparison Between NGS and Multiplex PCR Assays
Kiat Hon Tony Lim, Singapore
- P37.19:** Activin-A and GDF-11 as Predictive Biomarkers for Platinum Response in Non-Small Cell Lung Cancer
Jennifer Lim, Australia
- P37.20:** Diagnostic EGFR Mutations in Non Small Cell Lung Cancer With Specimens of Body Cavity Fluids
Nguyen Lam, Vietnam
- P37.21:** Improvement of PCR-Based Detection of ALK Rearrangements
Evgeny Imyanitov, Russia
- P37.22:** Unique Characterization of KRAS Mutation in Non-Small Cell Lung Cancer in Thai Population
Narumol Trachu, Thailand
- P37.23:** Real-World PD-L1 Expression in Lung Cancer and its Correlation with Driver Mutations
Tao Wang, China
- P37.24:** Identification of microRNAs in Non-Small-Cell Lung Cancer Based on Bioinformation Analysis
Lulu Feng, China
- P37.25:** Clinical Validation of Low-costs Next Generation Sequencing Panels in Solid Tumors
Yen-Lin Chen, Taiwan
- P37.26:** Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression using Routine Clinical and Conditioned Archives of Non-Small-Cell Lung Cancer
Tae Jung Kim, Korea
- P37.27:** Epidemiology of EGFR Positive Adenocarcinoma NSCLC From India: A Systematic Review and Meta-analysis
Veena Gupta, India
- P37.29:** Clinical Characteristics that Affect the Success Rate of BRAF-V600E Oncomine Dx Target Test
Yuki Sato, Japan
- P37.30:** Prevalence of Actionable Mutations among Indian Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review
Ruchir Raman, India
- P37.31:** Trends in the Detection of EGFR Exon 20 Insertions in Patients with NSCLC in the US
Huamao Lin, USA

- P37.32:** Epigenetic Imprinted Genes as Biomarkers for the Proactive Detection and Accurate Presurgical Diagnosis of Small Lung Nodules
Ning Zhou, China
- P37.33:** A look at EGFR, ALK, and PD-L1 Biomarker Test Availability, Adoption, and Test Ordering Behavior at Diagnosis of NSCLC in the United States
Jirawas Sornkom, UK
- P37.34:** Outcome Associations with p16, GATA-3, and TTF-1 Clone SP141 IHC Expression in Resected Stage I Lung Squamous Cell Carcinomas
Artem Shevtsov, USA
- P37.35:** Identification of DNA Methylation Markers to Distinguish Early-Stage Lung Adenocarcinomas from Benign Pulmonary Nodules
Feilong Zhao, China

P38: Pathology – Pathology/Staging

✗ NOT FOR CME CREDIT

-
- P38.01:** The Role of Pathology in The Proposed Subdivided N Descriptors of The TNM Staging System For Lung Cancer– A Single Center Experience
Pinar Bulutay, Turkey
- P38.02:** Reproducibility and Accuracy of Intra-Operative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas
Julian Villalba, USA
- P38.03:** Immunohistochemical, Histologic and Genomic Characterisation of Early Stage Pulmonary Invasive Mucinous Adenocarcinoma
Aaron Tan, Singapore
- P38.04:** 3D Analysis of Spread Through Air Spaces in Squamous Cell Carcinoma and Carcinoid Tumor Using Whole Block Imaging by Micro CT
Takashi Inoue, Japan
- P38.05:** Clinical, Genetic, Radiological, and Pathological Characteristics of Cribiform Adenocarcinoma of the Lung
Akihiko Yoshizawa, Japan
- P38.06:** Evaluation of Non-invasive Transcutaneous Bioconductance Measurement – a Risk-Stratification Biomarker for Suspicious Pulmonary Lesions
Dawei Yang, China
- P38.07:** Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes Among Chinese Patients
Yuchen Han, China
- P38.08:** Clinical Features and Survival Risk Factors of Lung Lymphoepithelioma-Like Carcinoma Based on the SEER Database Analysis
Chun-wei Xu, China
- P38.09:** Clinicopathological Characteristics of Combined Small-Cell Lung Cancer
Yuko Iida, Japan
- P38.10:** Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: A Single-Center Experience
Luigi Ventura, Italy
- P38.11:** Clinical and Molecular Characteristics of TSC1/2 Mutant Lung Cancer
Yanye Wang, China
- P38.12:** Lung Adenocarcinoma with Sarcomatoid Transformation after Tyrosine Kinase Inhibitor Treatment and Chemotherapy
Mong-Wei Lin, Taiwan
- P38.13:** Cytology-Histology Concordance for Diagnosis, Histological Subtyping and Molecular Profiling of Lung Cancer
Ioannis Tourkantonis, Greece

- P38.14:** Demographic and Molecular Epidemiologic Profile of Primary Lung Cancer in Eastern India
Satya Padmaja, India
- P38.15:** Interactive Genes Between Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition During Lung Cancer Metastasis
Jie Ma, China
- P38.16:** Expression of ROS1 Gene Rearrangement in Pulmonary Inflammatory Myofibroblastic Tumor With Cerebral Metastasis: Case Report
Ihsan Alloubi, Morocco
- P38.17:** Pulmonary Small Cell Carcinoma with Rhabdomyoblastic Differentiation: A Previously Unreported Occurrence
Jasper Johar, Canada
- P38.18:** A Rare Case of Pleomorphic Carcinoma Arising in Adulthood Type 1 Congenital Pulmonary Airway Malformation
Niccolò Daddi, Italy
- P38.19:** Lung Cancer in Young Adults: A Two-Center, Retrospective Study of the Clinical and Pathological Characteristics
Mora Guardamagna, Spain

P39: Patient Advocacy

 NOT FOR CME CREDIT

-
- P39.01:** Satisfaction with the Lung Cancer Care Pathway. Is it Time to Revise the Way We Monitor and Assess Patient Experience?
Yvonne Nartey, UK
- P39.02:** 'Making Moments Matter' – A Lung Cancer Campaign from the Marie Keating Foundation
Anne Marie Baird, Ireland
- P39.03:** Developing A Collaborative Northern Roadmap for Lung Cancer Care
Carolyn Roberts, Canada
- P39.04:** ALK Positive UK: 42% of UK Patients do not Receive Regular Brain MRI Scans Despite Data Showing up to 70% of Patients Develop Brain Metastases
Debra Montague, UK
- P39.05:** Access Disparities and Challenges in Lung Cancer Diagnostics and Treatment – A European Perspective
Anne Marie Baird, Switzerland
- P39.06:** Surviving Metastatic Non-Small Cell Lung Cancer – Experience and Supportive Care Needs of Patients Receiving Novel Therapies
Sarah Heynemann, Australia
- P39.07:** Evaluating the Success of the First Global Lung Cancer Coalition Patient Experience Survey
Vanessa Beattie, UK
- P39.08:** The Effect of COVID-19 on Anxiety in Canadian Lung Cancer Patients
Christina Sit, Canada
- P39.09:** Social Media Support of Lung Cancer Patient Associations During the Lockdown Restrictions in Italy: A Breath of Life During the COVID-19 Pandemic
Tindara Franchina, Italy

P40: Risk Reduction and Tobacco Control

✕ NOT FOR CME CREDIT

-
- P40.01:** Tobacco use in Adolescence and Associated Factors: Products, School, Family, Peers and Movies in Pandemic Period
Domenico Galetta, Italy
- P40.02:** Female Lung Cancer: An Emerging Issue in Bangladesh
Nausheen Hakim, USA
- P40.03:** Report on a Phytochemical-rich Dietary Intervention Trial to Prevent Lung Cancer: Implementation in a High-Risk Lung Screening Clinic
Marisa Bittoni, USA
- P40.04:** Knowledge, Attitudes and Perception of Lung Cancer Screening Among Smoking Soft-Ware Professionals in India
Venkata pradeep babu Koyyala, India
- P40.05:** Current Status of a Smoking Cessation Supportive Program on Nurses' Interventions: A Single Institutional Experience
Reiko Kori, Japan

P41: Screening and Early Detection – Lung Cancer Screening Programmes

 NOT FOR CME CREDIT

-
- P41.01:** Disparities in Lung Cancer Screening by Baseline Comorbidities:
An Analysis of the Behavioral Risk Factor Surveillance System Survey 2018
Qian Wang, USA
- P41.02:** Implementation Barriers In US-based Lung Cancer Screening Programs
Andrew Ciupek, USA
- P41.03:** Long-Term Results of Screening-Detected Lung Cancer in the Polish Cohort
Robert Dziedzic, Poland
- P41.04:** The SUMMIT Study: Pulmonary Nodule and Incidental Findings in the First 10,000
Participants of a Population-Based Low-Dose CT Screening Study
Jennifer Dickson, UK
- P41.05:** Challenges of Implementing Lung Cancer Screening in Brazil:
Preliminary Results of a Multicenter Group
Ricardo Santos, Brazil
- P41.06:** As Seen from the Rearview Mirror: A Retrospective Analysis of
Lung Cancer Screening in Patients with Lung Cancer
Coral Olazagasti, USA
- P41.07:** Lung Cancer Screening: What is the State of the Evidence about Implementation?
Nicole Rankin, Australia
- P41.09:** Comorbidity Profile and Diagnostic Complication Risk:
A Study of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Eric Robinson, USA
- P41.10:** Initial Low Dose CT for Lung Cancer Screening and Recalls at Kaiser Permanente Mid-Atlantic States
Monica Ter-Minassian, USA

P42: Screening and Early Detection – Risk Modelling and Artificial Intelligence

 NOT FOR CME CREDIT

-
- P42.01:** AI Assistance for Pulmonary Nodule Stratification: An Multiple-Reader Multiple-Case Study
Emma O'Dowd, UK
- P42.02:** Evaluating the Feasibility of a Deep Learning-Based Computer-Aided Detection System for Lung Nodule Detection in a Lung Cancer Screening Program
Sunyi Zheng, Netherlands
- P42.03:** A Dynamic Deep Learning Approach to Predict Clinical Outcomes of Patients with Advanced Non-Small Cell Lung Cancer under Nivolumab Monotherapy
Shun Lu, China
- P42.04:** Is AI Better for Prediction of Pathological Subtype in Pulmonary Nodules?
Shuaibo Wang, China
- P42.05:** Investigating the Accuracy of Clinical Mathematical Models for Estimating the Probability of Malignancy in Patients With Pulmonary Nodules
Kevin Zhang, China
- P42.06:** Automatic Lung Nodule Detection by a Deep Learning-Based CAD System: The Value of Slab Thickness in the Maximum Intensity Projection Technique
Sunyi Zheng, Netherlands
- P42.07:** Comparative Performance of Lung Cancer Risk Models to Define Lung Screening Eligibility in the United Kingdom
Hilary Robbins, France
- P42.08:** Association Between the Age at First-Live Birth and Lung Cancer Risk: Meta-Analysis and Mendelian Randomization Analysis
Yiyuan Ao, China

P43: Screening and Early Detection – Biomarkers

 NOT FOR CME CREDIT

- P43.01:** Utility of Sputum for Non-Invasive Assessment of Lung Cancer Risk with the LuCED® Test: Specimen Satisfactory Rate
Michael Meyer, USA
- P43.02:** A Multiplex Plasma Protein Panel for Detection of Lung Cancer in Ever Smokers Not Currently Eligible for Screening
Stephen Lam, Canada
- P43.03:** Sphingomyelin Is a Candidate Predictor for Lung Adenocarcinoma Recurrence After Radical Surgery
Yusuke Takanashi, Japan
- P43.04:** Efficient Isolation and Quantification of CTC in NSCLC Patients using Peptide-Functionalized Magnetic Nanoparticles
Naixin Liang, China

P44: Screening and Early Detection – Association of Lung Cancer with other Chronic Diseases

 NOT FOR CME CREDIT

P44.02: Mild Interstitial Pneumonia as a Risk Factor for Chemotherapy-Induced Acute Exacerbation of Interstitial Pneumonia in Patients with Lung Cancer

Takashi Umeda, Japan

P44.03: Combined Aortic Valve and Coronary Artery Calcifications in Lung Cancer Screening as Predictors of Death from Cardiovascular Disease

Yeqing Zhu, USA

P44.04: Evaluating Lung Cancer Screening in People Living With HIV

Shawn Jindal, USA

P44.05: Bone Density Measures Out-Perform Clinical Risk Scores in Detection of Vertebral Fractures in a Lung Cancer Screening Cohort

Nikita Patel, Australia

P45: Screening and Early Detection – Radiological Risk Stratification

 NOT FOR CME CREDIT

- P45.01:** Lung Cancer Probability and Clinical Outcomes of Baseline and New Ground-Glass Opacity Nodules Detected on Low-Dose CT Screening
Yeon Wook Kim, Korea
- P45.02:** Regional Emphysema Score Is Associated With Tumor Location and Poor Prognosis in Completely Resected NSCLC Patients
Chang Dong Yeo, Korea
- P45.03:** Lung Nodule Management Based on Diameter and Volume in Lung Cancer Screening with Low-Dose Computed Tomography
Yihui Du, Netherlands
- P45.04:** Radiologic and Clinical Features of Screening-Detected Pulmonary Invasive Mucinous Adenocarcinoma
Dae Hyeon Kim, Korea

P46: Screening and Early Detection – Gene-Based Risk Stratification

✖ NOT FOR CME CREDIT

- P46.01:** Intronic Noncoding RNA Expression of DCN is Related to Cancer-Associated Fibroblasts and NSCLC Patients' Prognosis
Jian Zhou, China
- P46.02:** Correlation of Monitoring ctDNA EGFRm using R-SuperARMS with Clinical Outcomes in Patients with Advanced Lung Adenocarcinoma
Jiuwei Cui, China
- P46.03:** DNA Methylation Analysis in Smokers and Non-Smokers (Passive and ex-Smokers)
Diana Monserrat Aguilar-Beltrán, Mexico
- P46.04:** Identify Lung Adenocarcinoma among Pulmonary Micro-nodules through Blood Gene Expression Profiles
Baohui Han, China
- P46.05:** A Blood Six-Gene Test for Early-Stage Lung Adenocarcinoma Screening in Asympomatic Population
Baohui Han, China
- P46.06:** Cell-Free DNA (cfDNA) Methylation Assay Allows for Early Detection and Identification of Lung Cancer
Kristi Kruusmaa, Spain
- P46.07:** An Extended Targeted RNA Sequencing for Fusion Detection with Oncomine Comprehensive Assay Plus
Alex View Hune Teoh, Singapore

P47: Small Cell Lung Cancer/NET – Biology / Translational

✗ NOT FOR CME CREDIT

-
- P47.01:** Plasma Exosomal Long RNA in SCLC Diagnosis and Prognosis
Chang Liu, China
- P47.02:** CCL19 Associates with Inferior Prognosis in Patients with SCLC Through Promoting Invasion and Metastasis
Qian Liu, China
- P47.03:** Understanding Lung Neuroendocrine Tumor Progression Combining Organoid Models and Multi-Omic Analyses
Nicolas Alcala, France
- P47.04:** Neuroendocrine Transformation from EGFR-wild type or TKI-naïve Non-Small Cell Lung Cancer: An Under-Recognized Phenomenon?
Xiao Chu, China
- P47.06:** Delta-Radiomics Features for Assessment of Individualized Therapeutic Response in Small Cell Lung Cancer – A Pilot Study
Jose Araujo Filho, USA
- P47.07:** Exploration of Aberrant Methylation Patterns in the Chemotherapy Insensitivity of Small Cell Lung Cancer
Peixin Chen, China
- P47.08:** Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Clinical Benefit of Immunotherapy in Small-Cell Lung Cancer
Xingsheng Hu, China
- P47.09:** Quantification and Classification of Tumor Infiltrating Leukocytes (TILs) and its Impact on Prognosis in Small Cell Lung Cancer (SCLC)
Yiying Guo, China
- P47.10:** Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung
Walter Wang, USA
- P47.11:** DLL-3 and ASCL-1 Expression Emerge as Promising Therapeutic Targets in High-Grade Neuroendocrine Lung Tumors: A Preliminary Study
Tabatha Prieto, Brazil
- P47.12:** Does Pulmonary Adenocarcinoma With Neuroendocrine Differentiation Deserve A New Classification?
Jiaxi He, China
- P47.13:** Galectin-9, A Novel Prognostic Factor in Small Cell Lung Cancer
Peixin Chen, China
- P47.14:** Clinicopathologic Features of Large Cell Neuroendocrine Carcinoma of Lung
Perran Fulden Yumuk, Turkey
- P47.15:** Mutational Landscape of Homologous Recombination Pathway in Small Cell Lung Cancer Patients
Xin Li, China

P48: Small Cell Lung Cancer/NET – Chemo – IO

✗ NOT FOR CME CREDIT

-
- P48.01:** Gemcitabine and Nivolumab for Subsequent Treatment of Metastatic Small Cell Lung Cancer
Thomas Lycan, USA
- P48.02:** NRG Oncology/Alliance LU005: Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer
Kristin Higgins, USA
- P48.03:** First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
Niels Reinmuth, Germany
- P48.04:** IMfirst; Phase IIIB Safety Study of Atezolizumab Plus Chemotherapy in a Real World Population of Untreated ES-SCLC
Rosario Garcia Campelo, Spain
- P48.05:** Anlotinib Plus Platinum-Etoposide in 1st-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Single-Arm Phase II Trial
Peng-Bo Deng, China
- P48.06:** Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial
Maria José De Miguel Luken, Spain
- P48.07:** Synergistic Antitumor Effects of Anlotinib Combination With Oral 5-Fluorouracil S-1 in Small Cell Lung Cancer
Haihua Yang, China
- P48.08:** Phase IV Clinical Study on the Safety and Efficacy of Lobaplatin-Based Regimen With Small Cell Lung Cancer
Ying Cheng, China
- P48.09:** Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial
Baohui Han, China
- P48.10:** Chemo-Immunotherapy in the Frontline of Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Indirect Comparisons
Antonio Galvano, Italy
- P48.11:** Anlotinib Versus Chemotherapy as a Third-Line or Further Treatment for Advanced Small Cell Lung Cancer
Yue Wang, China
- P48.12:** A Meta-Analysis of ICI +EP vs. EP for Untreated Extensive SCLC using GRADE System Approach for Certainty in the Evidence
Carolina Gabay, Argentina
- P48.13:** Immune Checkpoint Inhibitors Combined with Etoposide-Platinum as First-Line Therapy for Extensive-Stage SCLC: A Network Meta-Analysis
Jiuwei Cui, China

- P48.14:** **RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting**
Luis Paz-Ares, Spain
- P48.15:** **A Case from a Single-Arm, Phase Two, Open Label Study Assessing Sindilimab Plus Metaformin in Chemotherapy Failed PD-L1 Positive Advanced SCLC**
Lin Wu, China
- P48.16:** **Network Meta-Analysis of ICI for Extensive Small-Cell Lung Cancer (ESCLC) as Upfront Therapy**
Carolina Gabay, Argentina
- P48.17:** **Efficacy and Safety of AK104, an Anti-PD-1/CTLA-4 Bispecific Antibody, in a Patient with Large Cell Neuroendocrine Carcinoma of the Lung**
Sophia Frentzas, Australia
- P48.18:** **Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis**
Arani Sathiyapalan, Canada
- P48.19:** **Outcomes of Patients Treated with First Line Immunotherapy Plus Chemotherapy for ES-SCLC: Real World Outcomes from a Tertiary Academic Center**
Sandip Patel, USA
- P48.20:** **Trends in Trial Design, Interpretation and Survival in Phase III Clinical Trials on Extensive-Stage SCLC Between 2000 and 2019**
Chia Ching Lee, Singapore
- P48.21:** **Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN**
Yanan Zheng, USA
- P48.22:** **Semi-Mechanistic Models of the Time Course of Neutrophils and Platelets in Cancer Patients Treated With Lurbinectedin**
Salvador Fudio, Spain
- P48.23:** **Exposure-Response Analyses and Clinical Utility Index to Justify the Dosage of Lurbinectedin in Small-cell Lung Cancer**
Salvador Fudio, Spain
- P48.24:** **Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**
Bo Shen, China

P49: Small Cell Lung Cancer/NET – Radiotherapy

 NOT FOR CME CREDIT

-
- P49.01:** Treatment Planning QA of Hippocampal Avoidance Prophylactic Cranial Irradiation in the Multicenter Randomized Phase III Trial (NCT01780675)
Oscar Candiff, Netherlands
- P49.02:** Simultaneous Integrated Boost IMRT(54 Gy) versus Conventional IMRT (45 Gy) Twice Daily Combined With Chemotherapy for LS-SCLC
Fang Peng, China
- P49.03:** Chemoradiation with Cisplatin-Etoposide versus Carboplatin-Etoposide in Limited-Stage Small Cell Lung Cancer
Bruna Pellini, USA
- P49.04:** The use of Stereotactic Body Radiotherapy in Pulmonary Carcinoid Tumors: A Single Institution Retrospective Review
Katharine Thomas, USA

P50: Small Cell Lung Cancer/NET – Real World Outcomes

 NOT FOR CME CREDIT

-
- P50.01:** A Year Experience With Atezolizumab Plus Chemotherapy for Small Cell Lung Cancer in Alberta, Canada
Anifat Elegbede, Canada
- P50.02:** Survival Outcome Comparison in Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis Versus at Relapse
Anifat Elegbede, Canada
- P50.03:** Lung Neuroendocrine Tumors. 12-Years Experience of a Single Cancer Institution
Diego Diaz Garcia, Mexico
- P50.04:** Real-World Survival Outcomes with Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Tumors of Lung
Elizabeth Dudnik, Israel
- P50.05:** Clinical Features and Outcome of Small Cell Lung Cancer in Female Patients: From SEER Database and a Cohort
Jia Hou, China
- P50.06:** How much Platinum-Based Chemotherapy is Enough in Limited-Stage SCLC: A Propensity Score-Matched Analysis of a Prospective Trial
Fang Peng, China
- P50.07:** Fewer Liver and Lymph Node Metastases May Contribute to Survival Benefits for Patients With c-SCLC Compared With SCLC
Haiyong Wang, China
- P50.08:** Prevalence, Risk Factors, and Prognostic Factors of Small Cell Lung Cancer With Bone Metastasis: A SEER-Based Analysis
Qing Chen, China
- P50.09:** Estimates of First-Line Extensive Stage Small Cell Lung Cancer Treatment Rates from a U.S. Claims Database
Apar Kishor Ganti, USA
- P50.10:** Intravenous (IV) Versus IV/Oral Route of Etoposide Administration: Impact on Real-World SCLC Survival Outcomes
Anifat Elegbede, Canada
- P50.11:** Long-Term Survival after Surgical Resection of Carcinoid Tumors in a Population-Based Cohort
Meghan Taylor, USA
- P50.12:** A Novel Nomogram and Risk Classification System Predicting The Survival of Patients with Extensive-Stage Small Cell Lung Cancer
Ting Mei, China
- P50.13:** A Nomogram for Assessing Survival in Extensive-stage SCLC Patients with SVCS Referred To Thoracic Radiotherapy: Upfront vs. Consolidative?
Ting Mei, China

P51: Small Cell Lung Cancer/NET – Surgery

✕ NOT FOR CME CREDIT

P51.01: Total Lung Preservation: An Important Tool in Treatment of Bronchial Carcinoids (Neuroendocrine Tumours)

Prriya Eshpuniyani, India

P52: Staging – Prognosis and Staging

 NOT FOR CME CREDIT

-
- P52.01:** **Lepidic Component Identifies a Subgroup of Lung Adenocarcinoma with a Distinctive Prognosis: A Chinese Population-based Multicenter Study**
Erjia Zhu, China
- P52.02:** **Staging Lung Cancer: Are All Suspicious Lymph Nodes Pathologic?**
Maria Teresa Tsukazan, Brazil
- P52.03:** **Concordance of PET Scan and EBUS-TBNA for Mediastinal Staging of Stage 3 Non-Small Cell Lung Cancer**
Marie-Philippe Saltiel, Canada
- P52.04:** **Efficacy of Immune Checkpoint Inhibitor Monotherapy for Patients With Massive Non-Small-Cell Lung Cancer**
Taiki Hakozaiki, Japan
- P52.05:** **Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study)**
Virginia Calvo, Spain
- P52.06:** **“High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept**
Oliver Higuera, Spain
- P52.07:** **Nodal Disease and Pneumonectomy: Always a Bad Combination? A Single High Volume Centre Experience of Long Term Outcomes**
Mohamed Shoeib, UK
- P52.08:** **Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain**
Fernando Franco, Spain
- P52.09:** **Proposals for Revision of N Descriptors in the Forthcoming Edition of TNM Staging for NSCLC**
Haiyong Wang, China
- P52.10:** **Profile of Comorbidities and Cancer History in Patients with mNSCLC in the Spanish Population (Thoracic Tumors Registry)**
Fernando Franco, Spain
- P52.11:** **Prognostic Positioning of EGFR Mutated Advanced Lung Cancer in Relation to the Treatment Modalities**
Won-Il Choi, Korea
- P52.12:** **Incidence of Brain Metastasis in Advanced Non-Small Cell Lung Cancer at Presentation-An Experience From Tertiary Care Centre in South India**
Karthikeyan Kaliyamurthi, India

P53: Tumor Biology and Systems Biology – Basic and Translational Science – Misc. Topics

 NOT FOR CME CREDIT

-
- P53.01:** Triptolide Enhances Radiosensitivity of Lung Cancer Cells via G2/M Arrest, and Autophage
Seung Hyeun Lee, Korea
- P53.02:** Integrated Profiling of Advanced Non-Small-Cell Lung Cancer: The EORTC IMMUCan Project – Lung Cohort
Benjamin Besse, France
- P53.03:** Genome-Wide Gene-Smoking Interaction Study Identifies Novel Rare Variants in Non-Small Cell Lung Cancer in Population with European Descent
Yafang Li, USA
- P53.04:** KUgliptin, a Novel and Potent DPP4 Inhibitor, Improves of Combined Therapy with Immune Checkpoint Inhibitor (ICI) in Lung Cancer Immunotherapy
Hyun Seock Shin, Korea
- P53.05:** Evaluation of IGRT-Induced Imaging Doses and Secondary Cancer risk for SBRT Early Lung Cancer Patients in Silico Study
YanHua Duan, China
- P53.06:** Crizotinib Induces Apoptosis of Lung Cancer Cells Through JAK-STAT Pathway
Chun-wei Xu, China
- P53.07:** Clinicopathologic Characteristics of Patients With PTPN11 Mutations in East Asian Non-Small Cell Lung Cancer Patients
Chun-wei Xu, China
- P53.08:** Analysis of Mitochondria-Mediated OCIAD2 Oncogenic Function in Lung Adenocarcinoma
Jeongmin Hong, Japan
- P53.09:** Molecular Alterations of KIT Oncogene in a Large Cohort of Chinese Pan-Lung Cancer Patients
Zhifang Liu, China

P54: Tumor Biology and Systems Biology – Basic and Translational Science – Carcinogenesis

 NOT FOR CME CREDIT

- P54.01:** Development and Validation of a Novel Nomogram Integrated with Lung Cancer Susceptibility Genes for Squamous Cell Lung Cancer
Xiaoshun Shi, China
- P54.02:** Urethane-Induced Lung Carcinogenesis in Genetically Edited C57Bl/6 Mice with CHEK2 and GPRC5A Heterozygous Inactivating Mutations
Evgeny Imyanitov, Russia
- P54.03:** Multiple Microarray Analyses Identify Key Genes Associated with the Development of NSCLC from COPD
Lemeng Zhang, China
- P54.04:** A Study to Determine the Association of Trace Elements and Heavy Metals with Lung Cancer and their Correlation with Smoking
Ilavarasi Vanidassane, India
- P54.05:** The Heterogeneity of Air Pollution Particulate Matters and the Potential Tumorigenicity in Lung Progenitor Cells
Huei-Wen Chen, Taiwan

P55: Tumor Biology and Systems Biology – Basic and Translational Science – Cell Cycle

 NOT FOR CME CREDIT

P55.01: Different Types of CDK4 Mutations in East Asian Non-Small Cell Lung Cancer Patients

Chun-wei Xu, China

P56: Tumor Biology and Systems Biology – Basic and Translational Science – CT DNA

 NOT FOR CME CREDIT

P56.01: Postoperative ctDNA Positive Presents the High-risk of Recurrence in Resectable Non-Small Cell Lung Cancers

Jia-Tao Zhang, China

P57: Tumor Biology and Systems Biology – Basic and Translational Science – DNA Repair **NOT FOR CME CREDIT**

-
- P57.01:** Prevalence MSH6 Mutations in East Asian Non-Small Cell Lung Cancer Patients
Chun-wei Xu, China
- P57.02:** High Frequency of Heterozygous Truncating Germ-Line Mutations in DNA Repair Genes in Young-Onset and/or ALK-Rearranged Lung Cancer Patients
Evgeny Imyanitov, Russia
- P57.03:** Pathogenic Germline Mutations of Homologous Recombination Deficiency (HRD) Genes in Chinese Lung Cancer Patients
Minghui Wang, China
- P57.04:** Mutations of DNA Damage Repair Genes in Lung Adenocarcinoma and Their Association with Actionable Alterations
Zhiqi Yu, China

P58: Tumor Biology and Systems Biology – Basic and Translational Science – Epigenomics

 NOT FOR CME CREDIT

- P58.01:** Systematic Identification of Methylation Sites Associated with Lung Adenocarcinoma Prognosis
Xiaoshun Shi, China
- P58.02:** Bronchial Field Progenitor Basal Cells Show Methylome-Wide Characteristics Reflective of Lung Cancer Case-Control, Age, and Smoking Status
Khulan Batbayar, USA
- P58.03:** Investigation on the Role of Methylation in Field Cancerization of Non-Small Cell Lung Cancer
Qiushi Wang, China

P59: Tumor Biology and Systems Biology – Basic and Translational Science – Genomics NOT FOR CME CREDIT

-
- P59.01:** AR Mutations Defines a Unique Molecular Class of Non-Small Cell Lung Cancer in East Asian Patients
Chun-wei Xu, China
- P59.02:** The Impact of CFTR on Lung Adenocarcinoma Prognosis: an in Silica Analysis
Xiaoshun Shi, China
- P59.03:** Intratumoral Heterogeneity and Clonal Evolution in Large Non-Small Cell Lung Cancer (>7cm) Delineated by Multiregion Sequencing
Jia-Tao Zhang, China
- P59.04:** Sex-Related Differences in Genomic and Immune Profiling of Lung Adenocarcinoma
Xue-Tao Li, China
- P59.05:** Multi-Omic Analysis Between Tumor Tissues from Early and Late Stage Non-Small Cell Lung Cancer Patients
Bin Zhang, China
- P59.06:** Mutational Landscape and Differential Expression Analysis of Transcription Factors in Non-Small Cell Lung Cancer
Youyu Wang, China
- P59.07:** Molecular Profiling of Human Non-Small Cell Lung Cancer by Single-Cell RNA-Seq
Jie Wang, China
- P59.08:** THOR: Multi-Ethnic, Open Access Thoracic Cancer Genomics Resource
Anders Skanderup, Singapore

P60: Tumor Biology and Systems Biology – Basic and Translational Science – Immune Bio

 NOT FOR CME CREDIT

-
- P60.01:** Single-Cell Transcriptomics to Assess Response to Immunotherapy in Advanced Lung Cancer ex-vivo: Developing a Functional Predictive Assay
Venessa Chin, Australia
- P60.02:** Insight Into Intestinal Microbiome in NSCLC Patients: More Personalized Immunotherapy in the Crosshairs
Anna Grenda, Poland
- P60.03:** Identifying Patterns in Responses to PD-1 Immunotherapy for Patients With Squamous Cell Lung Cancer and Non-Squamous Cell Lung Cancer
Lihui Liu, China
- P60.04:** The Association of Patient HLA Class I Genotype and Genomic Alterations of Non-Small Cell Lung Cancer
Jinglong Wang, China
- P60.05:** Influence of Different Concentrations of Nivolumab on T Cell Activation in Patients with Non Small Cell Lung Cancer: in Vitro Study
Paweł Krawczyk, Poland
- P60.06:** Single Cell Sequencing Analysis Revealed Altered Lung Cancer Microenvironment by Neoadjuvant Immunotherapy
Changli Wang, China
- P60.07:** TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial
Alberto Cruz-Bermudez, Spain
- P60.08:** Impact of CD24 and CD47 Tumor Expression on Efficacy and Serum Cytokine Alteration with PD-1/L1 Inhibitors in Non-Small Cell Lung cancer
Yuichi Ozawa, Japan
- P60.09:** High Circulating Regulatory (FoxP3+) T Cells and TGF- β Predict the Response to Anti-PD-1 Immunotherapy in NSCLC Patients
Jiae Koh, Korea
- P60.10:** Tumor Neoantigen Burden and Immune Environment in Driver Alteration-Positive Lung Adenocarcinoma
Janakiraman Subramanian, USA
- P60.11:** TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial
Marta Casarrubios, Spain
- P60.12:** Baseline Tumor Immune Cell Infiltration and Activation can Predict Checkpoint Inhibitor Pneumonitis in Lung Cancer Patients
Jillian Bracht, Spain
- P60.13:** Association of KMT2C/D Mutations with Tumor Mutation Burden and Response to Immune Checkpoint Inhibitors in NSCLC
Ruiqi Liu, China

P61: Tumor Biology and Systems Biology – Basic and Translational Science – KRAS

✕ NOT FOR CME CREDIT

P61.01: Imipramine Blue (IP) plus MET Tyrosine Kinase Inhibitors (TKI) Suppress Lung Adenocarcinoma (LUAD) KRAS Mutation Tumor Growth

Rafael Rosell, Spain

P61.02: MCL1 Inhibition Enhances the Therapeutic Effect of MEK Inhibitors in KRAS-Mutant Lung Adenocarcinoma Cells

Makoto Tada, Japan

P62: Tumor Biology and Systems Biology – Basic and Translational Science – Metabolomics

 NOT FOR CME CREDIT

-
- P62.01:** 3D Cell Model Development for Optimizing Intrapleural Hyperthermic Chemotherapy in Advanced Lung Cancer
Mi Hyoung Moon, Korea
- P62.02:** Identification of Essential Genes in Malignant Pleural Mesothelioma Using Genome-Wide CRISPR/Cas9-Based Negative Selection Screen
Ece Cakiroglu, Turkey
- P62.03:** Increased GPX4 Drives Ferroptosis Resistance by Suppressing Radiation-Induced Lipid Peroxidation Confers Acquired Radioresistance in NSCLC
Wei Wang, China
- P62.04:** Metabolic Profile of Urine of Early Stage Non Small Cell Lung Cancer Patients Before and After Surgical Resection Using Mass Spectrometry
Naseer Ahmed, Canada
- P62.05:** Identifying Therapeutic Approaches to Treat KEAP1-Mutant Lung Adenocarcinoma
Sarah Best, Australia
- P62.06:** The Consideration of Effects of Statin on Metabolism in Statin-Resistant Cells and Statin-Sensitive Cells
Tomoko Warita, Japan
- P62.07:** Investigation of Metabolic Vulnerabilities Specific to STK11-mutant Lung Cancer
Yanyun Gao, Switzerland
- P62.08:** Expression Pattern and Prognostic Significance of Gluconeogenesis Enzymes in Lung Cancer
Elisabeth Smolle, Austria
- P62.09:** PLGF Regulates Stimulation of Cell Proliferation and Glycolysis of Lung Adenocarcinoma Through Wnt/ β -catenin Pathway
Baohui Han, China
- P62.10:** Rhophilin-2 Upregulates Glutamine Synthetase by Stabilizing c-Myc Protein and Confers Resistance to Glutamine Deprivation in Lung Cancer
Zhihua Guo, China

P63: Tumor Biology and Systems Biology – Basic and Translational Science – Metastases

✗ NOT FOR CME CREDIT

-
- P63.01:** Lymph Node Metastases of Lung Cancer and Blood Cell Circuit
Oleg Kshivets, Russia
- P63.02:** CDK9 Mediate Lung Adenocarcinoma A549 Cell Brain Metastasis in Murine Model
Bo Tian, China
- P63.03:** M1 Phenotype Polarization of Microglia via MIF/CD74 Axis for Radiosensitization in NSCLC Brain Metastasis
Xiaorong Dong, China
- P63.04:** Dysbiosis of Sputum and Gut Microbiota Modulate Development and Distant Metastasis of Non-Small Cell Lung Carcinomas
Jiaojiao Wang, China

P64: Tumor Biology and Systems Biology – Basic and Translational Science – miRNA

 NOT FOR CME CREDIT

- P64.01:** MiRNAs in Exosomes Isolated From the Blood of Non-Small Cell Lung Cancer Patients: Biomarkers for Lung Cancer Prediction and Prognosis
Chun-wei Xu, China
- P64.03:** RNA Modification Enzyme TruB1 Regulate Tumor Proliferation via MicroRNA let-7
Ryota Kurimoto, Japan
- P64.04:** Novel Inhibitory Action of microRNA on EZH2-Mediated Oncogenesis Through Girdin-AMPK Signaling in Small Cell Lung Cancer
Nobuyuki Koyama, Japan

P65: Tumor Biology and Systems Biology – Basic and Translational Science – NC RNA

✗ NOT FOR CME CREDIT

- P65.01:** LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in non-small-cell lung cancer
Zhaoxia Wang, China
- P65.02:** LINC01234 acts as an Oncogenic lncRNA that Interacts with HNRNPA2B1 and Regulates miR-106b Biogenesis
Zhaoxia Wang, China
- P65.03:** A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1 Regulation of Golgi Trafficking
Emily Harrison, USA
- P65.04:** Tracking circRNAs in Lung Adenocarcinoma Samples as Promising Biomarkers for Cancer Detection using the NanoString nCounter®
Carlos Pedraz-Valdunciel, Spain
- P65.05:** Circular RNA circTBCD Promotes Lung Cancer Progression by Targeting Key miRNAs in Bioinformatics Analysis
Yanting Dong, China

P66: Tumor Biology and Systems Biology – Basic and Translational Science – Outcomes

 NOT FOR CME CREDIT

- P66.01:** CD44 Confers Worsened Prognosis in Lung Adenocarcinoma and is Positively Correlated With PD-L1 and Immune Cells Infiltration
Haiyong Wang, China
- P66.02:** A Novel Risk Model of Lung Adenocarcinoma Based on Lung Cancer Susceptibility Genes
Xiaoshun Shi, China
- P66.03:** Unfavorable Survival of TTF-1- Negative Adenocarcinoma
Claus Steppert, Germany
- P66.04:** Real World Data: Immunotherapy in Lung Cancer Patients over 65 Years Old in Spain
Virginia Calvo, Spain

P67: Tumor Biology and Systems Biology – Basic and Translational Science – Proteomics

 NOT FOR CME CREDIT

P67.01: Differential Proteomics Analysis on Plasma from Anlotinib-Treated Advanced Non-Small Cell Lung Cancer Patients

Baohui Han, China

P68: Tumor Biology and Systems Biology – Basic and Translational Science – Radiomics

 NOT FOR CME CREDIT

P68.01: Qualitative Computed Tomographic Features Predict Epidermal Growth Factor Receptor Mutations in Advanced Lung Adenocarcinoma

Chong Kin Liam, Malaysia

P68.02: Computer Extracted Morphology Features of Tumor Nuclei Predict Response to Chemotherapy and Prognostic of OS in Small Cell Lung Cancer

Prantesh Jain, USA

P69: Tumor Biology and Systems Biology – Basic and Translational Science – RTK/EGFR **NOT FOR CME CREDIT**

-
- P69.01:** Real-World Data of EGFR-TKI Treatment Sequence in Non-Small Cell Lung Cancer Patients in Japan
Kentarou Ito, Japan
- P69.02:** Identification of Potential Core Gene in Immune Infiltrates of EGFR Mutant Lung Adenocarcinoma using Bioinformatics Analysis
Zhaoxia Wang, China
- P69.03:** Targeting the STAT3/PIM Kinase Pathway to Overcome EMT-Mediated Acquired Resistance to EGFR TKIs in NSCLC
Kathy Gately, Ireland
- P69.04:** Reduction of Drug Resistance Through Calcium Control in EGFR TKI Resistant Lung Cancer Cells
Sei-hoon Yang, Korea
- P69.05:** Molecular and Cellular Heterogeneity Underpin Treatment Response Across a Spectrum of EGFR-Mutant Non-Small Cell Lung Cancer
Ju Yuan, Singapore

P70: Tumor Biology and Systems Biology – Basic and Translational Science – RTK/OTHERS **NOT FOR CME CREDIT**

-
- P70.01:** Distribution of CCND1 Mutations in East Asian Patients With Non-Small Cell Lung Cancer
Chun-wei Xu, China
- P70.02:** Clinicopathologic Characteristics and Outcomes of East Asian Patients With Non-Small-Cell Lung Cancer and FLT3 Mutations
Chun-wei Xu, China
- P70.03:** Molecular Characterization of AKT1 Gene in East Asian Non-Small Cell Lung Cancer Patients
Chun-wei Xu, China
- P70.04:** Outcomes of Molecular Characteristics in East Asian IDH2-mutant Non-Small Cell Lung Cancer Patients
Chun-wei Xu, China
- P70.05:** The Association Between MAP2K1 Mutation Class and Clinical Features in MAP2K1-Mutant East Asian Non-Small Cell Lung Cancer Patients
Chun-wei Xu, China

P71: Tumor Biology and Systems Biology – Basic and Translational Science – RTK/VEGF NOT FOR CME CREDIT**P71.01: The Effects of Vascular Endothelial Cells on Regulating Post-Irradiation Microglia Phenotype in Irradiation-Induced Brain Injury**

Jiaojiao Wang, China

P71.02: Estrogen Promotes Resistance to Bevacizumab Treatment in Non-Small Cell Lung Cancer (NSCLC) Xenograft Models

Sonia Patel, USA

P72: Tumor Biology and Systems Biology – Basic and Translational Science – Tumor Microenvironment

 NOT FOR CME CREDIT

- P72.01:** Stress-Induced Upregulation of TNFSF4 in Cancer Associated Fibroblasts Facilitates Chemoresistance of Lung Adenocarcinoma
Yan Li, China
- P72.02:** Cellular Landscape of Tumor Immune Microenvironment and Genetic Signatures Identify Prognostic of LUAD
Si-Yang Liu, China
- P72.03:** Tumor Microenvironment Disparity in Multiple Primary Lung Cancers
Motohiro Izumi, Japan
- P72.04:** Statin Counteracts Cell Proliferation and EMT-Induction in NCI-H322M Cells Treated with TGF- β
Katsuhiko Warita, Japan
- P72.05:** From OR to Lab: Optimized Protocol for Functional Immune Profiling of Freshly Resected Human Non-Small Cell Lung Carcinoma (NSCLC) Specimens
Sylvia Alarcon, USA
- P72.06:** NLRP4-Mediated Type I Interferon Response Benefits Immune Checkpoint Therapy Through Redirecting CD8+ T Cell Distribution in TME
Liliang Xia, China
- P72.07:** Modulation of the Tumor Microenvironment by Targeting ERb/HER Oncogenic Network in Lung Cancer Produces Synergy when Followed by Immunotherapy
Abdulaziz Almotlak, Saudia Arabia
- P72.08:** Overexpression of LINC00942 is Associated With a Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma
Jie Yang, China
- P72.09:** Study of Relationship Between Proportion of CTLA-4 Positive Tregs in Tumor Infiltrating Lymphocytes and PD-L1 TPS
Satoshi Muto, Japan
- P72.10:** Prognostic Significance of IgA+ B Cells in Non-Small Cell Lung Cancer
Marie Vanderputten, Belgium

P73: Tumor Biology and Systems Biology – Basic and Translational Science – RTK/FGFR NOT FOR CME CREDIT

-
- P73.01:** Clinicopathologic Characteristics and Survival Outcome in East Asian Patients With Non-Small Cell Lung Cancer and FGFR2 Mutations
Chun-wei Xu, China
- P73.02:** The Landscape of FGFR Alteration in Chinese Patients with Lung Cancer
Huilin Wang, China
- P73.03:** A Kinome CRISPR Screen in FGFR-Amplified Lung Cancer
Zhang Yang, Swaziland

P74: Health Services Research/Health Economics – Real World Evidence

 NOT FOR CME CREDIT

P74.01: Barriers in Precision Medicine Implementation Among Advanced Nonsquamous Cell Lung Cancer-Patients: A Real-World Scenario

Flavia Duarte, Brazil

P74.02: Treatment Patterns of EGFR mt+ NSCLC IV pts: Real World Data of the NOWEL Network

Julia Roeper, Germany

P75: Immunotherapy (Phase II/III Trials) – Misc. Topics

✗ NOT FOR CME CREDIT

-
- P75.01:** Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial
Toyoaki Hida, Japan
- P75.02:** Non-Squamous NSCLC Patients Harbored STK11 or KEAP1 Mutation Showed Insensitivity to any Treatment Including Immunotherapy
Haiyong Wang, China
- P75.03:** KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC
Suman Rao, USA
- P75.04:** Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC
Petros Christopoulos, Germany
- P75.05:** Integrative Modeling of Tumor Burden and Metastatic Pattern for Second-Line anti-PD-L1 Therapy of Non-Small Cell Lung Cancer
Si-Cong Ma, China
- P75.06:** Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases
Shinkichi Takamori, Japan
- P75.07:** Association of FGFR4 Mutation With Immunotherapy Outcomes in Patients With Cancer
Lingshuang Liu, China
- P75.08:** KDM5C Mutation Is Associated with Better Immunotherapy Outcomes in Non-Small Cell Lung Cancer
Kun Wang, China
- P75.09:** Analysis of Immune Microenvironment and Prognosis of NSCLC Patients Harbored SMARCA4 Mutation
Haiyong Wang, China
- P75.10:** Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients
Yiqing Huang, Singapore
- P75.11:** Potential Predictive Value of TERT Mutation Status for Response to Immunotherapy in Cancer Patients
Xiangyun Wang, China
- P75.12:** Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy
Nitya Surya, USA
- P75.13:** Hyperprogressive Disease in Non-Small Cell Lung Cancer on pd-1 Inhibitor
Tae-Won Jang, Korea
- P75.14:** Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience
Domenico Galetta, Italy

- P75.15:** Predictive Factors of Survival in Non-Small Cell Lung Cancer Patients Without Durable Response to PD-1/L1 Inhibitors
Yuhei Harutani, Japan
- P75.16:** Real-World Data from a Spanish Institution
Inmaculada Ramos, Spain
- P75.17:** Baseline D-Dimer Levels Predict Prognosis in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Jinliang Wang, China
- P75.18:** Association of the LIPI With Survival and Response in Advanced NSCLC Patients Treated With Immune Checkpoint Inhibitors
Jinliang Wang, China
- P75.19:** Investigation of Lung Cancer Patients Receiving Immunotherapy with Pre-Existing Lung Disease
Kerri McGovern, USA
- P75.20:** Outcomes of Lung Cancer Patients with Leptomeningeal Metastases Following Immune Checkpoint Inhibitor Treatments: A Pooled Analysis
Meimei Zheng, China
- P75.21:** Impact of Diagnosis and Treatment of Concurrent Infections During Immunotherapy in Advanced Lung Cancer: A Retrospective Cohort Study
Domenico Galetta, Italy
- P75.22:** Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
Kewei Ma, China

P76: Targeted Therapy – Clinically Focused – EGFR

✖ NOT FOR CME CREDIT

- P76.01:** Impact of Clinicopathological Features on Efficacy of Osimertinib in Advanced NSCLC Patients With EGFR Mutations
Yubo Wang, China
- P76.02:** Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor
Chun-wei Xu, China
- P76.03:** Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Enriqueta Felip, Spain
- P76.04:** Prospective Study on Molecular Biomarkers in Advanced Lung Adenocarcinoma and Predilection for EGFR Mutation with Metastatic Sites
Mohanakrishnan Jayamani, India
- P76.05:** Radiotherapy with Concurrent Versus Sequential Osimertinib for Advanced Non-Small Cell Lung Cancer: a Multi-Center Toxicity Analysis
David Qian, USA
- P76.06:** A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma
Dong Shen, China
- P76.07:** Metformin Enhances the Efficacy of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients With Type 2 Diabetes Mellitus
Ruoshuang Han, China
- P76.08:** High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs
Jia Liu, Australia
- P76.09:** A Comparison of Sequential EGFR-TKI Therapy Versus First-Line Osimertinib in NSCLC: A Multi-Center, Retrospective Study
Chung-Shien Lee, USA
- P76.10:** Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
Tianqing Chu, China
- P76.100:** Primary Drug Resistance to EGFR-TKIs by EGFR p.V1010M Germline Mutation Combined with EGFR p.L858R Somatic Mutation and its Pedigree Analysis
Youfan Jiang, China
- P76.11:** Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Mutated NSCLC
Sangtian Liu, China

- P76.12:** **Impact of Inflammatory Markers and Body Mass Index on TKI Toxicity in Patients With Non-Small Cell Lung Cancer Harboring an EGFR Mutation**
Thanya Runciman, Peru
- P76.13:** **Osimertinib Delays but Not Prevents Central Nervous System Metastasis in EGFR-Mutant Advanced Non-Small Cell Lung Cancer**
Jianjiao Ni, China
- P76.14:** **Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI + Brain Radiation**
Nicholas Thomas, USA
- P76.15:** **Osimertinib Improved Overall Survival in mEGFR NSCLC Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status**
Jiyun Lee, Korea
- P76.16:** **EGFR-L858R NSCLC with Pleiotropic Resistance Mechanisms: T790M, C797S, SCLC-Transformation and KRAS, TP53, and BRAF Mutations**
Edyta Urbanska, Denmark
- P76.17:** **Prognostic Role of the Systemic Immune-Inflammatory Index (SII) in Driver-Mutation Positive NSCLC: Real-World EGFR-Mutant Disease**
Amanda Gibson, Canada
- P76.18:** **Tissue- and Plasma-Based Landscape of Resistance to Osimertinib**
Sun Min Lim, Korea
- P76.19:** **Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/ in trans-C797S Mutations After Resistance to Osimertinib**
Chang Lu, China
- P76.20:** **The Predictive Values of Non-Resistant Noncommon EGFR Mutations in Advanced Non-Small Cell Lung Cancer Patients**
Peng-Bo Deng, China
- P76.21:** **EGFR-KDD with Duplication of Exons 18-26 Responding to Afatinib Treatment in a Patient with Lung Adenocarcinoma**
Yiying Qian, China
- P76.22:** **Acquired an EGFR Amplification in EGFR Exon 20 insertion Lung Adenocarcinoma Resistant to First Line Osimertinib Treatment**
Chengwei Zhou, China
- P76.23:** **A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors**
Sho Mitsuya, Japan
- P76.24:** **A Randomized Phase 2 Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-Line Therapy for EGFR-Negative NSCLC (ALTER-L018)**
Lin Wu, China
- P76.25:** **Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKI and Once-Daily Thoracic RT: Predicting Values of Clinical and DVH Parameters**
Xuexi Yang, China

- P76.26:** Survival Outcomes in Patients Receiving Second Line Osimertinib Post First Line First Generation TKI Alone or in Combination with Chemotherapy
Satvik Khaddar, India
- P76.27:** ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
Byoung Chul Cho, Korea
- P76.28:** Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
Pingli Wang, China
- P76.29:** Clinical Observation of EGFR-TKI Combined With 89Sr in the Treatment of Non-Small Cell Lung Cancer With Osteoblastic Reaction
Yu-ming Jia, China
- P76.30:** The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in Patients with EGFR Mutated Advanced NSCLC
Sherin Rouhani, USA
- P76.31:** Clinical Study of Apatinib Combined with Radiation Therapy in Advanced Non-Small Cell Lung Cancer Patients with Brain Metastasis
Xiaqin Zhang, China
- P76.32:** Real-World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation Treated with First and Second Generation TKI
Dalia Juarez, Peru
- P76.33:** Concurrent EGFR and KRAS Mutations in Lung Adenocarcinoma: A Single Institution Case Series
Mahir Khan, USA
- P76.34:** Exosomal miRNAs Participate in Osimertinib Resistance Mainly Through Bypass Activation Mechanisms in Non-Small Cell Lung Cancer
Tangfeng Lv, China
- P76.35:** Genomic Characristic and Prognosis of Concomitant with EGFR Copy Numbers Variations in EGFR Mutated Lung Cancer Patients
Jiuwei Cui, China
- P76.36:** A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)
Juan Li, China
- P76.37:** Comprehensive Investigation of Uncommon EGFR Mutations in 14,429 Chinese Lung Cancer Patients
Yuzhi An, China
- P76.38:** Afatinib as a Potential Therapeutic Option for Non-Small Cell Lung Cancer Patients with EGFR G724S
Hongyun Zhao, China
- P76.39:** Acquired Resistance Mechanisms in T790M-Positive Advanced NSCLC Tested by Non-Invasive Molecular Testing (NIMT) and Their Clinical Relevance
Piyakarn Watcharenwong, Thailand

- P76.40:** Molecular Characteristics and Response to EGFR TKIs of EGFR L747 Position Mutation in Lung Cancer Patients
Wenfeng Fang, China
- P76.41:** Detection of Diverse EGFR c-terminal Truncations (C-trunc) and Sensitivity to Tyrosine Kinase Inhibitors (TKIs) in the Clinic
Christine Lovly, USA
- P76.42:** Osimertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M+. Activity in Patients with CNS Metastases. OSIREX
Josefa Terrasa, Spain
- P76.44:** Application of Longitudinal Exposure-Response Modelling to Support Dacomitinib Starting Dose in Patients with EGFR Mutation-Positive NSCLC
Weiwei Tan, USA
- P76.45:** Evolution of Epidermal Growth Factor Receptor (EGFR) Gene Mutations in EGFR-TKIs Treated Chinese NSCLC
Xin Yu, China
- P76.46:** First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
Wan-Ling Tan, Singapore
- P76.47:** Molecular Characteristics and Response to Diverse EGFR TKIs of NSCLC Patients Harboring EGFR E709-T710delinsX
Wenfeng Fang, China
- P76.48:** A CT-Based Radiomic Feature Predicts EGFR Mutation and Response to Targeted Therapy in NSCLC
Lin Wu, China
- P76.49:** The Impact of Baseline Systemic Inflammatory Status Parameters in Patients Treated with EGFR-Tyrosine Kinase Inhibitors
Petra Martin, Ireland
- P76.50:** Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure
Yu Feng, China
- P76.51:** ERβ1 Expression Patterns have Different Effects on EGFR TKIs Treatment Response in EGFR Mutant Lung Adenocarcinoma
Zhenxiang Li, China
- P76.52:** Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC
Alessandro Leonetti, Italy
- P76.53:** Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors
Taihei Ono, Japan
- P76.54:** Prognostic Value of Radiotherapy Pattern for Late-Stage Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinomas
Zhenxiang Li, China

- P76.55:** Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
Satoshi Igawa, Japan
- P76.56:** High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
Seung Hyeun Lee, Korea
- P76.57:** Resistance Mechanisms to Osimertinib Upon it's Line of Therapy in Patients with EGFR+ NSCLC and Beyond
Vered Fuchs, Israel
- P76.58:** Osimertinib for EGFR-Positive NSCLC Patients with Leptomeningeal Metastases Harboring T790M-Positive or T790M-Negative Mutations
Haiyan Xu, China
- P76.59:** Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
Baohui Han, China
- P76.60:** FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation
Qing Zhou, China
- P76.61:** Long Follow up Study of Comparing Erlotinib (ER) with Gefitinib (GE) for Previously Treated Advanced Non-Small Cell Lung Cancer: WJOG5108LFS
Ryo Toyozawa, Japan
- P76.62:** RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC
Andreas Saltos, USA
- P76.63:** Dacomitinib Induces a Drastic Response in Metastatic Brain Lesions of Patients with EGFR-mutant Non-Small-cell Lung Cancer: A Brief Report
Lin Wu, China
- P76.64:** Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harboring a T790M Resistance Mutation (OSCILLATE)
Benjamin Solomon, Australia
- P76.65:** CNS Efficacy of AST2818 in Patients with T790M-Positive Advanced NSCLC: Data from a Phase I-II Dose-Expansion Study
Yuankai Shi, China
- P76.66:** Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC
Jorge Nieva, USA
- P76.67:** Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
Adam Pluzanski, Poland

- P76.68:** The Impact of Eligibility for Anti-Angiogenic Treatment to the Prognosis of Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
Hiroaki Kodama, Japan
- P76.69:** Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US
Lauren Bartolome, USA
- P76.70:** Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
Jacqueline Aredo, USA
- P76.71:** RYK Confers Drug Tolerance to Osimertinib in Lung Cancer Cells with EGFR Mutations
Shuta Ohara, Japan
- P76.72:** A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases
Simon Ekman, Sweden
- P76.73:** MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
S. Martin Shreeve, USA
- P76.74:** PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC
Trishala Agrawal, USA
- P76.75:** Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer
Kiran Munawar, Pakistan
- P76.76:** EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer and the Role of Diabetes Mellitus and Metformin
Élia Cipriano, Portugal
- P76.77:** Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
Weineng Feng, China
- P76.78:** Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study
Qing Zhou, China
- P76.79:** Osimertinib in Poor PS Patients with T790M-Positive Advanced NSCLC after Progression of EGFR TKI Treatments (NEJ032B)
Ryota Saito, Japan
- P76.80:** The Role of Surgical Resection of Advanced Non-Small Cell Lung Cancer after a Response to EGFR-TKI
Po-Lan Su, Taiwan
- P76.81:** Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma Harboring EGFR-RAD51 Fusion: A Brief Report
Han-Min Wang, China

- P76.82:** Osimertinib versus First-Generation EGFR-TKIs in Untreated EGFR-Mutant NSCLC with Brain Metastasis: 362 Real-World Cases
Jianjiao Ni, China
- P76.83:** Brain Metastasis from Lung Cancers – Intermittent High Dose Afatinib as a Palliative Salvage Therapy for EGFR+ NSCLC
Jo Monsen, Norway
- P76.84:** EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Maisha Chowdhury, Canada
- P76.85:** Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
Sukhmani Padda, USA
- P76.87:** Efficacy of Dacomitinib in EGFR TKI Refractory Metastatic Non-Small Cell Lung Cancer (EGFR Mutant) with Leptomeningeal Metastases
Daniel Chan, Singapore
- P76.88:** Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs
Jun Ma, Singapore
- P76.89:** Is it Possible to Halt Cachexia in Poor Performance Patients with Metastatic EGFR Positive Lung Cancer?
Zhuang Boh, UK
- P76.90:** Molecular Characteristics of BRAF Mutations in EGFR Mutant NSCLC after Progression on EGFR TKIs and Response to Combination Targeted Therapy
Wenfeng Fang, China
- P76.91:** Analysis of P53 Lysine-Encoding Mutations Reveals a Relationship Between Codon 132 Mutations and EGFR Mutations in Lung Adenocarcinoma
Jing Zhang, China
- P76.92:** TKI and Intrathoracic Perfusion in First-line Stage IV Lung Adenocarcinoma with EGFR Mutation and Malignant Pleural Effusion
Weijia Huang, China
- P76.93:** The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Shun Lu, China
- P76.94:** Survival Analyses and Molecular Predictors of Outcomes in Patients Treated with Osimertinib for Metastatic NSCLC Harboring EGFR Mutation
Danilo Giffoni M. M. Mata, Canada
- P76.95:** Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung Adenocarcinoma
Kai-Cheng Peng, China

- P76.96:** **START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm+ Advanced NSCLC**
Jianying Zhou, China
- P76.97:** **Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis**
Dezhi Cheng, China
- P76.98:** **NSCLC Patients With Rare EGFR Mutations in Exons 18 and 19 Benefits From Treatment With EGFR Tyrosine Kinase Inhibitors**
Junying Xu, China
- P76.99:** **Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations**
Dongqing Lv, China

P77: Immunotherapy (Phase II/III Trials) – Combining Different Immunotherapeutic Approaches**✖ NOT FOR CME CREDIT**

-
- P77.01:** Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC
John Wrangle, USA
- P77.02:** Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
Byoung Chul Cho, Korea
- P77.03:** A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Caicun Zhou, China
- P77.04:** PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
David R. Spigel, USA
- P77.05:** Phase II Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC After Progression on First-Line Therapy: BTCRC-LUN15-017
Emily Sisel, USA

P78: Immunotherapy (Phase II/III Trials) – Immune Checkpoint Inhibitor Single Agent

✗ NOT FOR CME CREDIT

-
- P78.01:** Nivolumab in Second Line Non-Small Cell Lung Cancer
– Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057
Sanjay Popat, UK
- P78.02:** A CT-Based Radiomics Approach to Predict Nivolumab Response
in Advanced Non-Small-Cell Lung Cancer
Chang Liu, China
- P78.03:** Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2
in Pre-Treated Advanced NSCLC
Cheng Huang, China
- P78.04:** Efficacy and Safety Analysis of Atezolizumab Monotherapy in Patients
With Non-Small Cell Lung Cancer
Kazutoshi Komiya, Japan
- P78.05:** Patterns of irAE During First Line Pembrolizumab for NSCLC:
Incidence, Risk Factors, and Impact on Clinical Outcome
Cameron Wood, USA
- P78.06:** Dynamic Risk Prediction for Disease Control With Nivolumab in Advanced
or Recurrent Non-Small Cell Lung Cancer Patients (NewEpoch)
Tomoya Fukui, Japan
- P78.07:** High Grade Toxicity and Response to PD-1 Axis Inhibitors in Advanced NSCLC
Mor Moskovitz, Israel
- P78.08:** Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC)
Based on Experience From Expanded Access Program in Poland
Magdalena Knetki-Wróblewska, Poland
- P78.09:** Immunotherapy Beyond Progression for Patients with Advanced Non-Small Cell Lung Cancer
Jinliang Wang, China
- P78.10:** Immunotherapy in Non-Small Cell Lung Cancer with High PD-L1 Expression
and Coexistent RET- Fusion: The Description of Two Cases
Magdalena Knetki-Wróblewska, Poland
- P78.11:** Immunotherapy-Induced Coeliac Disease in the Curative Lung Cancer Patient on Adjuvant Durvalumab
Samantha Hopkins (Maiden Name Kestenbaum), UK
- P78.12:** A Rare Case of Dermatomyositis as Late Immune-Related Toxicity
During Anti-PD1 Treatment for Advanced Lung Cancer
Domenico Galetta, Italy
- P78.13:** Real-World Outcomes After Immunotherapy in NSCLCa: The Experience
of the Oncology Center of Hospital Moinhos De Vento
Fernando Venero, Brazil

- P78.14:** The Efficacy and Safety of ICIs in Treating Postoperative Recurrence of NSCLC: Results of Two Hospitals in Japan
Yuriko Yagi, Japan
- P78.15:** Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
Cristina Julian, USA
- P78.16:** Real-World Outcomes of Camrelizumab (SHR-1210) in Treating Advanced Non-Small Cell Lung Cancer: A Multicenter Prospective Study
Kangsheng Gu, China

P79: Immunotherapy (Phase II/III Trials) – Immunotherapy Plus Chemotherapy

✗ NOT FOR CME CREDIT

- P79.01:** TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezolizumab with Chemoradiation (AFT-16)
Woo Yul Byun, USA
- P79.02:** Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC
Caicun Zhou, China
- P79.03:** A Phase 3 Study of the PD-1 Inhibitor Retifanlimab (INCMGA00012) Plus Platinum-Based Chemotherapy in 1L mNSCLC: PODIUM-304
Shun Lu, China
- P79.04:** A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis
Dwight Owen, USA
- P79.05:** Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer
Caroline Huynh, Canada
- P79.06:** CHIO3: *ChEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage III*A/B Non-Small Cell Lung Cancer (AFT-46)
Linda Martin, USA
- P79.07:** Comparative Efficacy and Safety of PD-(L)1 Inhibitors Combined with 1st-Line Chemotherapy for Advanced NSCLC: A Meta-Analysis
Alessandro Di Federico, Italy
- P79.08:** Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
Shun Lu, China
- P79.09:** Neoadjuvant Combination Sintilimab plus Chemotherapy in Patients with Resectable Stage IIIA Non-Small Cell Lung Cancer
Kewei Ma, China

P80: Immunotherapy (Phase II/III Trials)**- Immunotherapy Plus Chemotherapy/ Immunotherapy Plus Targeted Therapy** **NOT FOR CME CREDIT****P80.01: A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC**

Baohui Han, China

P81: Immunotherapy (Phase II/III Trials)**– Immunotherapy Plus Chemotherapy/Immune Checkpoint Inhibitor Single Agent** NOT FOR CME CREDIT

-
- P81.01:** Efficacy and Safety of Camrelizumab in Patients with Advanced Lung Cancer: A Multicentre, Prospective, Observational Study
Yong Qian Shu, China
- P81.02:** Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
Shikang Zhao, China

P82: Immunotherapy (Phase II/III Trials) – Immunotherapy Plus Radiotherapy

 NOT FOR CME CREDIT

-
- P82.01:** Tumor Treating Fields (150 kHz) Concurrent with Immune Check Point Inhibitors for Stage 4 Non-Small Cell Lung Cancer (NSCLC) in Phase 3 LUNAR Study
Ticiana Leal, USA
- P82.02:** Stereotactic Ablative Radiotherapy with Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a phase 2 study
Juliana Beal, Brazil
- P82.03:** Immunotherapy in Combination with Hypofractionated Radiotherapy for Lung Cancer: A Real-World Experience
Naveen Mummudi, India
- P82.04:** Adaptive Radiation Therapy with Consolidation Sintilimab in Stage III NSCLC: Challenges in Recruiting Patients for Adjuvant Immunotherapy
Yinnan Meng, China

P83: Immunotherapy (Phase II/III Trials) – Immunotherapy Plus Targeted Therapy

✗ NOT FOR CME CREDIT

-
- P83.01:** Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC
Shengxiang Ren, China
- P83.02:** Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study
Suresh Ramalingam, USA
- P83.03:** Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation
Guanghai Gao, China
- P83.04:** Efficacy and Safety of Combining Programmed Cell Death-1 Inhibitor and Anti-Angiogenic Agent as Subsequent Therapy for Advanced NSCLC
Ziyi Xu, China

P84: Targeted Therapy – Clinically Focused – ALK

✗ NOT FOR CME CREDIT

- P84.01:** The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients
Laura Mezquita, Spain
- P84.02:** A Phase II Trial of Alectinib-Refractory Non-Small-Cell Lung Cancer with EML4-ALK Fusion Genes; Okayama Lung Cancer Study Group 1405
Toshihide Yokoyama, Japan
- P84.03:** GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients
Nir Peled, Israel
- P84.04:** HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis
Fang Wu, China
- P84.05:** Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial
Byoung Chul Cho, Korea
- P84.06:** Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes – Phase II ATALK Study
Alexis Cortot, France
- P84.07:** Distribution and Therapeutic Outcomes of Intergenic Sequence-ALK Fusion and Coexisting ALK Fusions in Lung Adenocarcinoma Patients
Meijuan Huang, China
- P84.08:** First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-Small Cell Lung Cancer: A Network Meta-Analysis
Huamao Lin, USA
- P84.09:** Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC
Ross Soo, Singapore
- P84.10:** The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data
Mor Moskovitz, Israel
- P84.11:** Real-World Brigatinib Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in the United States
Huamao Lin, USA
- P84.12:** Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor
Camila Xavier, Brazil
- P84.13:** Organoid Used as Preclinical Modal in ALK Inhibitor Selection: Report of a Case Harboring LRRTM4-ALK Fusion
Ziqi Jia, China

- P84.14:** Identification of Mechanisms of Resistance to ALK Inhibitors.
Next-Generation Sequencing-Based Liquid Biopsy Profiling
Atocha Romero, Spain
- P84.15:** Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China
Xue Yang, China
- P84.16:** Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer
Yago Garitaonaindia, Spain
- P84.17:** Impacts of Different EML4-ALK Variants on the Efficacy of ALK Inhibitors in ALK Positive NSCLC—A Real-World Study in China
Zihua Zou, China
- P84.18:** Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
Zhiwei Xiao, China
- P84.19:** A Review of Clinical Outcomes of Irish Patients With ALK Rearranged NSCLC
Hazel O'Sullivan, Ireland
- P84.20:** VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration
Kozo Yamamoto, Japan
- P84.21:** Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient
Flavia Duarte, Brazil
- P84.22:** Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
Diego Kaen, Argentina
- P84.23:** The Safety and Toxicities of ALK -TKIs in ALK-Positive NSCLC: A Systematic Review and Pool Analysis
Kewei Ma, China

P85: Targeted Therapy – Clinically Focused – MET

 NOT FOR CME CREDIT

-
- P85.01:** Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC
Julien Mazieres, France
- P85.02:** NGS could not Replace FISH Regarding to MET Amplification as an Optimal Biomarker
Lunxi Peng, China
- P85.03:** PD-L1 Expression and Efficacy of Immunotherapy in Japanese Patients with NSCLC Harboring MET Exon 14 Skipping Mutation
Yasuhiro Kato, Japan
- P85.04:** Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis
Ji-Youn Han, Korea
- P85.05:** MET Exon 14 Skipping Mutation Positive Non-Small Cell Lung Cancer: A Population-Based Cohort
Selina Wong, Canada
- P85.06:** Clinical and Genomic Features of Middle Intensity cMET Stain of Chinese Lung Cancer Patients
Xiaorong Dong, China
- P85.07:** Neutrophils Counts Deregulated by C-met TKIs and the Variation Predicts Treatment Response in NSCLC
Xiao-Rong Yang, China

P86: Targeted Therapy – Clinically Focused – New Target

✗ NOT FOR CME CREDIT

- P86.01:** Phase 1 Study of the AXL Inhibitor DS-1205 in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC
James Chih-Hsin Yang, Taiwan
- P86.02:** Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study
Yan Wang, China
- P86.03:** A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations
Martin Schuler, Germany
- P86.04:** The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
Fen Wang, China
- P86.05:** In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
Akira Hamada, Japan
- P86.06:** A Phase I Study of Anlotinib Combined with Platinum-Pemetrexed in Untreated Non-Squamous Non-Small Cell Lung Cancer
Meijuan Huang, China
- P86.07:** CDK12 Mutated Extensive Stage Small Cell Lung Cancer Showed an Exceptional Response to Olaparib and Paclitaxel
Jin Young Hwang, USA
- P86.08:** Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
Alison Schram, USA
- P86.09:** A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
Jianping Xiong, China
- P86.10:** Real-World Efficacy and Safety of Anlotinib with and without Immunotherapy in Advanced Non-Small Cell Lung Cancer
Qi Xiong, China
- P86.11:** A Real-World Feasibility Study of Patients with Solid Tumors Harboring NRG1 Gene Fusions: NSCLC Subset Analysis
Ajeet Gajra, USA
- P86.12:** Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Nahor Haddish-Berhane, USA

- P86.13:** Anlotinib is Active for the Patients Failed from the Prior Bevacizumab Treatment: Anti-Angiogenic Therapy might be Cross-Line Used
Jiang Zhu, China
- P86.14:** Next-Generation Sequencing Guided the Gene Mutations Associated with mTOR-Inhibitors in Chinese Lung Cancer Patients
Lin Wu, China
- P86.15:** Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
Gee-Chen Chang, Taiwan
- P86.16:** Rationale of a Phase II Trial of Nivolumab Combined with Anlotinib in Advanced NSCLC Previously Treated with Immunotherapy
Baohui Han, China
- P86.17:** Continuous Administration of Low-Dose Apatinib Combined With WBRT for Non-Small Cell Lung Cancer With Symptomatic Brain Metastases
Yu-ming Jia, China
- P86.18:** Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina
Juan Blaquier, Argentina
- P86.19:** Anlotinib in Advanced Lung Squamous Cell Carcinoma: A Real World Study
Shujie Song, China
- P86.20:** The Prevalence of NTRK1 Fusion in a Chinese Lung Cancer Cohort
Zhifang Liu, China
- P86.21:** Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC
Shuchen Chen, China
- P86.22:** Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study
Yong Fang, China
- P86.23:** Clinical Efficacy Analysis of Apatinib as a Second-Or Further-Line Treatment in Patients With Advanced NSCLC
Kewei Ma, China

P87: Targeted Therapy – Clinically Focused – RET

✗ NOT FOR CME CREDIT

-
- P87.01:** Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)
Nir Peled, Israel
- P87.02:** AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC
Benjamin Besse, France
- P87.03:** Characteristics and Outcomes of RET-Rearranged Non-Small Cell Lung Cancer from China: A Retrospective Study of Real-World
Mina Zhang, China
- P87.04:** Chemotherapy and Immunotherapy Outcomes of RET-Rearranged Lung Cancers: A Case Series
Estelamari Rodriguez, USA
- P87.05:** RET-Rearranged Squamous Cell Carcinoma of the Lung Responding to First-Line Immunotherapy plus Chemotherapy
Qing-yun Gao, China

P88: Targeted Therapy – Clinically Focused – ROS1

✗ NOT FOR CME CREDIT

-
- P88.01:** Comprehensive Profiling of ROS1 Fusions in Chinese Non-Small Cell Lung Cancer Patients
Hanlin Xu, China
- P88.02:** SDC4-ROS1 Fusion as a Mechanism of Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma
Chun-wei Xu, China
- P88.03:** Asymptomatic COVID-19 in a ROS1 positive Non Small Cell Lung Cancer
Ananda Datta, India
- P88.04:** Successful Low-Dose Treatment for Patients with ROS1-Rearranged NSCLC who Developed Crizotinib-Related Heart Failure
Takahiko Hashimoto, Japan
- P88.05:** A Recommended one-step Targeted Sequencing Technology for Identification of a Dual CD74-ROS1 in NSCLC
Quan Lin, China

P89: Targeted Therapy – Clinically Focused – Translational

 NOT FOR CME CREDIT

- P89.01:** Clinical and Genomic Features of EGFR-KDD/EGFR Rearrangements of Chinese Lung Cancer Patients
Chengzhi Zhou, China
- P89.02:** The Effect of Racial Diversity on the Landscape of Targetable Genomic Alterations in Patients with Lung Adenocarcinomas
Yanyan Lou, USA
- P89.03:** Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System
Desiree Hao, Canada
- P89.04:** Real-World First Line Targeted Therapy Duration Following ctDNA Testing in Advanced Non-Small Cell Lung Cancer
Chuck Hensel, USA
- P89.05:** Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis
Kathleen Kerrigan, USA
- P89.06:** Prospective Concordance Study of a Multi-Gene PCR Assay and NGS for the Detection of Targetable Gene Alterations in Lung Cancer
Shingo Matsumoto, Japan
- P89.07:** A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients With NSCLC
Meizi Jin, China
- P89.08:** Real-World Impact of Plasma Cell-Free DNA Next-Generation Sequencing to Detect Actionable Genomic Alterations in Advanced NSCLC
Beung-Chul Ahn, Korea
- P89.09:** The Landscape of Kinase Domain Duplication (KDD) in Chinese Lung Cancer Patients
Pingli Wang, China
- P89.10:** Genomic Alteration Features and Targeted Therapy Opportunities of Primary Thoracic Sarcoma Patients
Lixia Ju, China
- P89.11:** Mutational Profile of Multiple Lung Cancers in Xuanwei by Next-Generation Sequencing
Gang Guo, China
- P89.12:** Real World Outcomes in EGFR-Mutant Relapsed and De Novo Stage IV Non-Small Cell Lung Cancer (NSCLC)
Amanda Gibson, Canada
- P89.13:** Real-World Experience of NGS-Based Molecular Profiling in ‘Triple-Negative’ (EGFR/ALK/ROS1) Advanced NSCLC: Should we keep Testing Smokers?
Francesca Simionato, Italy
- P89.14:** Preliminary Study on CTCs and CTECs in Non-Small Cell Lung Cancer Received Chemotherapy Combined with Anti-Angiogenic Therapy
Lina Zhang, China

P89.15: Multiple Driver Oncogenes from Plasma of NSCLC Patients

Sita Andarini, Indonesia

P89.18: Comprehensive Molecular Characterization of Chinese Patients with Oesophageal Cancer Related with Age

Lianke Liu, China

P90: Targeted Therapy – Clinically Focused – Misc. Topics

 NOT FOR CME CREDIT

- P90.01:** Clinical Characteristics and Outcome of Patients with Non-Small Cell Lung Cancer Harboring BRAF Mutations
Mina Zhang, China
- P90.02:** BRAF Mutation And Peridiagnosis Thromboembolic Events In Advanced NSCLC Patients
Inmaculada Aparicio Salcedo, Spain
- P90.03:** A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Alex Spira, USA
- P90.04:** RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Pooled Analysis of RAS Pathway Mutations in Advanced NSCLC
Helen Adderley, UK

P92: Mesothelioma, Thymoma and Other Thoracic Malignancies – Misc. Topics

 NOT FOR CME CREDIT

- P92.01:** Genetic Landscape and Potential Therapy Regimen of Thymic Tumor
Naixin Liang, China

P94: Pathology, Molecular Pathology and Diagnostic Biomarkers – Misc. Topics

 NOT FOR CME CREDIT

P94.01: Comparison of Driver Mutations in Primary and Metastatic Lung Cancer
Xin Hong, China